FN Clarivate Analytics Web of Science
VR 1.0
PT J
AU Kido, T
   Miyagawa, S
   Goto, T
   Tamai, K
   Ueno, T
   Toda, K
   Kuratani, T
   Sawa, Y
AF Kido, Takashi
   Miyagawa, Shigeru
   Goto, Takasumi
   Tamai, Katsuto
   Ueno, Takayoshi
   Toda, Koichi
   Kuratani, Toru
   Sawa, Yoshiki
TI The administration of high-mobility group box 1 fragment prevents
   deterioration of cardiac performance by enhancement of bone marrow
   mesenchymal stem cell homing in the delta-sarcoglycan-deficient hamster
SO PLOS ONE
LA English
DT Article
ID HEPATOCYTE GROWTH-FACTOR; DILATED CARDIOMYOPATHY; MYOCARDIAL-INFARCTION;
   HEART; TISSUE; HMSCS; DIFFERENTIATION; TSG-6; VEGF; MICE
AB Objectives
   We hypothesized that systemic administration of high-mobility group box 1 fragment attenuates the progression of myocardial fibrosis and cardiac dysfunction in a hamster model of dilated cardiomyopathy by recruiting bone marrow mesenchymal stem cells thus causing enhancement of a self-regeneration system.
   Methods
   Twenty-week-old J2N-k hamsters, which are 6-sarcoglycan-deficient, were treated with systemic injection of high-mobility group box 1 fragment (HMGB1, n = 15) or phosphate buffered saline (control, n = 11). Echocardiography for left ventricular function, cardiac histology, and molecular biology were analyzed. The life-prolonging effect was assessed separately using the HMGB1 and control groups, in addition to a monthly HMGB1 group which received monthly systemic injections of high-mobility group box 1 fragment, 3 times (HMGB1, n = 11, control, n = 9, monthly HMGB1, n = 9).
   Results
   The HMGB1 group showed improved left ventricular ejection fraction, reduced myocardial fibrosis, and increased capillary density. The number of platelet-derived growth factor receptor-alpha and CD106 positive mesenchymal stem cells detected in the myocardium was significantly increased, and intra-myocardial expression of tumor necrosis factor a stimulating gene 6, hepatic growth factor, and vascular endothelial growth factor were significantly upregulated after high-mobility group box 1 fragment administration. Improved survival was observed in the monthly HMGB1 group compared with the control groups.
   Conclusions
   Systemic high-mobility group box 1 fragment administration attenuates the progression of left ventricular remodeling in a hamster model of dilated cardiomyopathy by enhanced homing of bone marrow mesenchymal stem cells into damaged myocardium, suggesting that high-mobility group box 1 fragment could be a new treatment for dilated cardiomyopathy.
C1 [Kido, Takashi; Miyagawa, Shigeru; Goto, Takasumi; Ueno, Takayoshi; Toda, Koichi; Kuratani, Toru; Sawa, Yoshiki] Osaka Univ, Dept Cardiovasc Surg, Grad Sch Med, Osaka, Japan.
   [Tamai, Katsuto] Osaka Univ, Dept Stem Cell Therapy Sci, Grad Sch Med, Osaka, Japan.
RP Sawa, Y (reprint author), Osaka Univ, Dept Cardiovasc Surg, Grad Sch Med, Osaka, Japan.
EM sawa-p@surg1.med.osaka-u.ac.jp
CR Abbott JD, 2004, CIRCULATION, V110, P3300, DOI 10.1161/01.CIR.0000147780.30124.CF
   Aikawa E, 2015, SCI REP-UK, V5, DOI 10.1038/srep11008
   Askari AT, 2003, LANCET, V362, P697, DOI 10.1016/S0140-6736(03)14232-8
   Chamberlain G, 2007, STEM CELLS, V25, P2739, DOI 10.1634/stemcells.2007-0197
   Chen Y, 2008, INT J BIOCHEM CELL B, V40, P815, DOI 10.1016/j.biocel.2008.01.007
   Chen Y, 2010, J CELL MOL MED, V14, P1494, DOI 10.1111/j.1582-4934.2009.00912.x
   Choi H, 2011, BLOOD, V118, P330, DOI 10.1182/blood-2010-12-327353
   DEC GW, 1994, NEW ENGL J MED, V331, P1564, DOI 10.1056/NEJM199412083312307
   Fischer-Rasokat U, 2009, CIRC-HEART FAIL, V2, P417, DOI 10.1161/CIRCHEARTFAILURE.109.855023
   Fujii T, 2005, J BIOL CHEM, V280, P23041, DOI 10.1074/jcb.M409397200
   Guo XF, 2018, STEM CELL RES THER, V9, DOI 10.1186/s13287-018-0773-9
   Hack AA, 1998, J CELL BIOL, V142, P1279, DOI 10.1083/jcb.142.5.1279
   He ZG, 2016, SCI REP-UK, V6, DOI 10.1038/srep38438
   Hoshikawa E, 2011, AM J CARDIOL, V107, P1065, DOI 10.1016/j.amjcard.2010.11.033
   Hu XF, 2007, CIRCULATION, V116, P654, DOI 10.1161/CIRCULATIONAHA.106.672451
   Itoh M, 2015, EUROPACE, V17, P1407, DOI 10.1093/europace/euu361
   Jiang YH, 2002, NATURE, V418, P41, DOI 10.1038/nature00870
   Kawamura M, 2015, TISSUE ENG PT A, V21, P2272, DOI [10.1089/ten.tea.2014.0036, 10.1089/ten.TEA.2014.0036]
   Kober L, 2016, NEW ENGL J MED, V375, P1221, DOI 10.1056/NEJMoa1608029
   Kondoh H, 2005, J THORAC CARDIOV SUR, V130, P295, DOI 10.1016/j.jtcvs.2004.11.001
   Kota DJ, 2013, DIABETES, V62, P2048, DOI 10.2337/db12-0931
   Lee RH, 2014, P NATL ACAD SCI USA, V111, P16766, DOI 10.1073/pnas.1416121111
   Lee RH, 2009, CELL STEM CELL, V5, P54, DOI 10.1016/j.stem.2009.05.003
   Luk A, 2009, J CLIN PATHOL, V62, P219, DOI 10.1136/jcp.2008.060731
   Maekawa K, 2013, J MOL CELL CARDIOL, V59, P76, DOI 10.1016/j.yjmcc.2013.02.008
   Markel TA, 2008, AM J PHYSIOL-HEART C, V295, pH2308, DOI 10.1152/ajpheart.00565.2008
   Megeney LA, 1999, P NATL ACAD SCI USA, V96, P220, DOI 10.1073/pnas.96.1.220
   Mela T, 1999, AM J CARDIOL, V83, P1277, DOI 10.1016/S0002-9149(99)00074-0
   Meng ER, 2008, STEM CELLS DEV, V17, P805, DOI 10.1089/scd.2008.0276
   Mitsuhashi S, 2003, J BIOCHEM, V134, P269, DOI 10.1093/jb/mvg140
   Miwa H, 2018, DEVELOPMENT, V145, DOI 10.1242/dev.155879
   Miyagawa S, 2002, CIRCULATION, V105, P2556, DOI 10.1161/01.CIR.0000016722.37138.F2
   Nakamura K, 2002, CIRCULATION, V105, P2867, DOI 10.1161/01.CIR.0000018605.14470.DD
   Nakamura T, 2005, AM J PHYSIOL-HEART C, V288, pH2131, DOI 10.1152/ajpheart.01239.2003
   Neufeld G, 1999, FASEB J, V13, P9
   Osmanov T, 2013, BIOCHEM BIOPH RES CO, V432, P231, DOI 10.1016/j.bbrc.2013.02.008
   Palumbo R, 2004, J CELL BIOL, V164, P441, DOI 10.1083/jcb.200304135
   Roura S, 2007, EUR J HEART FAIL, V9, P995, DOI 10.1016/j.ejhearl.2007.07.008
   Sasaki M, 2008, J IMMUNOL, V180, P2581, DOI 10.4049/jimmunol.180.4.2581
   Seth S, 2010, J AM COLL CARDIOL, V55, P1643, DOI 10.1016/j.jacc.2009.11.070
   Shafei AE, 2018, J CELL BIOCHEM, V119, P5274, DOI 10.1002/jcb.26637
   Tamai K, 2011, P NATL ACAD SCI USA, V108, P6609, DOI 10.1073/pnas.1016753108
   Theiss HD, 2007, EUR HEART J, V28, P1258, DOI 10.1093/eurheartj/ehm011
   Uemura R, 2006, CIRC RES, V98, P1414, DOI 10.1161/01.RES.0000225952.61196.39
   Vrtovec B, 2013, CIRC RES, V112, P165, DOI 10.1161/CIRCRESAHA.112.276519
   Weintraub RG, 2017, LANCET, V390, P400, DOI 10.1016/S0140-6736(16)31713-5
   Zisa D, 2009, AM J PHYSIOL-REG I, V297, pR1503, DOI 10.1152/ajpregu.00227.2009
NR 47
TC 0
Z9 0
U1 0
U2 2
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD DEC 5
PY 2018
VL 13
IS 12
AR e0202838
DI 10.1371/journal.pone.0202838
PG 15
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA HD0QO
UT WOS:000452212400004
PM 30517097
OA DOAJ Gold, Green Published
DA 2019-07-19
ER

PT J
AU Jafari, SMS
   Wiedmer, C
   Cazzaniga, S
   Frangez, Z
   Shafighi, M
   Beltraminelli, H
   Weber, B
   Simon, HU
   Hunger, RE
AF Jafari, S. Morteza Seyed
   Wiedmer, Christina
   Cazzaniga, Simone
   Frangez, Ziva
   Shafighi, Maziar
   Beltraminelli, Helmut
   Weber, Benedikt
   Simon, Hans-Uwe
   Hunger, Robert E.
TI Correlation of Vascular Endothelial Growth Factor subtypes and their
   receptors with melanoma progression: A next-generation Tissue Microarray
   (ngTMA) automated analysis
SO PLOS ONE
LA English
DT Article
ID LYMPH-NODE METASTASIS; FACTOR-C EXPRESSION; TUMOR LYMPHANGIOGENESIS;
   VEGF-C; CUTANEOUS MELANOMA; TYROSINE KINASES; ANGIOGENESIS; CANCER;
   PROMOTES; DENSITY
AB Introduction
   Finding new markers to assess prognosis of melanoma without the necessity to perform a surgical interventions is an important goal in melanoma research. The current study aimed to assess the correlation of clinical course and prognosis of primary and metastatic melanoma with expression of VEGF family and their receptors.
   Methods
   A ngTMA block was made from the randomly selected paraffin tissue blocks of the patients with melanocytic nevi, primary and metastatic melanoma. Then sections cut from ngTMA-block were immunohistochemically stained with proper antibodies. Expression of these proteins was investigated using automated image analysis and compared among the study groups.
   Results
   We analyzed the tissue of 238 patients with following diagnoses: 101 (42.4%) with a diagnosis of nevus, 86 (36.1%) Malignant melanoma and 51 (21.4%) metastasis. Median follow-up time for the malignant lesions was 5.71 years. Among the tested antigen, VEGF-C (p = 0.016), VEGF-R2 (p<0.001) and VEGF-R3 (p = 0.002) were significantly higher expressed in the metastatic tissues. When these scores were assessed in multiple regression models, the only independent factor linked to patient's diagnosis was VEGF-R2 (p<0.001). In addition, groups of highly correlated variables (VEGF-C and VEGF-R3, VEGF-A and VEGF-R1) were found to form separate sub-clusters. On the other side, high values of VEGF-C were associated with both overall and disease-free survival with a statically significant HR of 2.76 (95% CI: 1.27, 5.98; p = 0.01) and 2.82 (95% CI: 1.62, 4.91; p<0.001), respectively.
   Conclusions
   This study shows that VEGF-C and VEGF-R2 might represent new prognostic marker in MM. However, further prospective studies are warranted to test their real efficacy as a prognostic marker.
C1 [Jafari, S. Morteza Seyed; Wiedmer, Christina; Cazzaniga, Simone; Beltraminelli, Helmut; Weber, Benedikt; Hunger, Robert E.] Univ Bern, Univ Hosp Bern, Inselspital, Dept Dermatol, Bern, Switzerland.
   [Cazzaniga, Simone] Ctr Studi GISED, Bergamo, Italy.
   [Frangez, Ziva; Simon, Hans-Uwe] Univ Bern, Inst Pharmacol, Bern, Switzerland.
   [Shafighi, Maziar] Univ Bern, Dept Biomed Res, Bern, Switzerland.
   [Weber, Benedikt] Med Univ Vienna, Dept Dermatol, Vienna, Austria.
RP Jafari, SMS (reprint author), Univ Bern, Univ Hosp Bern, Inselspital, Dept Dermatol, Bern, Switzerland.
EM seyedjafarism@yahoo.com
OI Seyed Jafari, S. Morteza/0000-0002-6466-2199; Cazzaniga,
   Simone/0000-0001-8161-6138
FU Swiss National Science Foundation [310030_166473]; Bern Cancer League;
   European Union's Horizon 2020 research and innovation program under the
   Marie Sklodowska-Curie grant [642295]
FX This study was supported by Swiss National Science Foundation (grant
   310030_166473), Bern Cancer League, the European Union's Horizon 2020
   research and innovation program under the Marie Sklodowska-Curie grant
   agreement No 642295 (MEL-PLEX).
CR Achen MG, 1998, P NATL ACAD SCI USA, V95, P548, DOI 10.1073/pnas.95.2.548
   Achen MG, 2005, CANCER CELL, V7, P121, DOI 10.1016/j.ccr.2005.01.017
   Agostino NM, 2015, SPRINGERPLUS, V4, DOI 10.1186/s40064-015-0951-5
   Akagi K, 2000, BRIT J CANCER, V83, P887, DOI 10.1054/bjoc.2000.1396
   Andre T, 2000, INT J CANCER, V86, P174, DOI 10.1002/(SICI)1097-0215(20000415)86:2<174::AID-IJC5>3.0.CO;2-E
   Balch CM, 2011, J SURG ONCOL, V104, P379, DOI 10.1002/jso.21876
   Balch CM, 2009, J CLIN ONCOL, V27, P6199, DOI 10.1200/JCO.2009.23.4799
   Balch CM, 2001, J CLIN ONCOL, V19, P3622, DOI 10.1200/JCO.2001.19.16.3622
   Beasley NJP, 2002, CANCER RES, V62, P1315
   BENJAMINI Y, 1995, J R STAT SOC B, V57, P289
   Bennassar A, 2012, DERMATOL THER, V25, P432, DOI 10.1111/j.1529-8019.2012.01537.x
   Budczies J, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0051862
   Bunone G, 1999, AM J PATHOL, V155, P1967, DOI 10.1016/S0002-9440(10)65515-0
   Carmeliet P, 2000, NATURE, V407, P249, DOI 10.1038/35025220
   Dadras SS, 2003, AM J PATHOL, V162, P1951, DOI 10.1016/S0002-9440(10)64328-3
   Dadras SS, 2005, MODERN PATHOL, V18, P1232, DOI 10.1038/modpathol.3800410
   Dhondt J, 2011, FASEB J, V25, P1461, DOI 10.1096/fj.10-170944
   Dummer R, 2011, SWISS MED WKLY, V141, DOI 10.4414/smw.2011.13320
   Eggert A, 2000, CLIN CANCER RES, V6, P1900
   Ellis MC, 2010, AM J SURG, V199, P663, DOI 10.1016/j.amjsurg.2010.01.019
   Emmett MS, 2011, AM J CANCER RES, V1, P852
   Felcht M, 2015, J DTSCH DERMATOL GES, V13, P125, DOI 10.1111/ddg.12580
   Fellmer PT, 1999, SURGERY, V126, P1056, DOI 10.1067/msy.2099.101432
   Garbe C, 2012, EUR J CANCER, V48, P2375, DOI 10.1016/j.ejca.2012.06.013
   Griffioen AW, 2000, PHARMACOL REV, V52, P237
   Hoshida T, 2006, CANCER RES, V66, P8065, DOI 10.1158/0008-5472.CAN-06-1392
   Hunger RE, 2015, EUR J DERMATOL, V25, P472, DOI 10.1684/ejd.2015.2626
   Hunger RE, 2015, J AM ACAD DERMATOL, V72, P1054, DOI 10.1016/j.jaad.2015.03.029
   Jafari SMS, 2016, SWISS MED WKLY, V146, DOI 10.4414/smw.2016.14358
   Jafari SMS, 2017, APPL IMMUNOHISTO M M, V25, pE12, DOI 10.1097/PAI.0000000000000370
   Jolliffe IT, 2016, PHILOS T R SOC A, V374, DOI 10.1098/rsta.2015.0202
   Joukov V, 1997, EMBO J, V16, P3898, DOI 10.1093/emboj/16.13.3898
   Korpelainen EI, 1998, CURR OPIN CELL BIOL, V10, P159, DOI 10.1016/S0955-0674(98)80137-3
   Kozlowski M, 2010, EUR J CARDIO-THORAC, V38, P260, DOI 10.1016/j.ejcts.2010.01.061
   Kurebayashi J, 1999, JPN J CANCER RES, V90, P977, DOI 10.1111/j.1349-7006.1999.tb00844.x
   Liu WB, 2011, INT J ONCOL, V39, P1213, DOI 10.3892/ijo.2011.1138
   Massi D, 2006, J CLIN PATHOL, V59, P166, DOI 10.1136/jcp.2005.028431
   Neufeld G, 1999, FASEB J, V13, P9
   Niki T, 2000, CLIN CANCER RES, V6, P2431
   Ohta Y, 1999, BRIT J CANCER, V81, P54, DOI 10.1038/sj.bjc.6690650
   Ohta Y, 2000, J THORAC CARDIOV SUR, V119, P804, DOI 10.1016/S0022-5223(00)70017-1
   Pepper MS, 2003, J CELL BIOL, V163, P209, DOI 10.1083/jcb.200308082
   Pradeep C R, 2005, Integr Cancer Ther, V4, P315, DOI 10.1177/1534735405282557
   Rokach L, 2005, DATA MINING AND KNOWLEDGE DISCOVERY HANDBOOK, P321, DOI 10.1007/0-387-25465-X_15
   Ruggeri B, 2003, CANCER RES, V63, P5978
   Saharinen P, 2004, TRENDS IMMUNOL, V25, P387, DOI 10.1016/j.it.2004.05.003
   Salven P, 1998, AM J PATHOL, V153, P103, DOI 10.1016/S0002-9440(10)65550-2
   Shibuya M, 2006, EXP CELL RES, V312, P549, DOI 10.1016/j.yexcr.2005.11.012
   Shushanov S, 2000, INT J CANCER, V86, P47, DOI 10.1002/(SICI)1097-0215(20000401)86:1<47::AID-IJC7>3.0.CO;2-R
   Skobe M, 2001, NAT MED, V7, P192, DOI 10.1038/84643
   Sladden MJ, 2009, COCHRANE DATABASE SY, V4
   Sotiropoulou N, 2010, PATHOLOGY, V42, P629, DOI 10.3109/00313025.2010.522174
   Squires MH, 2013, CURR ONCOL REP, V15, P465, DOI 10.1007/s11912-013-0333-5
   Stacker SA, 2004, APMIS, V112, P539, DOI 10.1111/j.1600-0463.2004.apm11207-0812.x
   Stacker SA, 2001, NAT MED, V7, P186, DOI 10.1038/84635
   Streit M, 2003, ONCOGENE, V22, P3172, DOI 10.1038/sj.onc.1206457
   Tobler NE, 2006, J LEUKOCYTE BIOL, V80, P691, DOI 10.1189/jlb.1105653
   Tsurusaki T, 1999, BRIT J CANCER, V80, P309, DOI 10.1038/sj.bjc.6690356
   Veikkola T, 2001, EMBO J, V20, P1223, DOI 10.1093/emboj/20.6.1223
   Warne R.T., 2014, PRACTICAL ASSESSMENT, V19
   Weigel RJ, 1999, SURGERY, V126, P1061
   Yancopoulos GD, 2000, NATURE, V407, P242, DOI 10.1038/35025215
   Yonemura Y, 1999, CLIN CANCER RES, V5, P1823
   Zhang F, 2009, P NATL ACAD SCI USA, V106, P6152, DOI 10.1073/pnas.0813061106
   Zlobec Inti, 2014, J Vis Exp, P51893, DOI 10.3791/51893
NR 65
TC 0
Z9 0
U1 0
U2 1
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD NOV 8
PY 2018
VL 13
IS 11
AR e0207019
DI 10.1371/journal.pone.0207019
PG 16
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA GZ5ZX
UT WOS:000449512300064
PM 30408085
OA DOAJ Gold, Green Published
DA 2019-07-19
ER

PT J
AU Ciarlillo, D
   Celeste, C
   Carmeliet, P
   Boerboom, D
   Theoret, C
AF Ciarlillo, Domenic
   Celeste, Christophe
   Carmeliet, Peter
   Boerboom, Derek
   Theoret, Christine
TI A hypoxia response element in the Vegfa promoter is required for basal
   Vegfa expression in skin and for optimal granulation tissue formation
   during wound healing in mice
SO PLOS ONE
LA English
DT Article
ID ENDOTHELIAL GROWTH-FACTOR; INDUCIBLE FACTOR-1-ALPHA; CONSTITUTIVE
   EXPRESSION; KERATINOCYTE PROLIFERATION; ANGIOGENESIS; CELLS; HIF-1;
   OXYGEN; HIF-1-ALPHA; RECEPTORS
AB Hypoxia in skin wounds is thought to contribute to healing through the induction of hypoxia inducible factor-1 (HIF-1). Although HIF-1 can regulate the expression of vascular endothelial growth factor A (Vegfa), whether hypoxia and HIF-1 are required to induce Vegfa expression in the context of wound healing is unknown. To test this hypothesis, we evaluated Vegfa expression and wound healing in mutant mice that lack a functional HIF-1 binding site in the Vegfa promoter. Full-thickness excisional wounds were made using a biopsy punch, left to heal by second intention, and granulation tissue isolated on a time course during healing. mRNA levels of Vegfa and its target genes platelet-derived growth factors B (Pdgfb) and stromal cell-derived factor-1 (Sdf1) were measured by RT-qPCR, and HIF-1alpha and VEGFA protein levels measured by immunoblotting. Lower levels of Vegfa, Pdgf1 and Sdf1 mRNA were found in intact skin of mutant mice relative to wild-type controls (n = 6 mice / genotype), whereas levels in granulation tissue during wound healing were unaltered. VEGFA protein levels were also lower in intact skin of the mutant versus the wild-type mice. Decreased Vegfa mRNA levels in skin of mutant mice could not be attributed to decreased HIF-1alpha protein expression, and were therefore a consequence of the loss of HIF-1 responsiveness of the Vegfa promoter. Comparative histologic analyses of healing wounds in mutant and wild-type mice (n = 8 mice / genotype) revealed significant defects in granulation tissue in the mutant mice, both in terms of quantity and capillary density, although epithelialization and healing rates were unaltered. We conclude that HIF-1 is not a major regulator of Vegfa expression during wound healing; rather, it serves to maintain basal levels of expression of Vegfa and its target genes in intact skin, which are required for optimal granulation tissue formation in response to wounding.
C1 [Ciarlillo, Domenic; Celeste, Christophe; Boerboom, Derek; Theoret, Christine] Univ Montreal, Fac Med Vet, Dept Biomed Vet, St Hyacinthe, PQ, Canada.
   [Carmeliet, Peter] Univ Leuven, Vesalius Res Ctr, Lab Angiogenesis & Vasc Metab, Leuven, Belgium.
RP Theoret, C (reprint author), Univ Montreal, Fac Med Vet, Dept Biomed Vet, St Hyacinthe, PQ, Canada.
EM christine.theoret@umontreal.ca
OI Theoret, Christine/0000-0002-7893-2495
FU Natural Sciences and Engineering Research Council of Canada [250231]
FX This work was supported by the Natural Sciences and Engineering Research
   Council of Canada (CT), grant #250231 (http://www.nserc-crsng.gc.ca).
   The funder had no role in study design, data collection and analysis,
   decision to publish, or preparation of the manuscript.
CR Akakura N, 2001, CANCER RES, V61, P6548
   Ben-Shoshan J, 2008, STEM CELLS, V26, P2634, DOI 10.1634/stemcells.2008-0369
   Berra E, 2000, CANCER METAST REV, V19, P139, DOI 10.1023/A:1026506011458
   Carmeliet P, 1996, NATURE, V380, P435, DOI 10.1038/380435a0
   Carmeliet P, 2005, NATURE, V438, P932, DOI 10.1038/nature04478
   Ceradini DJ, 2005, TRENDS CARDIOVAS MED, V15, P57, DOI 10.1016/j.tcm.2005.02.002
   Cho YS, 2008, BBA-MOL CELL RES, V1783, P323, DOI 10.1016/j.bbamcr.2007.11.017
   Cowburn AS, 2013, P NATL ACAD SCI USA, V110, P17570, DOI 10.1073/pnas.1306942110
   Curry JM, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003405
   Davidson JM, 2013, ADV WOUND CARE, V2, P142, DOI 10.1089/wound.2012.0424
   de Jonge HJM, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0000898
   Dery MAC, 2005, INT J BIOCHEM CELL B, V37, P535, DOI 10.1016/j.biocel.2004.08.012
   Deschene K, 2011, WOUND REPAIR REGEN, V19, P250, DOI 10.1111/j.1524-475X.2010.00663.x
   Eichmann A, 2012, CURR OPIN CELL BIOL, V24, P188, DOI 10.1016/j.ceb.2012.02.002
   Ferrara N, 2003, NAT MED, V9, P669, DOI 10.1038/nm0603-669
   Galiano RD, 2004, WOUND REPAIR REGEN, V12, P485, DOI 10.1111/j.1067-1927.2004.12404.x
   Jain RK, 2003, NAT MED, V9, P685, DOI 10.1038/nm0603-685
   Maharaj ASR, 2007, MICROVASC RES, V74, P100, DOI 10.1016/j.mvr.2007.03.004
   Manalo DJ, 2005, BLOOD, V105, P659, DOI 10.1182/blood-2004-07-2958
   Michaels J, 2007, WOUND REPAIR REGEN, V15, P665, DOI 10.1111/j.1524-475X.2007.00273.x
   Milanini J, 1998, J BIOL CHEM
   Neufeld G, 1999, FASEB J, V13, P9
   Oosthuyse B, 2001, NAT GENET, V28, P131, DOI 10.1038/88842
   Petit I, 2007, TRENDS IMMUNOL, V28, P299, DOI 10.1016/j.it.2007.05.007
   Ripple MO, 2013, J BIOL CHEM, V288, P2933, DOI 10.1074/jbc.M112.430082
   Rodriguez PG, 2008, DERMATOL SURG, V34, P1159, DOI 10.1111/j.1524-4725.2008.34254.x
   Romagnani P, 2004, TRENDS IMMUNOL, V25, P201, DOI 10.1016/j.it.2004.02.006
   Rousseau S, 2000, TRENDS CARDIOVAS MED, V10, P321, DOI 10.1016/S1050-1738(01)00072-X
   Schreml S, 2010, BRIT J DERMATOL, V163, P257, DOI 10.1111/j.1365-2133.2010.09804.x
   Semenza GL, 2000, J APPL PHYSIOL, V88, P1474
   Sen CK, 2002, J BIOL CHEM, V277, P33284, DOI 10.1074/jbc.M203391200
   Sen CK, 2009, WOUND REPAIR REGEN, V17, P1, DOI DOI 10.1111/J.1524-475X.2008.00436.X
   Shih SC, 2001, GROWTH FACTORS, V19, P19, DOI 10.3109/08977190109001073
   Stadelmann WK, 1998, AM J SURG, V176, p39S, DOI 10.1016/S0002-9610(98)00184-6
   Tandara AA, 2004, WORLD J SURG, V28, P294, DOI 10.1007/s00268-003-7400-2
   Tsuzuki Y, 2000, CANCER RES, V60, P6248
   Wilgus TA, 2008, LAB INVEST, V88, P579, DOI 10.1038/labinvest.2008.36
   Wise LM, 2012, CELL MICROBIOL, V14, P1376, DOI 10.1111/j.1462-5822.2012.01802.x
NR 38
TC 4
Z9 4
U1 0
U2 3
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD JUL 7
PY 2017
VL 12
IS 7
AR e0180586
DI 10.1371/journal.pone.0180586
PG 14
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA FA5DZ
UT WOS:000405464100078
PM 28686658
OA DOAJ Gold, Green Published
DA 2019-07-19
ER

PT J
AU Song, YS
   Joo, HW
   Park, IH
   Shen, GY
   Lee, Y
   Shin, JH
   Kim, H
   Kim, KS
AF Song, Yi-Sun
   Joo, Hyun-Woo
   Park, In-Hwa
   Shen, Guang-Yin
   Lee, Yonggu
   Shin, Jeong Hun
   Kim, Hyuck
   Kim, Kyung-Soo
TI Bone marrow mesenchymal stem cell-derived vascular endothelial growth
   factor attenuates cardiac apoptosis via regulation of cardiac miRNA-23a
   and miRNA-92a in a rat model of myocardial infarction
SO PLOS ONE
LA English
DT Article
ID ISCHEMIC-HEART; FUNCTIONAL IMPROVEMENT; MOUSE MODEL; TRANSPLANTATION;
   MICRORNAS; VEGF; CARDIOMYOCYTES; EXPRESSION; ANGIOGENESIS; MECHANISMS
AB Bone marrow-mesenchymal stem cell (BM-MSC) therapy improves the recovery of cardiac function after myocardial infarction (MI); however, the underlying molecular mechanisms are not completely understood. Recent studies have shown that microRNAs (miRNAs) modulate the pathophysiology of cardiovascular diseases. Here, we investigated the mechanisms underlying the effects of BM-MSC-derived paracrine factors and cardiac miRNAs on myocardial regeneration after MI. In our study, MI was induced by permanent ligation of the left anterior descending (LAD) coronary artery. BM-MSCs transplanted in infarcted rats significantly downregulated the expression of miRNA-23a and miRNA-92a and inhibited apoptosis in the myocardium. An in vitro experiment showed that supernatant from BM-MSCs cultured under hypoxia contained higher levels of vascular endothelial growth factor (VEGF) than that from BM-MSCs under normoxia. In addition, inhibition of miRNA-23a and miRNA-92a reduced cardiac apoptosis. Moreover, the VEGF-containing BM-MSC supernatant inhibited miRNA-23a and miRNA-92a expression and reduced apoptotic signaling in cardiomyocytes under hypoxia. These effects were inhibited when the supernatant was treated with neutralizing antibodies against VEGF. Our results indicate that the paracrine factor, VEGF, derived from transplanted BM-MSCs, regulated the expression of miRNAs such as miRNA-23a and miRNA-92a and exerted anti-apoptotic effects in cardiomyocytes after MI.
C1 [Song, Yi-Sun; Joo, Hyun-Woo; Park, In-Hwa; Kim, Kyung-Soo] Hanyang Univ, Grad Sch Biomed Sci & Engn, Seoul, South Korea.
   [Shen, Guang-Yin; Kim, Kyung-Soo] Hanyang Univ, Coll Med, Dept Internal Med, Seoul, South Korea.
   [Lee, Yonggu; Shin, Jeong Hun] Hanyang Univ, Guri Hosp, Dept Internal Med, Guri, South Korea.
   [Kim, Hyuck] Hanyang Univ, Coll Med, Dept Thorac & Cardiovasc Surg, Seoul, South Korea.
RP Kim, KS (reprint author), Hanyang Univ, Grad Sch Biomed Sci & Engn, Seoul, South Korea.
EM kskim@hanyang.ac.kr
RI Lee, Yonggu/Q-3832-2018
OI Lee, Yonggu/0000-0002-3757-3692
FU Basic Science Research Program through the National Research Foundation
   of Korea (NRF) - Ministry of Education [NRF-2015R1D1A1A02062008]
FX This research was supported by Basic Science Research Program through
   the National Research Foundation of Korea (NRF) funded by the Ministry
   of Education (NRF-2015R1D1A1A02062008).
CR Amado LC, 2005, P NATL ACAD SCI USA, V102, P11474, DOI 10.1073/pnas.0504388102
   Amsalem Y, 2007, CIRCULATION, V116, pI38, DOI 10.1161/CIRCULATIONAHA.106.680231
   Bonauer A, 2009, SCIENCE, V324, P1710, DOI 10.1126/science.1174381
   Bronnum H, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0056280
   Chen SL, 2004, AM J CARDIOL, V94, P92, DOI 10.1016/j.amjcard.2004.03.034
   Chhabra R, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005848
   Chou SH, 2014, CELL TRANSPLANT, V23, P513, DOI 10.3727/096368914X678436
   Clifford DM, 2012, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD006536.pub3
   Condorelli G, 2014, J AM COLL CARDIOL, V63, P2177, DOI 10.1016/j.jacc.2014.01.050
   Fang CH, 2012, CELL TRANSPLANT, V21, P1687, DOI 10.3727/096368912X653039
   Feygin J, 2007, AM J PHYSIOL-HEART C, V293, pH1772, DOI 10.1152/ajpheart.00242.2007.
   Frost RJA, 2010, J CARDIOVASC TRANSL, V3, P280, DOI 10.1007/s12265-010-9173-y
   Gnecchi M, 2005, NAT MED, V11, P367, DOI 10.1038/nm0405-367
   Gnecchi M, 2006, FASEB J, V20, P661, DOI 10.1096/fj.05-5211com
   GOMEZ JP, 1994, PFLUG ARCH EUR J PHY, V428, P241, DOI 10.1007/BF00724503
   Gulyaeva LF, 2016, J TRANSL MED, V14, DOI 10.1186/s12967-016-0893-x
   Ha M, 2014, NAT REV MOL CELL BIO, V15, P509, DOI 10.1038/nrm3838
   Hare JM, 2009, J AM COLL CARDIOL, V54, P2277, DOI 10.1016/j.jacc.2009.06.055
   Hinkel R, 2013, CIRCULATION, V128, P1066, DOI 10.1161/CIRCULATIONAHA.113.001904
   Hodgkinson CP, 2016, CIRC RES, V118, P95, DOI 10.1161/CIRCRESAHA.115.305373
   Iekushi K, 2012, CIRCULATION, V125, P1765, DOI 10.1161/CIRCULATIONAHA.111.079699
   Imanishi Y, 2008, J MOL CELL CARDIOL, V44, P662, DOI 10.1016/j.yjmcc.2007.11.001
   Jin JY, 2009, EUR J HEART FAIL, V11, P147, DOI 10.1093/eurjhf/hfn017
   Karantalis V, 2015, CIRC RES, V116, P1413, DOI 10.1161/CIRCRESAHA.116.303614
   Katritsis DG, 2005, CATHETER CARDIO INTE, V65, P321, DOI 10.1002/ccd.20406
   Kilkenny C, 2012, VET CLIN PATH, V41, P27, DOI 10.1111/j.1939-165X.2012.00418.x
   Kishore R, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0060161
   Lee KM, 2012, BIOCHEM BIOPH RES CO, V428, P50, DOI 10.1016/j.bbrc.2012.09.145
   Liu LF, 2014, APOPTOSIS, V19, P19, DOI 10.1007/s10495-013-0899-2
   Markel TA, 2008, AM J PHYSIOL-HEART C, V295, pH2308, DOI 10.1152/ajpheart.00565.2008
   Marko SB, 2008, AM J PHYSIOL-HEART C, V294, pH2646, DOI 10.1152/ajpheart.00291.2008
   Matsubayashi K, 2003, CIRCULATION, V108, P219, DOI 10.1161/01.cir.0000087450.34497.9a
   Matsuura K, 2009, J CLIN INVEST, V119, P2204, DOI 10.1172/JCI37456
   Mazo M, 2008, EUR J HEART FAIL, V10, P454, DOI 10.1016/j.ejheart.2008.03.017
   Nagaya N, 2004, AM J PHYSIOL-HEART C, V287, pH2670, DOI 10.1152/ajpheart.01071.2003
   Neufeld G, 1999, FASEB J, V13, P9
   Nguyen BK, 2010, J CARDIOVASC TRANSL, V3, P547, DOI 10.1007/s12265-010-9171-0
   Papageorgiou N, 2012, CURR MED CHEM, V19, P2605, DOI 10.2174/092986712800493048
   Patten RD, 1998, AM J PHYSIOL-HEART C, V274, pH1812
   Port JD, 2011, PHYSIOL GENOMICS, V43, P1087, DOI 10.1152/physiolgenomics.00074.2011
   Ren XP, 2009, CIRCULATION, V119, P2357, DOI 10.1161/CIRCULATIONAHA.108.814145
   Romaine SPR, 2015, HEART, V101, P921, DOI 10.1136/heartjnl-2013-305402
   Seideman J, 2002, J IMMUNOL METHODS, V267, P165, DOI 10.1016/S0022-1759(02)00168-0
   Shi B, 2010, BMC CARDIOVASC DISOR, V10, DOI 10.1186/1471-2261-10-11
   Shin JH, 2014, CARDIOVASC DRUG THER, V28, P211, DOI 10.1007/s10557-014-6519-8
   Song YS, 2014, CELL TRANSPLANT
   Takahashi M, 2006, AM J PHYSIOL-HEART C, V291, pH886, DOI 10.1152/ajpheart.00142.2006
   Tang YL, 2004, REGUL PEPTIDES, V117, P3, DOI 10.1016/j.regpep.2003.09.005
   Thygesen K, 2012, J AM COLL CARDIOL, V60, P1581, DOI 10.1016/j.jacc.2012.08.001
   Uemura R, 2006, CIRC RES, V98, P1414, DOI 10.1161/01.RES.0000225952.61196.39
   van Rooij E, 2008, P NATL ACAD SCI USA, V105, P13027, DOI 10.1073/pnas.0805038105
   van Rooij E, 2006, P NATL ACAD SCI USA, V103, P18255, DOI 10.1073/pnas.0608791103
   Vanlangenakker N, 2011, CELL DEATH DIFFER, V18, P656, DOI 10.1038/cdd.2010.138
   Weir C, 2008, HEART LUNG CIRC, V17, P395, DOI 10.1016/j.hlc.2008.01.006
   Zhang BS, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0100298
NR 55
TC 5
Z9 5
U1 1
U2 6
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD JUN 29
PY 2017
VL 12
IS 6
AR e0179972
DI 10.1371/journal.pone.0179972
PG 18
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA EZ3JX
UT WOS:000404608300083
PM 28662151
OA DOAJ Gold, Green Published
DA 2019-07-19
ER

PT J
AU Sartakhti, JS
   Manshaei, MH
   Basanta, D
   Sadeghi, M
AF Sartakhti, Javad Salimi
   Manshaei, Mohammad Hossein
   Basanta, David
   Sadeghi, Mehdi
TI Evolutionary emergence of angiogenesis in avascular tumors using a
   spatial public goods game
SO PLOS ONE
LA English
DT Article
ID COOPERATION; CANCER; DYNAMICS; NORMALIZATION; HETEROGENEITY;
   VASCULATURE; COMPETITION; MECHANISMS; RESISTANCE; DIFFUSION
AB Natural selection in cancer often results in the emergence of increasingly malignant tumor cells that display many if not all of the hallmarks of cancer. One of the most important traits acquired during cancer progression is angiogenesis. Tumor cells capable of secreting pro-angiogenic factors can be seen as cooperators where the improved oxygenation, nutrient delivery and waste disposal resulting from angiogenesis could be seen as a public good. Under this view, the relatively costly secretion of molecular signals required to orchestrate angiogenesis would be undertaken exclusively by cooperating tumor cells but the benefits of angiogenesis would be felt by neighboring tumor cells regardless of their contribution to the process. In this work we detail a mathematical model to better understand how clones capable of secreting pro-angiogenic factors can emerge in a tumor made of non-cooperative tumor cells. Given the importance of the spatial configuration of the tumor in determining the efficacy of the secretion of pro-angiogenic factors as well as the benefits of angiogenesis we have developed a spatial game theoretic approach where interactions and public good diffusion are described by graphs. The results show that structure of the population affects the evolutionary dynamics of the pro-angiogenic clone. Specifically, when the benefit of angiogenesis is represented by sigmoid function with regards to the number of pro-angiogenic clones then the probability of the coexistence of pro-angiogenic and angiogenesis-neutral clones increases. Our results demonstrate that pro-angiogenic clone equilibrates into clusters that appear from surrounding vascular tissues towards the center of tumor. These clusters appear notably less dense after anti-angiogenic therapy.
C1 [Sartakhti, Javad Salimi; Manshaei, Mohammad Hossein] Isfahan Univ Technol, Dept Elect & Comp Engn, Esfahan 8415683111, Iran.
   [Basanta, David] H Lee Moffitt Canc Ctr & Res Inst, Integrated Math Oncol, Tampa, FL 33612 USA.
   [Sadeghi, Mehdi] Natl Inst Genet Engn & Biotechnol, Tehran, Iran.
   [Sadeghi, Mehdi] Inst Res Fundamental Sci, Sch Biol Sci, Tehran, Iran.
RP Manshaei, MH (reprint author), Isfahan Univ Technol, Dept Elect & Comp Engn, Esfahan 8415683111, Iran.
EM manshaei@cc.iut.ac.ir
OI Basanta, David/0000-0002-8527-0776
CR Ahmad SA, 2002, SEMIN CANCER BIOL, V12, P105, DOI 10.1006/scbi.2001.0418
   Anderson ARA, 1998, B MATH BIOL, V60, P857, DOI 10.1006/bulm.1998.0042
   Archetti M, 2013, BRIT J CANCER, V109, P1056, DOI 10.1038/bjc.2013.336
   Archetti M, 2016, J THEOR BIOL, V396, P191, DOI 10.1016/j.jtbi.2016.02.027
   Archetti M, 2015, P NATL ACAD SCI USA, V112, P1833, DOI 10.1073/pnas.1414653112
   Archetti M, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0108526
   Archetti M, 2014, J THEOR BIOL, V341, P1, DOI 10.1016/j.jtbi.2013.09.017
   Axelrod R, 2006, P NATL ACAD SCI USA, V103, P13474, DOI 10.1073/pnas.0606053103
   Azam F, 2010, EUR J CANCER, V46, P1323, DOI 10.1016/j.ejca.2010.02.020
   Bach L.A., 2003, J THEORETICAL MED, V5, P47, DOI DOI 10.1080/10273660310001630443
   Bach LA, 2001, EUR J CANCER, V37, P2116, DOI 10.1016/S0959-8049(01)00246-5
   Bejan A, 2011, J APPL PHYS, V110, DOI 10.1063/1.3606555
   Bergers G, 2003, NAT REV CANCER, V3, P401, DOI 10.1038/nrc1093
   Bickel ST, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0091992
   Chen MH, 2016, PHYS LETT A, V380, P40, DOI 10.1016/j.physleta.2015.09.047
   Chen MH, 2015, APPL MATH COMPUT, V251, P192, DOI 10.1016/j.amc.2014.11.052
   Crowther M, 2001, J LEUKOCYTE BIOL, V70, P478
   Csikasz-Nagy A, 2013, SEMIN CANCER BIOL, V23, P293, DOI 10.1016/j.semcancer.2013.05.009
   Dobay A, 2014, J EVOLUTION BIOL, V27, P1869, DOI 10.1111/jeb.12437
   Eichhorn ME, 2007, LANGENBECK ARCH SURG, V392, P371, DOI 10.1007/s00423-007-0150-0
   Fang JS, 2008, SEMIN CANCER BIOL, V18, P330, DOI 10.1016/j.semcancer.2008.03.011
   Gibbs MN, 2000, IEEE T NEURAL NETWOR, V11, P1458, DOI 10.1109/72.883477
   GIMBRONE MA, 1976, JNCI-J NATL CANCER I, V56, P305, DOI 10.1093/jnci/56.2.305
   Goel S, 2011, PHYSIOL REV, V91, P1071, DOI 10.1152/physrev.00038.2010
   Goymer P, 2008, NATURE, V454, P1047, DOI 10.1038/4541046a
   Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013
   Hermann PC, 2010, SEMIN CANCER BIOL, V20, P77, DOI 10.1016/j.semcancer.2010.03.004
   Hofbauer J., 1998, EVOLUTIONARY GAMES P
   Jain RK, 2005, SCIENCE, V307, P58, DOI 10.1126/science.1104819
   Jana BK, 2010, IMPACT OF CLIMATE CHANGE ON NATURAL RESOURCE MANAGEMENT, P1, DOI 10.1007/978-90-481-3581-3
   JOUANNEAU J, 1994, P NATL ACAD SCI USA, V91, P286, DOI 10.1073/pnas.91.1.286
   Julou T, 2013, P NATL ACAD SCI USA, V110, P12577, DOI 10.1073/pnas.1301428110
   Krock Bryan L, 2011, Genes Cancer, V2, P1117, DOI 10.1177/1947601911423654
   Kunz Manfred, 2003, Mol Cancer, V2, P23, DOI 10.1186/1476-4598-2-23
   Merlo LMF, 2006, NAT REV CANCER, V6, P924, DOI 10.1038/nrc2013
   Morikawa S, 2002, AM J PATHOL, V160, P985, DOI 10.1016/S0002-9440(10)64920-6
   Nadell CD, 2010, PLOS COMPUT BIOL, V6, DOI 10.1371/journal.pcbi.1000716
   Nagy JD, 2004, B MATH BIOL, V66, P663, DOI 10.1016/j.bulm.2003.10.001
   Nagy JD, 2012, MATH BIOSCI ENG, V9, P843, DOI 10.3934/mbe.2012.9.843
   Neufeld G, 1999, FASEB J, V13, P9
   NOWELL PC, 1976, SCIENCE, V194, P23, DOI 10.1126/science.959840
   Sartakhti JS, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0168856
   Shoham Yoav, 2008, MULTIAGENT SYSTEMS A
   Spencer SL, 2006, PLOS COMPUT BIOL, V2, P939, DOI 10.1371/journal.pcbi.0020108
   Tarnita CE, 2009, P NATL ACAD SCI USA, V106, P8601, DOI 10.1073/pnas.0903019106
   Tomlinson IPM, 1997, BRIT J CANCER, V75, P157, DOI 10.1038/bjc.1997.26
   Tonini T, 2003, ONCOGENE, V22, P6549, DOI 10.1038/sj.onc.1206816
   Vasudev NS, 2014, ANGIOGENESIS, V17, P471, DOI 10.1007/s10456-014-9420-y
   Veikkola T, 1999, SEMIN CANCER BIOL, V9, P211, DOI 10.1006/scbi.1998.0091
   Willett CG, 2004, NAT MED, V10, P145, DOI 10.1038/nm988
   Ziyad Safiyyah, 2011, Genes Cancer, V2, P1085, DOI 10.1177/1947601911432334
   Zong WX, 2006, GENE DEV, V20, P1, DOI 10.1101/gad.1376506
NR 52
TC 1
Z9 1
U1 0
U2 2
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD APR 11
PY 2017
VL 12
IS 4
AR e0175063
DI 10.1371/journal.pone.0175063
PG 17
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA ET0JS
UT WOS:000399949000018
PM 28399181
OA DOAJ Gold, Green Published
DA 2019-07-19
ER

PT J
AU Liu, SL
   Lin, HX
   Qiu, F
   Zhang, WJ
   Niu, CH
   Wen, W
   Sun, XQ
   Ye, LP
   Wu, XQ
   Lin, CY
   Song, LB
   Guo, L
AF Liu, Sai-Lan
   Lin, Huan-Xin
   Qiu, Fang
   Zhang, Wei-Jing
   Niu, Chun-Hao
   Wen, Wen
   Sun, Xiao-Qing
   Ye, Li-Ping
   Wu, Xian-Qiu
   Lin, Chu-Yong
   Song, Li-Bing
   Guo, Ling
TI Overexpression of Kinesin Family Member 20A Correlates with Disease
   Progression and Poor Prognosis in Human Nasopharyngeal Cancer: A
   Retrospective Analysis of 105 Patients
SO PLOS ONE
LA English
DT Article
ID INTENSITY-MODULATED RADIOTHERAPY; III RANDOMIZED-TRIAL; PHASE-III;
   CONCURRENT CHEMORADIOTHERAPY; PANCREATIC-CANCER; FREE SURVIVAL;
   CARCINOMA; GROWTH; TUMOR; LYMPHANGIOGENESIS
AB Background
   Numerous studies have shown Kinesin family member 20A (KIF20A) may play a critical role in the development and progression of cancer. However, the clinical value of KIF20A in nasopharyngeal carcinoma (NPC) is unknown. Here, we investigated the expression pattern of KIF20A in NPC and its correlation with clinicopathological features of patients.
   Methods
   Real-time PCR and Western blotting were used to quantify KIF20A expression in NPC cell lines and clinical specimens compared with normal controls. KIF20A protein expression was also examined in archived paraffin embedded tumor samples from 105 patients with pathologically confirmed NPC by immunohistochemistry (IHC). Statistical analyses were applied to assess the associations between KIF20A expression and the clinicopathological features and survival outcomes. Effects on migration and invasion were assessed by wound healing and transwell invasion assays after KIF20A silencing.
   Results
   KIF20A was significantly overexpressed at both the mRNA and protein levels in NPC cell lines and human tumor tissues. 45/105 (42.9%) of NPC specimens expressed high levels of KIF20A among the KIF20A detectable cases. Statistical analysis revealed that high KIF20A expression was significantly associated with gender (P = 0.046), clinical stage (P<0.001), T category (P = 0.022), N category (P<0.001), distant metastasis (P = 0.001) and vital status (P = 0.001). Moreover, Higher KIF20A expression patients had shorter overall survival (OS) and progression-free survival (PFS) (P = 0.001 and P = 0.001; log-rank test). In multivariate analysis, KIF20A was an independent prognostic factor for OS and PFS in the entire cohort (P = 0.033, P = 0.008). Knock down of KIF20A expression significantly suppressed NPC cell's migration and invasion.
   Conclusions
   KIF20A is overexpressed and may serve as an independent prognostic biomarker in NPC. Targeting KIF20A reduces migration and invasion of NPC cells.
C1 [Liu, Sai-Lan; Lin, Huan-Xin; Qiu, Fang; Zhang, Wei-Jing; Niu, Chun-Hao; Wen, Wen; Sun, Xiao-Qing; Ye, Li-Ping; Wu, Xian-Qiu; Lin, Chu-Yong; Song, Li-Bing; Guo, Ling] Sun Yat Sen Univ, Collaborat Innovat Ctr Canc Med, State Key Lab Oncol South China, Ctr Canc, Guangzhou, Guangdong, Peoples R China.
   [Liu, Sai-Lan; Qiu, Fang; Wen, Wen; Guo, Ling] Sun Yat Sen Univ, Ctr Canc, Dept Nasopharyngeal Carcinoma, Guangzhou, Guangdong, Peoples R China.
   [Lin, Huan-Xin; Sun, Xiao-Qing] Sun Yat Sen Univ, Ctr Canc, Dept Radiotherapy, Guangzhou, Guangdong, Peoples R China.
   [Zhang, Wei-Jing; Niu, Chun-Hao] Sun Yat Sen Univ, Ctr Canc, Dept Gynaecol Oncol, Guangzhou, Guangdong, Peoples R China.
RP Guo, L (reprint author), Sun Yat Sen Univ, Collaborat Innovat Ctr Canc Med, State Key Lab Oncol South China, Ctr Canc, Guangzhou, Guangdong, Peoples R China.; Guo, L (reprint author), Sun Yat Sen Univ, Ctr Canc, Dept Nasopharyngeal Carcinoma, Guangzhou, Guangdong, Peoples R China.
EM guoling@sysucc.org.cn
FU National Natural Science Foundation of China [81572848]; Sci-Tech
   Project Foundation of Guangdong Province, China [20126031800255];
   Guangzhou Science and Technology Planning Project China [2014J4100181]
FX This work was partly supported by the National Natural Science
   Foundation of China (No. 81572848), the Sci-Tech Project Foundation of
   Guangdong Province, China (No. 20126031800255), and the Guangzhou
   Science and Technology Planning Project China (No.2014J4100181). The
   funders had no role in study design, data collection and analysis,
   decision to publish, or preparation of the manuscript.
CR Al-Sarraf M, 1998, J CLIN ONCOL, V16, P1310, DOI 10.1200/JCO.1998.16.4.1310
   ALTUN M, 1995, INT J RADIAT ONCOL, V32, P859, DOI 10.1016/0360-3016(95)00516-2
   Cao Su-Mei, 2011, Chin J Cancer, V30, P114
   Chan ATC, 2002, J CLIN ONCOL, V20, P2038, DOI 10.1200/JCO.2002.08.149
   Chen QY, 2011, JNCI-J NATL CANCER I, V103, P1761, DOI 10.1093/jnci/djr432
   Chua MLK, 2016, LANCET, V387, P1012, DOI 10.1016/S0140-6736(15)00055-0
   Claerhout S, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0024662
   Ding ZC, 2012, CLIN DEV IMMUNOL, V2012, DOI DOI 10.1155/2012/890178
   Echard A, 1998, SCIENCE, V279, P580, DOI 10.1126/science.279.5350.580
   Exertier P, 2013, ONCOTARGET, V4, P2302, DOI 10.18632/oncotarget.1490
   Feng J, 2012, CELL SIGNAL, V24, P1116, DOI 10.1016/j.cellsig.2012.01.013
   Foo KF, 2002, ANN ONCOL, V13, P150, DOI 10.1093/annonc/mdf002
   Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9
   Hasegawa T, 2002, HUM PATHOL, V33, P111, DOI 10.1053/hupa.2002.30184
   Hirokawa N, 1998, CURR OPIN CELL BIOL, V10, P60, DOI 10.1016/S0955-0674(98)80087-2
   Ho JR, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0039469
   Imai K, 2011, BRIT J CANCER, V104, P300, DOI 10.1038/sj.bjc.6606052
   Kam MKM, 2003, INT J RADIAT ONCOL, V56, P145, DOI 10.1016/S0360-3016(03)00075-0
   Khongkow P, 2016, ONCOGENE, V35, P990, DOI 10.1038/onc.2015.152
   Kristensen CA, 2007, ACTA ONCOL, V46, P214, DOI 10.1080/02841860600635862
   Lai F, 2000, GENE, V248, P117, DOI 10.1016/S0378-1119(00)00135-9
   Lai SZ, 2011, INT J RADIAT ONCOL, V80, P661, DOI 10.1016/j.ijrobp.2010.03.024
   Lesterhuis WJ, 2011, NAT REV DRUG DISCOV, V10, P591, DOI 10.1038/nrd3500
   Lin JC, 2003, J CLIN ONCOL, V21, P631, DOI 10.1200/JCO.2003.06.158
   Liu LP, 2015, GUT, V64, P26, DOI 10.1136/gutjnl-2013-306388
   Neufeld G, 1999, FASEB J, V13, P9
   Perri F, 2011, WORLD J CLIN ONCOL, V2, P377, DOI 10.5306/wjco.v2.i12.377
   Rath O, 2012, NAT REV CANCER, V12, P527, DOI 10.1038/nrc3310
   Sakowicz R, 2004, CANCER RES, V64, P3276, DOI 10.1158/0008-5472.CAN-03-3839
   Shi C, 2016, ONCOTARGET, DOI 10.18632/oncotarget.8518.
   Shi DB, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0043898
   Stangel D, 2015, J SURG RES, V197, P91, DOI 10.1016/j.jss.2015.03.070
   Suarez C, 2010, EUR ARCH OTO-RHINO-L, V267, P1811, DOI 10.1007/s00405-010-1385-x
   Sugahara KN, 2010, SCIENCE, V328, P1031, DOI 10.1126/science.1183057
   Suzuki N, 2014, J IMMUNOTHER, V37, P36, DOI 10.1097/CJI.0000000000000012
   Tan EH, 1999, ANN ONCOL, V10, P235, DOI 10.1023/A:1008390929826
   Tomita Y, 2013, CLIN CANCER RES, V19, P4508, DOI 10.1158/1078-0432.CCR-13-0197
   Wakisaka N, 2012, ORAL ONCOL, V48, P703, DOI 10.1016/j.oraloncology.2012.02.003
   Walter S, 2012, NAT MED, V18, P1254, DOI 10.1038/nm.2883
   Wee Joseph Tien Seng, 2010, Chin J Cancer, V29, P517
   Wu Y, 2006, INT J CANCER, V119, P1519, DOI 10.1002/ijc.21865
   Yamashita J, 2012, ACTA DERM-VENEREOL, V92, P593, DOI 10.2340/00015555-1416
   Yu MC, 2002, SEMIN CANCER BIOL, V12, P421, DOI 10.1016/S1044-579X(02)00085-8
   Zhang MX, 2015, EUROPEAN J CANC
   Zou JX, 2014, MOL CANCER RES, V12, P539, DOI 10.1158/1541-7786.MCR-13-0459
NR 45
TC 10
Z9 10
U1 0
U2 11
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD JAN 12
PY 2017
VL 12
IS 1
AR e0169280
DI 10.1371/journal.pone.0169280
PG 18
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA EH7JQ
UT WOS:000391949500038
PM 28081138
OA DOAJ Gold, Green Published
DA 2019-07-19
ER

PT J
AU Vieira, AE
   Repeke, CE
   Ferreira, SD
   Colavite, PM
   Biguetti, CC
   Oliveira, RC
   Assis, GF
   Taga, R
   Trombone, APF
   Garlet, GP
AF Vieira, Andreia Espindola
   Repeke, Carlos Eduardo
   Ferreira Junior, Samuel de Barros
   Colavite, Priscila Maria
   Biguetti, Claudia Cristina
   Oliveira, Rodrigo Cardoso
   Assis, Gerson Francisco
   Taga, Rumio
   Favaro Trombone, Ana Paula
   Garlet, Gustavo Pompermaier
TI Intramembranous Bone Healing Process Subsequent to Tooth Extraction in
   Mice: Micro-Computed Tomography, Histomorphometric and Molecular
   Characterization
SO PLOS ONE
LA English
DT Article
ID MESENCHYMAL STEM-CELLS; EXPERIMENTAL PERIAPICAL LESIONS; ALVEOLAR BONE;
   OSTEOBLAST DIFFERENTIATION; MATRIX METALLOPROTEINASES; POLARIZATION
   METHOD; TISSUE DESTRUCTION; NECROSIS-FACTOR; IN-VITRO; REPAIR
AB Bone tissue has a significant potential for healing, which involves a significant the interplay between bone and immune cells. While fracture healing represents a useful model to investigate endochondral bone healing, intramembranous bone healing models are yet to be developed and characterized. In this study, a micro-computed tomography, histomorphometric and molecular (RealTimePCRarray) characterization of post tooth-extraction alveolar bone healing was performed on C57Bl/6 WT mice. After the initial clot dominance (0h), the development of a provisional immature granulation tissue is evident (7d), characterized by marked cell proliferation, angiogenesis and inflammatory cells infiltration; associated with peaks of growth factors (BMP-2-4-7, TGF beta 1, VEGFa), cytokines (TNF alpha, IL-10), chemokines & receptors (CXCL12, CCL25, CCR5, CXCR4), matrix (Col1a1-2, ITGA4, VTN, MMP1a) and MSCs (CD105, CD106, OCT4, NANOG, CD34, CD146) markers expression. Granulation tissue is sequentially replaced by more mature connective tissue (14d), characterized by inflammatory infiltrate reduction along the increased bone formation, marked expression of matrix remodeling enzymes (MMP-2-9), bone formation/maturation (RUNX2, ALP, DMP1, PHEX, SOST) markers, and chemokines & receptors associated with healing (CCL2, CCL17, CCR2). No evidences of cartilage cells or tissue were observed, strengthening the intramembranous nature of bone healing. Bone microarchitecture analysis supports the evolving healing, with total tissue and bone volumes as trabecular number and thickness showing a progressive increase over time. The extraction socket healing process is considered complete (21d) when the dental socket is filled by trabeculae bone with well-defined medullary canals; it being the expression of mature bone markers prevalent at this period. Our data confirms the intramembranous bone healing nature of the model used, revealing parallels between the gene expression profile and the histomorphometric events and the potential participation of MCSs and immune cells in the healing process, supporting the forthcoming application of the model for the better understanding of the bone healing process.
C1 [Vieira, Andreia Espindola; Repeke, Carlos Eduardo; Ferreira Junior, Samuel de Barros; Colavite, Priscila Maria; Biguetti, Claudia Cristina; Oliveira, Rodrigo Cardoso; Assis, Gerson Francisco; Taga, Rumio; Garlet, Gustavo Pompermaier] Univ Sao Paulo, Bauru Sch Dent, Dept Biol Sci, Bauru, SP, Brazil.
   [Favaro Trombone, Ana Paula] Univ Sagrado Coracao, Dept Biol & Allied Hlth Sci, Bauru, Brazil.
RP Garlet, GP (reprint author), Univ Sao Paulo, Bauru Sch Dent, Dept Biol Sci, Bauru, SP, Brazil.
EM garletgp@usp.br
RI Assis, Gerson/E-5871-2012; Biguetti, Claudia/F-5118-2012; Garlet, Ana
   Paula Trombone/N-9346-2013; Taga, Rumio/E-5794-2012; de Oliveira,
   Rodrigo Cardoso/E-2551-2012; Garlet, Gustavo Pompermaier/E-6762-2012
OI Garlet, Ana Paula Trombone/0000-0002-8102-6098; de Oliveira, Rodrigo
   Cardoso/0000-0003-3070-5960; Garlet, Gustavo
   Pompermaier/0000-0002-5071-8382; Vieira, Andreia
   Espindola/0000-0002-1344-1185
FU Sao Paulo Research Foundation (FAPESP) [09/11496-1, 10/15755-9];
   National Counsel of Technological and Scientific Development (CNPq)
   [470933/2011-9]
FX This study was supported by grants and scholarships from the Sao Paulo
   Research Foundation (FAPESP) (#09/11496-1 and #10/15755-9) and the
   National Counsel of Technological and Scientific Development (CNPq)
   (#470933/2011-9). The funders had no role in the study design, data
   collection and analysis, decision to publish, or preparation of the
   manuscript.
CR Accorsi-Mendonca T, 2008, J MOL HISTOL, V39, P201, DOI 10.1007/s10735-007-9152-z
   Ai-Aql ZS, 2008, J DENT RES, V87, P107, DOI 10.1177/154405910808700215
   AMLER MH, 1969, ORAL SURG ORAL MED O, V27, P309, DOI 10.1016/0030-4220(69)90357-0
   Araujo-Pires AC, 2015, J BONE MINER RES, V30, P400, DOI 10.1002/jbmr.2376
   Araujo-Pires AC, 2014, J ENDODONT, V40, P1560, DOI 10.1016/j.joen.2014.02.012
   Bais MV, 2009, BONE, V45, P254, DOI 10.1016/j.bone.2009.04.239
   Bandyopadhyay A, 2006, PLOS GENET, V2, P2116, DOI 10.1371/journal.pgen.0020216
   BENJAMINI Y, 1995, J R STAT SOC B, V57, P289
   Berendsen AD, 2014, MATRIX BIOL, V35, P223, DOI 10.1016/j.matbio.2013.12.004
   Bonewald LF, 2011, J BONE MINER RES, V26, P229, DOI 10.1002/jbmr.320
   Bossini PS, 2012, EXP GERONTOL, V47, P136, DOI 10.1016/j.exger.2011.11.005
   Bouxsein ML, 2010, J BONE MINER RES, V25, P1468, DOI 10.1002/jbmr.141
   Caetano-Lopes J, 2009, AUTOIMMUN REV, V8, P250, DOI 10.1016/j.autrev.2008.07.038
   Campos K, 2015, J ENDODONT, V41, P212, DOI 10.1016/j.joen.2014.10.003
   Carano RAD, 2003, DRUG DISCOV TODAY, V8, P980, DOI 10.1016/S1359-6446(03)02866-6
   Cardaropoli G, 2003, J CLIN PERIODONTOL, V30, P809, DOI 10.1034/j.1600-051X.2003.00366.x
   Cardoso CL, 2011, ACTA CIR BRAS, V26, P365, DOI 10.1590/S0102-86502011000500007
   Chamberlain G, 2007, STEM CELLS, V25, P2739, DOI 10.1634/stemcells.2007-0197
   Claudino M, 2010, EUR J ORAL SCI, V118, P19, DOI 10.1111/j.1600-0722.2009.00706.x
   Clover AJP, 2011, BURNS, V37, P1386, DOI 10.1016/j.burns.2011.08.001
   Coleman R, 2011, ACTA HISTOCHEM, V113, P231, DOI 10.1016/j.acthis.2010.02.002
   Dai J, 2007, J DENT RES, V86, P937, DOI 10.1177/154405910708601006
   Dallas SL, 2013, ENDOCR REV, V34, P658, DOI 10.1210/er.2012-1026
   Taddei SRD, 2012, AM J ORTHOD DENTOFAC, V141, P153, DOI 10.1016/j.ajodo.2011.07.019
   Devlin H, 1997, J BONE MINER RES, V12, P2061, DOI 10.1359/jbmr.1997.12.12.2061
   Dimitriou R, 2005, INJURY, V36, P1392, DOI 10.1016/j.injury.2005.07.019
   Discepoli N, 2013, J CLIN PERIODONTOL, V40, P638, DOI 10.1111/jcpe.12074
   Einhorn TA, 2015, NAT REV RHEUMATOL, V11, P45, DOI 10.1038/nrrheum.2014.164
   Eming SA, 2009, SEMIN CELL DEV BIOL, V20, P517, DOI 10.1016/j.semcdb.2009.04.009
   Aranha AMF, 2013, J ENDODONT, V39, P83, DOI 10.1016/j.joen.2012.10.015
   Ferreira SB, 2011, J DENT RES, V90, P632, DOI 10.1177/0022034510395021
   Franceschi RT, 2003, CONNECT TISSUE RES, V44, P109, DOI 10.1080/03008200390152188
   Garavello-Freltas I, 2003, J PHOTOCH PHOTOBIO B, V70, P81, DOI 10.1016/S1011-1344(03)00058-7
   Garlet GP, 2007, CLIN EXP IMMUNOL, V147, P128, DOI 10.1111/j.1365-2249.2006.03260.x
   Garlet GP, 2014, J DENT RES, V93, P834, DOI 10.1177/0022034514544300
   Garlet GP, 2010, J DENT RES, V89, P1349, DOI 10.1177/0022034510376402
   Garlet GP, 2013, J APPL ORAL SCI, V21, P98, DOI [10.1590/1678-77572013ed002, 10.1590/1678-77572013ed004]
   Garlet GP, 2012, J ENDODONT, V38, P185, DOI 10.1016/j.joen.2011.09.011
   Garlet TP, 2010, J ENDODONT, V36, P244, DOI 10.1016/j.joen.2009.09.004
   Glowacki AJ, 2013, P NATL ACAD SCI USA, V110, P18525, DOI 10.1073/pnas.1302829110
   Goodman SC, 2014, J ENDODONT, V40, P830, DOI 10.1016/j.joen.2013.10.021
   Graves Dana T, 2011, J Oral Microbiol, V3, DOI 10.3402/jom.v3i0.5304
   Hankenson KD, 2011, INJURY, V42, P556, DOI 10.1016/j.injury.2011.03.035
   Ishida Y, 2008, J IMMUNOL, V180, P569, DOI 10.4049/jimmunol.180.1.569
   Javed A, 2010, ORAL MAXIL SURG CLIN, V22, P283, DOI 10.1016/j.coms.2010.05.001
   JURGENS TM, 1990, PHARMACEUT RES, V7, P742, DOI 10.1023/A:1015871723330
   Kanczler JM, 2008, EUR CELLS MATER, V15, P100, DOI 10.22203/eCM.v015a08
   Kanyama M, 2003, ARCH ORAL BIOL, V48, P723, DOI 10.1016/S0003-9969(03)00153-5
   Kato T, 2011, EXP DERMATOL, V20, P669, DOI 10.1111/j.1600-0625.2011.01286.x
   Knight MN, 2013, ADV WOUND CARE, V2, P306, DOI 10.1089/wound.2012.0420
   Konnecke I, 2014, BONE, V64, P155, DOI 10.1016/j.bone.2014.03.052
   Korpi JT, 2009, EUR J ORAL SCI, V117, P248, DOI 10.1111/j.1600-0722.2009.00620.x
   Kuroshima S, 2013, J DENT RES, V92, P553, DOI 10.1177/0022034513487558
   Lalani Z, 2003, J ORAL MAXIL SURG, V61, P1061, DOI 10.1016/S0278-2391(03)00319-7
   Lattouf R, 2014, J HISTOCHEM CYTOCHEM, V62, P751, DOI 10.1369/0022155414545787
   Lee SH, 2008, BMB REP, V41, P495, DOI 10.5483/BMBRep.2008.41.7.495
   Lieberman JR, 2002, J BONE JOINT SURG AM, V84A, P1032, DOI 10.2106/00004623-200206000-00022
   Lin Z, 2011, J PERIODONTOL, V82, P1007, DOI 10.1902/jop.2010.100577
   Lorenzo J, 2005, IMMUNOL REV, V208, P5, DOI 10.1111/j.0105-2896.2005.00340.x
   Martin TJ, 2009, CRIT REV EUKAR GENE, V19, P73, DOI 10.1615/CritRevEukarGeneExpr.v19.i1.40
   McGrory K, 2004, BIOCHEM BIOPH RES CO, V324, P317, DOI 10.1016/j.bbrc.2004.09.056
   MONTES GS, 1991, MEM I OSWALDO CRUZ, V86, P1
   Morko J, 2009, BONE, V44, P717, DOI 10.1016/j.bone.2008.11.019
   Neufeld G, 1999, FASEB J, V13, P9
   Arantes RVN, 2015, J PERIODONTOL, V86, P162, DOI 10.1902/jop.2014.140259
   Ohira T, 2004, J DENT RES, V83, P546, DOI 10.1177/154405910408300707
   Okamoto T, 1990, Rev Odontol UNESP, V19, P63
   Page-McCaw A, 2007, NAT REV MOL CELL BIO, V8, P221, DOI 10.1038/nrm2125
   Pagni G, 2012, INT J DENT, DOI 10.1155/2012/151030
   Pereira NB, 2014, TOXICON, V84, P7, DOI 10.1016/j.toxicon.2014.03.003
   PIERARD GE, 1989, MATRIX, V9, P68, DOI 10.1016/S0934-8832(89)80021-6
   Pittenger MF, 1999, SCIENCE, V284, P143, DOI 10.1126/science.284.5411.143
   Repeke CE, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0022526
   Repeke CE, 2009, J CLIN PERIODONTOL, V36, P726, DOI 10.1111/j.1600-051X.2009.01447.x
   Sato H, 2007, CELLS TISSUES ORGANS, V186, P104, DOI 10.1159/000103513
   Scala A, 2014, CLIN ORAL IMPLAN RES, V25, P288, DOI 10.1111/clr.12148
   Schipani E, 2009, J BONE MINER RES, V24, P1347, DOI [10.1359/JBMR.090602, 10.1359/jbmr.090602]
   Schmidt-Bleek K, 2012, CELL TISSUE RES, V347, P567, DOI 10.1007/s00441-011-1205-7
   Sedgwick JD, 2000, IMMUNOL TODAY, V21, P110, DOI 10.1016/S0167-5699(99)01573-X
   Shah K, 2013, CURR OSTEOPOROS REP, V11, P130, DOI 10.1007/s11914-013-0146-3
   Sinha KM, 2013, J CELL BIOCHEM, V114, P975, DOI 10.1002/jcb.24439
   Sodek J, 2000, PERIODONTOL 2000, V24, P99, DOI 10.1034/j.1600-0757.2000.2240106.x
   Stover DA, 2011, MOL BIOL EVOL, V28, P533, DOI 10.1093/molbev/msq221
   Takayanagi H, 2005, J PERIODONTAL RES, V40, P287, DOI 10.1111/j.1600-0765.2005.00814.x
   Takayanagi H, 2007, NAT REV IMMUNOL, V7, P292, DOI 10.1038/nri2062
   Teofilo JM, 2011, IMPLANT DENT, V20, pE7, DOI 10.1097/ID.0b013e31820fbacf
   Thomas MV, 2011, J DENT RES, V90, P1052, DOI 10.1177/0022034510393967
   Ting K, 1999, AM J PATHOL, V155, P1993, DOI 10.1016/S0002-9440(10)65518-6
   TING K, 1993, J BONE MINER RES, V8, P1377
   Torisawa YS, 2014, NAT METHODS, V11, P663, DOI [10.1038/NMETH.2938, 10.1038/nmeth.2938]
   Trombelli L, 2008, J CLIN PERIODONTOL, V35, P630, DOI 10.1111/j.1600-051X.2008.01246.x
   Trombone AP, 2010, GENES IMMUN, V11, P479, DOI 10.1038/gene.2010.13
   Tsiridis E, 2007, INJURY, V38, pS11, DOI 10.1016/j.injury.2007.02.006
   Tsuji K, 2006, NAT GENET, V38, P1424, DOI 10.1038/ng1916
   Upton Z, 2008, J INVEST DERMATOL, V128, P1535, DOI 10.1038/sj.jid.5701148
   Vaday GG, 2001, J LEUKOCYTE BIOL, V69, P885
   Rodrigues MTV, 2011, J APPL ORAL SCI, V19, P260, DOI 10.1590/S1678-77572011000300015
   Vu TH, 2000, GENE DEV, V14, P2123, DOI 10.1101/gad.815400
   Wang X, 2013, INT ORTHOP, V37, P2491, DOI 10.1007/s00264-013-2059-2
   Wu YF, 2010, MATRIX BIOL, V29, P701, DOI 10.1016/j.matbio.2010.09.002
   Yang XH, 2014, CALCIFIED TISSUE INT, V94, P338, DOI 10.1007/s00223-013-9815-6
   Yugoshi Luciana Ibara, 2002, Braz. Dent. J., V13, P92, DOI 10.1590/S0103-64402002000200003
NR 102
TC 28
Z9 29
U1 1
U2 16
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD MAY 29
PY 2015
VL 10
IS 5
AR UNSP e0128021
DI 10.1371/journal.pone.0128021
PG 22
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA CJ2MQ
UT WOS:000355319400065
PM 26023920
OA DOAJ Gold, Green Published
DA 2019-07-19
ER

PT J
AU Qi, X
   Yuan, YH
   Xu, K
   Zhong, HS
   Zhang, Z
   Zhai, H
   Guan, GF
   Yu, GB
AF Qi, Xun
   Yuan, Yonghui
   Xu, Ke
   Zhong, Hongshan
   Zhang, Zhen
   Zhai, Huan
   Guan, Gefei
   Yu, Guibo
TI (2-Hydroxypropyl)-beta-Cyclodextrin Is a New Angiogenic Molecule for
   Therapeutic Angiogenesis
SO PLOS ONE
LA English
DT Article
ID PERIPHERAL ARTERIAL-DISEASE; NITRIC-OXIDE; ENDOTHELIAL-CELL;
   GENE-THERAPY; BLOOD-FLOW; STEM-CELL; IN-VITRO; PROLIFERATION; PDGF;
   ANGIOPOIETIN-1
AB Background
   Peripheral artery disease (PAD), which is caused by atherosclerosis, results in progressive narrowing and occlusion of the peripheral arteries and inhibits blood flow to the lower extremities. Therapeutic angiogenesis is a promising strategy for treating ischemia caused by PAD. Nitric oxide (NO) has been shown to be a key mediator of angiogenesis. It has been demonstrated that beta-cyclodextrincan stimulate vessel growth in rabbit corneas. In this study, we assessed the mechanism of action and therapeutic potential of a new angiogenic molecule, (2-hydroxypropyl)-beta-cyclodextrin (2HP-beta-CD).
   Methods and Results
   2HP-beta-CD significantly increased vascular endothelial growth factor A (VEGF-A) and platelet- derived growth factor BB (PDGF-BB) peptides in human umbilical vein endothelial cells (HUVECs) and also increased basic fibroblast growth factor (bFGF) peptide in human aortic smooth muscle cells (HASMCs). 2HP-beta-CD stimulated both proliferation and migration of HUVECs in an endothelial nitric oxide synthase (eNOS)/NO-dependent manner, whereas NO was found to be involved in proliferation, but not migration, of HASMCs. In a unilateral hindlimb ischemia model in mice, 2HP-beta-CD injections not only promoted blood flow recovery and increased microvessel densities in ischemic muscle, but also promoted coverage of the vessels with smooth muscle cells, thus stabilizing the vessels. Administration of 2HP-beta CD increased the expression of several angiogenic factors, including VEGF-A, PDGF-BB and transforming growth factor beta-1 (TGF-beta 1) in ischemic muscle. Injections of 2HP-beta CD also stimulated protein kinase B and extracellular regulated protein kinases (ERK), leading to an increase in phosphorylation of eNOS in ischemic muscle. Treatment with the NOS inhibitor, N omega-nitro-L-arginine methyl ester (L-NAME), showed that stimulation of blood flow induced by 2HP-beta-CD was partially dependent on NO.
   Conclusions
   Therapeutic angiogenesis by 2HP-beta-CD may be beneficial to patients with PAD.
C1 [Qi, Xun; Xu, Ke; Zhong, Hongshan; Zhai, Huan; Yu, Guibo] China Med Univ, Affiliated Hosp 1, Dept Radiol, Shenyang 110001, Peoples R China.
   [Qi, Xun; Xu, Ke; Zhong, Hongshan; Zhai, Huan; Yu, Guibo] China Med Univ, Affiliated Hosp 1, Key Lab Diagnost Imaging & Intervent Radiol Liaon, Shenyang 110001, Peoples R China.
   [Yuan, Yonghui] Liaoning Canc Hosp & Inst, Hosp Infect Management Off, Shenyang, Peoples R China.
   [Zhang, Zhen] China Med Univ, Affiliated Hosp 1, Dept Ultrasound, Shenyang 110001, Peoples R China.
   [Guan, Gefei] China Med Univ, Affiliated Hosp 1, Dept Neurosurg, Shenyang 110001, Peoples R China.
RP Xu, K (reprint author), China Med Univ, Affiliated Hosp 1, Dept Radiol, Shenyang 110001, Peoples R China.
EM kexu@vip.sina.com; zhonghongshan@hotmail.com
FU National Natural Science Foundations of China [81201168, 81171443,
   81471809]; Science and Technology Plan Project of Liaoning Province
   [2013225086]; General Scientific Research Project from Education
   Department of Liaoning Province [L2012282]
FX This work was supported by the National Natural Science Foundations of
   China (Grant No. 81201168, 81171443 and 81471809)
   http://www.nsfc.gov.cn/, Science and Technology Plan Project of Liaoning
   Province (Grant No. 2013225086) http://www.lninfo.gov.cn/ and General
   Scientific Research Project from Education Department of Liaoning
   Province (Grant No. L2012282) http://www.lnen.cn/. The funders had no
   role in study design, data collection and analysis, decision to publish,
   or preparation of the manuscript.
CR Aranguren XL, 2009, J MOL MED, V87, P3, DOI 10.1007/s00109-008-0394-3
   BATTEGAY EJ, 1994, J CELL BIOL, V125, P917, DOI 10.1083/jcb.125.4.917
   Bouloumie A, 1999, CARDIOVASC RES, V41, P773, DOI 10.1016/S0008-6363(98)00228-4
   Carmeliet P, 2000, NAT MED, V6, P389, DOI 10.1038/74651
   Carmeliet P, 2003, NAT MED, V9, P653, DOI 10.1038/nm0603-653
   ENENSTEIN J, 1992, EXP CELL RES, V203, P499, DOI 10.1016/0014-4827(92)90028-7
   Epstein SE, 2001, CARDIOVASC RES, V49, P532, DOI 10.1016/S0008-6363(00)00217-0
   Fernandes DJ, 2004, BRIT J PHARMACOL, V142, P1182, DOI 10.1038/sj.bjp.0705809
   Ferrara N, 2005, NATURE, V438, P967, DOI 10.1038/nature04483
   FOLKMAN J, 1995, NAT MED, V1, P27, DOI 10.1038/nm0195-27
   FOLKMAN J, 1989, SCIENCE, V243, P1490, DOI 10.1126/science.2467380
   Goerges AL, 2004, J BIOL CHEM, V279, P2307, DOI 10.1074/jbc.M308482200
   Hellberg C, 2010, RECENT RESULTS CANC, V180, P103, DOI 10.1007/978-3-540-78281-0_7
   Hirsch AT, 2006, CIRCULATION, V113, pE463, DOI 10.1161/CIRCULATIONAHA.106.174526
   Hirsch AT, 2001, JAMA-J AM MED ASSOC, V286, P1317, DOI 10.1001/jama.286.11.1317
   HUANG PL, 1995, NATURE, V377, P239, DOI 10.1038/377239a0
   Iwaguro H, 2002, CIRCULATION, V105, P732, DOI 10.1161/hc0602.103673
   KECK PJ, 1989, SCIENCE, V246, P1309, DOI 10.1126/science.2479987
   Lawall H, 2010, THROMB HAEMOSTASIS, V103, P696, DOI 10.1160/TH09-10-0688
   Lee M, 2008, TISSUE ENG PT A, V14, P1395, DOI 10.1089/ten.tea.2007.0232
   Liddell Robert P, 2004, Tech Vasc Interv Radiol, V7, P40, DOI 10.1053/j.tvir.2004.01.002
   Losordo DW, 2004, CIRCULATION, V109, P2692, DOI 10.1161/01.CIR.0000128596.49339.05
   Losordo DW, 1998, CIRCULATION, V98, P2800, DOI 10.1161/01.CIR.98.25.2800
   Ma FX, 2005, HISTOL HISTOPATHOL, V20, P275, DOI 10.14670/HH-20.275
   Meijer WT, 1998, ARTERIOSCL THROM VAS, V18, P185, DOI 10.1161/01.ATV.18.2.185
   Michel JB, 1998, PATHOL BIOL, V46, P181
   Murohara T, 1998, J CLIN INVEST, V101, P2567, DOI 10.1172/JCI1560
   Neufeld G, 1999, FASEB J, V13, P9
   Nishishita T, 2004, J CELL BIOCHEM, V91, P584, DOI 10.1002/jcb.10718
   Norgren L, 2007, J VASC SURG, V45, pS5, DOI [10.1016/j.jvs.2006.12.037, 10.1016/j.ejvs.2006.09.024]
   Norrby K, 2006, APMIS, V114, P79, DOI 10.1111/j.1600-0463.2006.apm_235.x
   Obst M, 2004, J HYPERTENS, V22, P1889, DOI 10.1097/00004872-200410000-00010
   Ouma GO, 2013, ANGIOLOGY, V64, P466, DOI 10.1177/0003319712464514
   Qi X, 2010, EUR J PHARMACOL, V634, P121, DOI 10.1016/j.ejphar.2010.02.038
   Rissanen TT, 2001, EUR J CLIN INVEST, V31, P651, DOI 10.1046/j.1365-2362.2001.00864.x
   Rosen EM, 1997, CIBA F SYMP, V212, P215
   Rudic RD, 1998, J CLIN INVEST, V101, P731, DOI 10.1172/JCI1699
   Saddar S, 2013, CIRC RES, V112, P140, DOI 10.1161/CIRCRESAHA.112.280081
   Simons M, 2005, CIRCULATION, V111, P1556, DOI 10.1161/01.CIR.0000159345.00591.8F
   Strauss Laura, 2002, Pathology and Oncology Research, V8, P47
   Suri C, 1996, CELL, V87, P1171, DOI 10.1016/S0092-8674(00)81813-9
   Szejtli J, 1998, CHEM REV, V98, P1743, DOI 10.1021/cr970022c
   Takahashi T, 1999, NAT MED, V5, P434
   TAKESHITA S, 1994, J CLIN INVEST, V93, P662, DOI 10.1172/JCI117018
   Urano T, 2008, ARTERIOSCL THROM VAS, V28, P827, DOI 10.1161/ATVBAHA.107.149674
   Vinals F, 2001, MOL CELL BIOL, V21, P7218, DOI 10.1128/MCB.21.21.7218-7230.2001
   Weitz JI, 1996, CIRCULATION, V94, P3026, DOI 10.1161/01.CIR.94.11.3026
   YANG EY, 1990, J CELL BIOL, V111, P731, DOI 10.1083/jcb.111.2.731
   YANG YP, 1994, P NATL ACAD SCI USA, V91, P4407, DOI 10.1073/pnas.91.10.4407
   Zabner J, 1997, ADV DRUG DELIVER REV, V27, P17, DOI 10.1016/S0169-409X(97)00019-7
   Ziche M, 1997, J CLIN INVEST, V99, P2625, DOI 10.1172/JCI119451
NR 51
TC 7
Z9 7
U1 0
U2 14
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD MAY 5
PY 2015
VL 10
IS 5
AR UNSP e0125323
DI 10.1371/journal.pone.0125323
PG 16
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA CH3PT
UT WOS:000353943400029
PM 25944736
OA DOAJ Gold, Green Published
DA 2019-07-19
ER

PT J
AU Kim, HR
   Kim, KW
   Kim, BM
   Cho, ML
   Lee, SH
AF Kim, Hae-Rim
   Kim, Kyoung-Woon
   Kim, Bo-Mi
   Cho, Mi-La
   Lee, Sang-Heon
TI The Effect of Vascular Endothelial Growth Factor on Osteoclastogenesis
   in Rheumatoid Arthritis
SO PLOS ONE
LA English
DT Article
ID COLLAGEN-INDUCED ARTHRITIS; COLONY-STIMULATING FACTOR; SYNOVIAL
   FIBROBLASTS; BONE-RESORPTION; INHIBITORY FACTOR; KEY REGULATOR;
   T-LYMPHOCYTES; UP-REGULATION; FACTOR VEGF; CELLS
AB Vascular endothelial growth factor (VEGF) has angiogenic, inflammatory, and bone-destructive roles in rheumatoid arthritis (RA). We aimed to determine the unique role of VEGF in osteoclastogenesis in RA. VEGF-induced receptor activator of nuclear factor kappa B ligand (RANKL) expression was determined in RA synovial fibroblasts by real-time PCR, luciferase assays, and ELISA. Osteoclastogenesis in peripheral blood monocytes cultured with VEGF was assessed by determining the numbers of tartrate-resistant acid phosphatase (TRAP)-positive multinucleated cells. Synovial fluid RANKL was correlated with VEGF concentration in the RA patients. VEGF stimulated the expression of RANKL in RA synovial fibroblasts. The RANKL promoter activity was upregulated by VEGF in the synovial fibroblasts transfected with RANKL-reporter plasmids. The VEGF-induced RANKL expression was decreased by the inhibition of both VEGF receptors (VEGFR) 1 and 2, Src, protein kinase C (PKC) and p38 MAPK. VEGF induced osteoclast differentiation from monocytes in the absence of RANKL and this was decreased by the inhibition of VEGFR1 and 2, Src, PKC and p38 MAPK. On coculturing with VEGF-prestimulated RA synovial fibroblasts, the monocytes differentiated into osteoclasts, and the osteoclastogenesis decreased by inhibition of Src and PKC pathways. VEGF plays dual roles on osteoclastogenesis in RA: direct induction of osteoclastogenesis from the precursors and stimulation of RANKL production in synovial fibroblasts, which is mediated by Src and PKC pathways. The axis of VEGF and RANKL could be a potential therapeutic target for RA-associated bone destruction.
C1 [Kim, Hae-Rim; Lee, Sang-Heon] Konkuk Univ, Sch Med, Dept Rheumatol, Res Inst Med Sci, Seoul, South Korea.
   [Kim, Kyoung-Woon; Kim, Bo-Mi; Cho, Mi-La] Catholic Univ Korea, Conversant Res Consortium Immunol Dis, Seoul St Marys Hosp, Coll Med, Seoul, South Korea.
   [Kim, Kyoung-Woon; Kim, Bo-Mi; Cho, Mi-La] Catholic Univ Korea, Rheumatism Res Ctr, Catholic Res Inst Med Sci, Seoul, South Korea.
RP Cho, ML (reprint author), Catholic Univ Korea, Conversant Res Consortium Immunol Dis, Seoul St Marys Hosp, Coll Med, Seoul, South Korea.
EM iammila@catholic.ac.kr; shlee@kuh.ac.kr
FU National Research Foundation of Korea (NRF) - Ministry of Education,
   Science, and Technology [NRF-2010-0024198, NRF-2013R1A1A1008171]
FX This research was supported by the Basic Science Research Program
   through the National Research Foundation of Korea (NRF) funded by the
   Ministry of Education, Science, and Technology (NRF-2010-0024198 and
   NRF-2013R1A1A1008171). http://www.nrf.re.kr. The funders had no role in
   study design, data collection and analysis, decision to publish, or
   preparation of the manuscript.
CR Aldridge SE, 2005, BRIT J CANCER, V92, P1531, DOI 10.1038/sj.bjc.6602417
   ALTMAN R, 1986, ARTHRITIS RHEUM, V29, P1039, DOI 10.1002/art.1780290816
   ARNETT FC, 1988, ARTHRITIS RHEUM, V31, P315, DOI 10.1002/art.1780310302
   Brentano F, 2005, ARTHRITIS RHEUM-US, V52, P2656, DOI 10.1002/art.21273
   Cho CS, 2000, J IMMUNOL, V164, P5055, DOI 10.4049/jimmunol.164.10.5055
   Cho ML, 2006, IMMUNOL LETT, V105, P159, DOI [10.1016/j.imlet.2006.02.003, 10.1016/j.imlet.2005.10.020]
   Choi ST, 2009, CLIN RHEUMATOL, V28, P333, DOI 10.1007/s10067-008-1075-x
   De Bandt M, 2003, J IMMUNOL, V171, P4853, DOI 10.4049/jimmunol.171.9.4853
   Ferrara N, 2003, NAT MED, V9, P669, DOI 10.1038/nm0603-669
   FREEMAN MR, 1995, CANCER RES, V55, P4140
   Fujikawa Y, 1996, ANN RHEUM DIS, V55, P816, DOI 10.1136/ard.55.11.816
   Fujikawa Y, 2001, BONE, V28, P261, DOI 10.1016/S8756-3282(00)00453-1
   Garcia-Gomez A, 2013, INVEST NEW DRUG, V31, P200, DOI 10.1007/s10637-012-9845-3
   Gronthos S, 2007, TRENDS ENDOCRIN MET, V18, P108, DOI 10.1016/j.tem.2007.02.002
   Harada M, 1998, SCAND J RHEUMATOL, V27, P377
   HARRIS ED, 1990, NEW ENGL J MED, V322, P1277
   Ikeda M, 2000, J PATHOL, V191, P426
   Kasama T, 2000, CLIN EXP IMMUNOL, V121, P533, DOI 10.1046/j.1365-2249.2000.01272.x
   KELLGREN JH, 1957, ANN RHEUM DIS, V16, P494, DOI 10.1136/ard.16.4.494
   Kikuchi K, 1998, BRIT J DERMATOL, V139, P1049
   Kim HR, 2007, J RHEUMATOL, V34, P927
   Kim HR, 2014, ARTHRITIS RHEUMATOL, V66, P538, DOI 10.1002/art.38286
   Kim KW, 2007, ARTHRITIS RHEUM-US, V56, P1076, DOI 10.1002/art.22439
   Kim KW, 2012, ARTHRITIS RHEUM-US, V64, P1015, DOI 10.1002/art.33446
   Kim W, 2006, NY TIMES BK REV, P1
   Koch AE, 1998, ARTHRITIS RHEUM-US, V41, P951, DOI 10.1002/1529-0131(199806)41:6<951::AID-ART2>3.0.CO;2-D
   KOCH AE, 1994, J IMMUNOL, V152, P4149
   Kong YY, 1999, NATURE, V397, P315
   Konisti S, 2012, NAT REV RHEUMATOL, V8, P153, DOI 10.1038/nrrheum.2011.205
   Lee SS, 2001, CLIN EXP RHEUMATOL, V19, P321
   Lee TH, 2002, J BIOL CHEM, V277, P10445, DOI 10.1074/jbc.M107348200
   Marumo T, 1999, DIABETES, V48, P1131, DOI 10.2337/diabetes.48.5.1131
   McLaren J, 1996, J CLIN INVEST, V98, P482, DOI 10.1172/JCI118815
   Mould AW, 2003, ARTHRITIS RHEUM, V48, P2660, DOI 10.1002//art.11232
   Namiki A, 1995, J BIOL CHEM, V270, P31189, DOI 10.1074/jbc.270.52.31189
   Neufeld G, 1999, FASEB J, V13, P9
   Niida S, 1999, J EXP MED, V190, P293, DOI 10.1084/jem.190.2.293
   Oura H, 2003, BLOOD, V101, P560, DOI 10.1182/blood-2002-05-1516
   PERTOVAARA L, 1994, J BIOL CHEM, V269, P6271
   Ryu S, 2006, CLIN RHEUMATOL, V25, P16, DOI 10.1007/s10067-005-1081-1
   Sawano A, 2001, BLOOD, V97, P785, DOI 10.1182/blood.V97.3.785
   Szekanecz Zoltan, 2005, Current Drug Targets - Inflammation and Allergy, V4, P319, DOI 10.2174/1568010054022187
   Takahashi H, 2005, CLIN SCI, V109, P227, DOI 10.1042/CS20040370
   Tunyogi-Csapo M, 2008, ARTHRITIS RHEUM-US, V58, P2397, DOI 10.1002/art.23653
   Wu YL, 2005, ARTHRITIS RHEUM-US, V52, P3257, DOI 10.1002/art.21354
   Yang QL, 2008, MATRIX BIOL, V27, P589, DOI 10.1016/j.matbio.2008.06.005
   Yasuda H, 1998, P NATL ACAD SCI USA, V95, P3597, DOI 10.1073/pnas.95.7.3597
   Yoo SA, 2005, J IMMUNOL, V174, P5846, DOI 10.4049/jimmunol.174.9.5846
   Yoo SA, 2008, MEDIAT INFLAMM, DOI 10.1155/2008/129873
   Zhou JL, 2009, J ORTHOP SCI, V14, P313, DOI 10.1007/s00776-009-1329-8
NR 50
TC 14
Z9 16
U1 0
U2 6
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD APR 20
PY 2015
VL 10
IS 4
AR e0124909
DI 10.1371/journal.pone.0124909
PG 18
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA CG3XA
UT WOS:000353211700129
PM 25894998
OA DOAJ Gold, Green Published
DA 2019-07-19
ER

PT J
AU Christou, C
   Oliver, RA
   Yu, Y
   Walsh, WR
AF Christou, Chris
   Oliver, Rema A.
   Yu, Yan
   Walsh, William R.
TI The Masquelet Technique for Membrane Induction and the Healing of Ovine
   Critical Sized Segmental Defects
SO PLOS ONE
LA English
DT Article
ID BONE MORPHOGENETIC PROTEINS; ORTHOPEDIC TRAUMA SURGERY; MARROW STROMAL
   CELLS; GRAFT SUBSTITUTES; GROWTH-FACTORS; PARTICLE-SIZE; TGF-BETA;
   MODEL; RECONSTRUCTION; RECEPTORS
AB The healing of critical sized segmental defects is an ongoing clinical problem. No method has achieved pre-eminence. The Masquelet technique is a relatively new innovation involving the induction of a fibrous tissue membrane around the bone defect site taking advantage of the body's foreign body reaction to the presence of a polymethylmethacrylate (PMMA) spacer. The aim of this study was to investigate the properties and characteristics of this induced membrane and its effectiveness when used in conjunction with allograft or an allograft/autograft mix as filler materials in an ovine critical sized defect model. The resultant induced membrane was found to be effective in containing the graft materials in situ. It was demonstrated to be an organised pseudosynovial membrane which expressed bone morphogenic protein 2 (BMP2), transforming growth factor-beta (TGF beta), vascular endothelial growth factor (VEGF), von Willerbrand factor (vWF), interleukin 6 (IL-6) and interleukin 8 (IL-8). While more new bone growth was evident in the test groups compared to the controls animals at 12 weeks, the volumes were not statistically different and no defects were fully bridged. Of the two graft material groups, the allograft/autograft mix was shown to have a more rapid graft resorption rate than the allograft only group. While the Masquelet technique proved effective in producing a membrane to enclose graft materials, its ability to assist in the healing of critical sized segmental defects when compared to empty controls remained inconclusive.
C1 [Christou, Chris; Oliver, Rema A.; Yu, Yan; Walsh, William R.] Univ New South Wales Australia, Surg & Orthopaed Res Labs, Sydney, NSW, Australia.
RP Christou, C (reprint author), Univ New South Wales Australia, Surg & Orthopaed Res Labs, Sydney, NSW, Australia.
EM c.christou@unsw.edu.au
OI Christou, Chris/0000-0003-3231-0356; Walsh, William/0000-0002-5023-6148
CR Aho OM, 2013, J BONE JOINT SURG AM, V95A, P597, DOI 10.2106/JBJS.L.00310
   Antonova E, 2013, BMC MUSCULOSKEL DIS, V14, DOI 10.1186/1471-2474-14-42
   Argintar E, 2011, INJURY, V42, P730, DOI 10.1016/j.injury.2010.11.016
   Balaguer T, 2010, TISSUE ENG PT A, V16, P3495, DOI [10.1089/ten.tea.2010.0227, 10.1089/ten.TEA.2010.0227]
   Bishop GB, 2007, INT ORTHOP, V31, P721, DOI 10.1007/s00264-007-0424-8
   Carragee EJ, 2011, SPINE J, V11, P471, DOI 10.1016/j.spinee.2011.04.023
   CHARNLEY J, 1970, Journal of Bone and Joint Surgery British Volume, V52, P340
   Cobos JA, 2000, J ORTHOP TRAUMA, V14, P54, DOI 10.1097/00005131-200001000-00011
   De Long WG, 2007, J BONE JOINT SURG AM, V89A, P649, DOI 10.2106/JBJS.F.00465
   Deckers MML, 2000, ENDOCRINOLOGY, V141, P1667, DOI 10.1210/en.141.5.1667
   Dorozhkin SV, 2010, BIOMATERIALS, V31, P1465, DOI 10.1016/j.biomaterials.2009.11.050
   Edgar CM, 2007, BONE, V40, P1389, DOI 10.1016/j.bone.2007.01.001
   Farhadieh RD, 2004, J CRANIOFAC SURG, V15, P714, DOI 10.1097/00001665-200409000-00003
   Feghali Carol A., 1997, Frontiers in Bioscience (online), V2, pD12
   Ferrara N, 2003, NAT MED, V9, P669, DOI 10.1038/nm0603-669
   Finkemeier CG, 2002, J BONE JOINT SURG AM, V84A, P454, DOI 10.2106/00004623-200203000-00020
   Franchimont N, 2005, BONE, V37, P601, DOI 10.1016/j.bone.2005.06.002
   Gabay C, 2006, ARTHRITIS RES THER, V8, DOI 10.1186/ar1917
   Geiger F, 2007, BONE, V41, P516, DOI 10.1016/j.bone.2007.06.018
   Giannoudis PV, 2005, INJURY, V36, P20, DOI 10.1016/j.injury.2005.07.029
   GOLDRING SR, 1983, J BONE JOINT SURG AM, V65, P575, DOI 10.2106/00004623-198365050-00001
   Govender S, 2002, J BONE JOINT SURG AM, V84A, P2123, DOI 10.2106/00004623-200212000-00001
   Gruber HE, 2013, J ORTHOP TRAUMA, V27, P290, DOI 10.1097/BOT.0b013e3182691288
   Gugala Z, 2002, INJURY, V33, P71, DOI 10.1016/S0020-1383(02)00135-3
   Jin FC, 2013, CONNECT TISSUE RES, V54, P283, DOI 10.3109/03008207.2013.811499
   Malinin Theodore I, 2007, Open Orthop J, V1, P19, DOI 10.2174/1874325000701010019
   Masquelet A C, 2000, Ann Chir Plast Esthet, V45, P346
   Masquelet AC, 2003, LANGENBECK ARCH SURG, V388, P344, DOI 10.1007/s00423-003-0379-1
   Masquelet AC, 2010, ORTHOP CLIN N AM, V41, P27, DOI 10.1016/j.ocl.2009.07.011
   McAnulty RJ, 2007, INT J BIOCHEM CELL B, V39, P666, DOI 10.1016/j.biocel.2006.11.005
   Neufeld G, 1999, FASEB J, V13, P9
   Pallesen L, 2002, INT J ORAL MAX IMPL, V17, P498
   Pelissier P, 2004, J ORTHOPAED RES, V22, P73, DOI 10.1016/S0736-0266(03)00165-7
   Pluhar GE, 2006, J BONE JOINT SURG BR, V88B, P960, DOI 10.1302/0301-620X.88B7.17056
   Rabillard M, 2009, VET COMP ORTHOPAED, V22, P460, DOI 10.3415/VCOT-09-04-0048
   Russell N, 2013, BIOMATERIALS, V34, P8185, DOI 10.1016/j.biomaterials.2013.07.022
   Sporn MB, 2006, CYTOKINE GROWTH F R, V17, P3, DOI 10.1016/j.cytogfr.2005.09.012
   Stafford PR, 2010, INJURY, V41, pS72, DOI 10.1016/S0020-1383(10)70014-0
   Starke RD, 2011, BLOOD, V117, P1071, DOI 10.1182/blood-2010-01-264507
   Street J, 2002, P NATL ACAD SCI USA, V99, P9656, DOI 10.1073/pnas.152324099
   Szpalski Marek, 2005, Acta Orthop Belg, V71, P133
   Tate MLK, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0028702
   Taylor BC, 2012, J AM ACAD ORTHOP SUR, V20, P142, DOI 10.5435/JAAOS-20-03-142
   VAIL TB, 1994, VET SURG, V23, P386, DOI 10.1111/j.1532-950X.1994.tb00499.x
   Viateau V, 2006, VET SURG, V35, P445, DOI 10.1111/j.1532-950X.2006.00173.x
   Viateau V, 2010, ORTHOP CLIN N AM, V41, P49, DOI 10.1016/j.ocl.2009.07.010
   Wyatt LE, 1998, PLAST RECONSTR SURG, V102, P1922, DOI 10.1097/00006534-199811000-00017
   Yu Y, 2002, J BIOMED MATER RES, V60, P392, DOI 10.1002/jbm.1289
NR 48
TC 28
Z9 35
U1 2
U2 11
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD DEC 2
PY 2014
VL 9
IS 12
AR e114122
DI 10.1371/journal.pone.0114122
PG 19
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA AU8TQ
UT WOS:000345869700101
PM 25461340
OA DOAJ Gold, Green Published
DA 2019-07-19
ER

PT J
AU Mesti, T
   Savarin, P
   Triba, MN
   Le Moyec, L
   Ocvirk, J
   Banissi, C
   Carpentier, AF
AF Mesti, Tanja
   Savarin, Philippe
   Triba, Mohamed N.
   Le Moyec, Laurence
   Ocvirk, Janja
   Banissi, Claire
   Carpentier, Antoine F.
TI Metabolic Impact of Anti-Angiogenic Agents on U87 Glioma Cells
SO PLOS ONE
LA English
DT Article
ID MAGNETIC-RESONANCE-SPECTROSCOPY; GROWTH-FACTOR VEGF; IN-VIVO; H-1-NMR
   SPECTROSCOPY; MELANOMA-CELLS; GLIOBLASTOMA; THERAPY; BEVACIZUMAB;
   AUTOCRINE; INVASION
AB Background: Glioma cells not only secrete high levels of vascular endothelial growth factor (VEGF) but also express VEGF receptors (VEGFR), supporting the existence of an autocrine loop. The direct impact on glioma cells metabolism of drugs targeting the VEGF pathway, such as Bevacizumab (Bev) or VEGFR Tyrosine Kinase Inhibitor (TKI), is poorly known.
   Material and Methods: U87 cells were treated with Bev or SU1498, a selective VEGFR2 TKI. VEGFR expression was checked with FACS flow cytometry and Quantitative Real-Time PCR. VEGF secretion into the medium was assessed with an ELISA kit. Metabolomic studies on cells were performed using High Resolution Magic Angle Spinning Spectroscopy (HR-MAS).
   Results: U87 cells secreted VEGF and expressed low level of VEGFR2, but no detectable VEGFR1. Exposure to SU1498, but not Bev, significantly impacted cell proliferation and apoptosis. Metabolomic studies with HR MAS showed that Bev had no significant effect on cell metabolism, while SU1498 induced a marked increase in lipids and a decrease in glycerophosphocholine. Accordingly, accumulation of lipid droplets was seen in the cytoplasm of SU1498-treated U87 cells.
   Conclusion: Although both drugs target the VEGF pathway, only SU1498 showed a clear impact on cell proliferation, cell morphology and metabolism. Bevacizumab is thus less likely to modify glioma cells phenotype due to a direct therapeutic pressure on the VEGF autocrine loop. In patients treated with VEGFR TKI, monitoring lipids with magnetic resonance spectroscopic (MRS) might be a valuable marker to assess drug cytotoxicity.
C1 [Mesti, Tanja; Banissi, Claire] Univ Paris 05, Hop Europeen Georges Pompidou, Lab Rech Biochirurg, Paris, France.
   [Savarin, Philippe; Triba, Mohamed N.] Univ Paris 13, CNRS, UMR 7244, Bobigny, France.
   [Le Moyec, Laurence] Univ Evry, INSERM, U902, Unite Biol Integrat Adaptat Exercice, Evry, France.
   [Ocvirk, Janja] Inst Oncol Ljubljana, Div Med Oncol, Ljubljana, Slovenia.
   [Carpentier, Antoine F.] Univ Paris 13, Unite Format & Rech Sante Med & Biol Humaine, Bobigny, France.
   [Carpentier, Antoine F.] Hop Avicenne, AP HP, F-93009 Bobigny, France.
RP Carpentier, AF (reprint author), Univ Paris 13, Unite Format & Rech Sante Med & Biol Humaine, Bobigny, France.
EM antoine.carpentier@avc.aphp.fr
FU European Association for Neuro Oncology (EANO) fellowship; Association
   Oligocyte; EANO; Association pour le Developpement des Neurosciences a
   Avicenne (ADNA)
FX TM was the recipient of the 2012 European Association for Neuro Oncology
   (EANO) fellowship. The study was supported by the Association Oligocyte
   (assoligocyte.wordpress.com), the EANO (wwww.eano.eu), and the
   Association pour le Developpement des Neurosciences a Avicenne (ADNA).
   The funders had no role in study design, data collection and analysis,
   decision to publish, or preparation of the manuscript.
CR Adamcic U, 2012, NEOPLASIA, V14, P612, DOI 10.1593/neo.11948
   Batchelor TT, 2013, J CLIN ONCOL, V31, P3212, DOI 10.1200/JCO.2012.47.2464
   Batchelor TT, 2010, J CLIN ONCOL, V28, P2817, DOI 10.1200/JCO.2009.26.3988
   Beckonert O, 2007, NAT PROTOC, V2, P2692, DOI 10.1038/nprot.2007.376
   Chahal M, 2010, NEURO-ONCOLOGY, V12, P822, DOI 10.1093/neuonc/noq017
   Chamberlain MC, 2011, J NEURO-ONCOL, V101, P319, DOI 10.1007/s11060-010-0251-4
   Cloughesy T, 2010, LANCET ONCOL, V11, P1120, DOI 10.1016/S1470-2045(10)70269-2
   Cuperlovic-Culf M, 2010, DRUG DISCOV TODAY, V15, P610, DOI 10.1016/j.drudis.2010.06.012
   DELAGLIO F, 1995, J BIOMOL NMR, V6, P277, DOI 10.1007/BF00197809
   Delikatny EJ, 2002, CANCER RES, V62, P1394
   Francescone R, 2012, J BIOL CHEM, V287, P24821, DOI 10.1074/jbc.M111.334540
   Friedman HS, 2009, J CLIN ONCOL, V27, P4733, DOI 10.1200/JCO.2008.19.8721
   Grau S, 2011, J NEURO-ONCOL, V104, P103, DOI 10.1007/s11060-010-0480-6
   Griffin JL, 2006, ANAL CHEM, V78, P1546, DOI 10.1021/ac051418o
   Griffin JL, 2003, CANCER RES, V63, P3195
   Hamerlik P, 2012, J EXP MED, V209, P507, DOI 10.1084/jem.20111424
   Henriksson R, 2013, J CLIN ONCOL S
   Huang HG, 2005, NEUROL RES, V27, P371, DOI 10.1179/016164105X39833
   Jeon JY, 2012, AM J NEURORADIOL, V33, P2095, DOI 10.3174/ajnr.A3091
   Kaur B, 2005, NEURO-ONCOLOGY, V7, P134, DOI 10.1215/S1152851704001115
   Keunen O, 2011, P NATL ACAD SCI USA, V108, P3749, DOI 10.1073/pnas.1014480108
   Kim H, 2011, CANCER RES, V71, P3745, DOI 10.1158/0008-5472.CAN-10-2991
   Knizetova P, 2008, CELL CYCLE, V7, P2553, DOI 10.4161/cc.7.16.6442
   Kronthaler J, 2012, OMICS, V16, P90, DOI 10.1089/omi.2011.0048
   Kunkel P, 2001, CANCER RES, V61, P6624
   Law M, 2003, AM J NEURORADIOL, V24, P1989
   Lehtimaki KK, 2003, J BIOL CHEM, V278, P45915, DOI 10.1074/jc.M306209200
   Lucio-Eterovic AK, 2009, CLIN CANCER RES, V15, P4589, DOI 10.1158/1078-0432.CCR-09-0575
   Martinho O, 2013, TRANSL ONCOL, V6, P187, DOI 10.1593/tlo.12400
   Mentlein R, 2004, J NEURO-ONCOL, V67, P9, DOI 10.1023/B:NEON.0000021737.89357.cc
   Mirbahai L, 2012, NMR BIOMED, V25, P1253, DOI 10.1002/nbm.2796
   Morvan D, 2003, MAGNET RESON MED, V49, P241, DOI 10.1002/mrm.10368
   MOSMANN T, 1983, J IMMUNOL METHODS, V65, P55, DOI 10.1016/0022-1759(83)90303-4
   Neufeld G, 1999, FASEB J, V13, P9
   Paez-Ribes M, 2009, CANCER CELL, V15, P220, DOI 10.1016/j.ccr.2009.01.027
   Pan XY, 2013, METABOLOMICS, V9, P722, DOI 10.1007/s11306-012-0483-8
   Ratai EM, 2013, NEURO-ONCOLOGY, V15, P936, DOI 10.1093/neuonc/not044
   Reardon DA, 2011, J NATL COMPR CANC NE, V9, P414, DOI 10.6004/jnccn.2011.0038
   Robinson CJ, 2001, J CELL SCI, V114, P853
   Stupp R, 2005, NEW ENGL J MED, V352, P987, DOI 10.1056/NEJMoa043330
   Triba MN, 2010, NMR BIOMED, V23, P1009, DOI 10.1002/nbm.1516
   Trygg J, 2002, J CHEMOMETR, V16, P119, DOI 10.1002/cem.695
   Vink H, 2000, AM J PHYSIOL-HEART C, V278, pH285
   von Baumgarten L, 2011, CLIN CANCER RES, V17, P6192, DOI 10.1158/1078-0432.CCR-10-1868
   Wen PY, 2010, J CLIN ONCOL, V28, P1963, DOI 10.1200/JCO.2009.26.3541
   Wick A, 2011, ANN NEUROL, V69, P586, DOI 10.1002/ana.22336
   Xu CS, 2013, SCI WORLD J, DOI 10.1155/2013/417413
NR 47
TC 17
Z9 17
U1 1
U2 10
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD JUN 12
PY 2014
VL 9
IS 6
AR e99198
DI 10.1371/journal.pone.0099198
PG 11
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA AK8TP
UT WOS:000338701300044
PM 24922514
OA DOAJ Gold, Green Published
DA 2019-07-19
ER

PT J
AU Zeilbeck, LF
   Muller, B
   Knobloch, V
   Tamm, ER
   Ohlmann, A
AF Zeilbeck, Ludwig F.
   Mueller, Birgit
   Knobloch, Verena
   Tamm, Ernst R.
   Ohlmann, Andreas
TI Differential Angiogenic Properties of Lithium Chloride In Vitro and In
   Vivo
SO PLOS ONE
LA English
DT Article
ID ENDOTHELIAL GROWTH-FACTOR; GLYCOGEN-SYNTHASE KINASE-3;
   DIABETIC-RETINOPATHY; VASCULAR DEVELOPMENT; RETINAL VASCULATURE;
   SIGNALING PATHWAY; BIPOLAR DISORDER; BETA-CATENIN; FACTOR VEGF; NORRIN
AB Wnt/beta-catenin signaling induced by the Norrin/Frizzled-4 pathway has been shown to improve capillary repair following oxygen induced retinopathy (OIR) in the mouse, a model for retinopathy of prematurity. Here we investigated if treatment with the monovalent cation lithium that has been shown to augment Wnt/beta-catenin signaling in vitro and in vivo has similar effects. In cultured human microvascular endothelial cells, LiCl as well as SB 216763, another small molecule that activates Wnt/beta-catenin signaling, induced proliferation, survival and migration, which are all common parameters for angiogenic properties in vitro. Moreover, treatment with both agents caused an increase in the levels of beta-catenin and their translocation to nuclei while quercetin, an inhibitor of Wnt/b-catenin signaling, completely blocked the effects of LiCl on proliferation. In mice with OIR, intraperitonal or intravitreal treatment with LiCl markedly increased the retinal levels of beta-catenin, but did not improve capillary repair. In contrast, repair was significantly improved following intravitreal treatment with Norrin. The effects of LiCl on HDMEC in vitro have minor relevance for OIR in vivo, and the influence of the Norrin/Frizzled-4 pathway on capillary repair in OIR is not reproducible upon enhancing Wnt/beta-catenin signaling by LiCl treatment strongly indicating the presence of additional and essential mechanisms.
C1 [Zeilbeck, Ludwig F.; Mueller, Birgit; Knobloch, Verena; Tamm, Ernst R.; Ohlmann, Andreas] Univ Regensburg, Inst Human Anat & Embryol, D-93053 Regensburg, Germany.
RP Ohlmann, A (reprint author), Univ Regensburg, Inst Human Anat & Embryol, D-93053 Regensburg, Germany.
EM andreas.ohlmann@ur.de
RI ; Tamm, Ernst/G-4174-2016
OI Ohlmann, Andreas/0000-0002-7101-9361; Tamm, Ernst/0000-0002-6679-8743
FU Deutsche Forschungsgemeinschaft [FOR 1075, TP7]; PRO RETINA-Foundation
FX The study was supported by the Deutsche Forschungsgemeinschaft (Research
   Unit FOR 1075, TP7; URL: http://www.dfg.de/), and the PRO
   RETINA-Foundation (URL: http://www.pro-retina-stiftung.de/). The funders
   had no role in study design, data collection and analysis, decision to
   publish, or preparation of the manuscript.
CR Bain J, 2007, BIOCHEM J, V408, P297, DOI 10.1042/BJ20070797
   Bressler NM, 2011, NEW ENGL J MED, V365, P1520, DOI 10.1056/NEJMct0908432
   Chiu CT, 2013, PHARMACOL REV, V65, P105, DOI 10.1124/pr.111.005512
   Clifford RL, 2008, J BIOL CHEM, V283, P35337, DOI 10.1074/jbc.M803342200
   Coghlan MP, 2000, CHEM BIOL, V7, P793, DOI 10.1016/S1074-5521(00)00025-9
   Doble BW, 2003, J CELL SCI, V116, P1175, DOI 10.1242/jcs.00384
   Gould TD, 2004, NEUROPSYCHOPHARMACOL, V29, P32, DOI 10.1038/sj.npp.1300283
   Grimes CA, 2001, PROG NEUROBIOL, V65, P391, DOI 10.1016/S0301-0082(01)00011-9
   Guo SZ, 2009, STROKE, V40, P652, DOI 10.1161/STROKEAHA.108.524504
   Ho AC, 2012, OPHTHALMOLOGY, V119, P2179, DOI 10.1016/j.ophtha.2012.07.058
   Kaga S, 2006, J MOL CELL CARDIOL, V40, P138, DOI 10.1016/j.yjmcc.200509.009
   Kim WY, 2009, NAT NEUROSCI, V12, P1390, DOI 10.1038/nn.2408
   Kim YR, 2008, STROKE, V39, P439, DOI 10.1161/STROKEAHA.107.492215
   Klein PS, 1996, P NATL ACAD SCI USA, V93, P8455, DOI 10.1073/pnas.93.16.8455
   Marmol F, 2008, PROG NEURO-PSYCHOPH, V32, P1761, DOI 10.1016/j.pnpbp.2008.08.012
   Miller JW, 2013, OPHTHALMOLOGY, V120, P106, DOI 10.1016/j.ophtha.2012.07.038
   Neufeld G, 1999, FASEB J, V13, P9
   O'Brien WT, 2004, J NEUROSCI, V24, P6791, DOI 10.1523/JNEUROSCI.4753-03.2004
   Ohlmann A, 2005, J NEUROSCI, V25, P1701, DOI 10.1523/JNEUROSCI.4756-04.2005
   Ohlmann A, 2012, PROG RETIN EYE RES, V31, P243, DOI 10.1016/j.preteyeres.2012.02.002
   Ohlmann A, 2010, J NEUROSCI, V30, P183, DOI 10.1523/JNEUROSCI.3210-09.2010
   Park CH, 2005, BIOCHEM BIOPH RES CO, V328, P227, DOI 10.1016/j.bbrc.2004.12.151
   Phiel CJ, 2001, ANNU REV PHARMACOL, V41, P789, DOI 10.1146/annurev.pharmtox.41.1.789
   Resnikoff S, 2004, B WORLD HEALTH ORGAN, V82, P844
   Richter M, 1998, INVEST OPHTH VIS SCI, V39, P2450
   Seitz R, 2010, J NEUROSCI, V30, P5998, DOI 10.1523/JNEUROSCI.0730-10.2010
   Shibuya M, 2013, J BIOCHEM, V153, P13, DOI 10.1093/jb/mvs136
   SMITH LEH, 1994, INVEST OPHTH VIS SCI, V35, P101
   Stambolic V, 1996, CURR BIOL, V6, P1664, DOI 10.1016/S0960-9822(02)70790-2
   Staton CA, 2004, INT J EXP PATHOL, V85, P233, DOI 10.1111/j.0959-9673.2004.00396.x
   STONE J, 1995, J NEUROSCI, V15, P4738
   Tang J, 2011, PROG RETIN EYE RES, V30, P343, DOI 10.1016/j.preteyeres.2011.05.002
   Wada A, 2009, J PHARMACOL SCI, V110, P14, DOI 10.1254/jphs.09R02CR
   Wang H, 2010, BIOCHEM PHARMACOL, V80, P1386, DOI 10.1016/j.bcp.2010.07.034
   Wang YS, 2001, J NEUROSCI, V21, P4761, DOI 10.1523/JNEUROSCI.21-13-04761.2001
   Wirostko B, 2008, PROG RETIN EYE RES, V27, P608, DOI 10.1016/j.preteyeres.2008.09.002
   Xu Q, 2004, CELL, V116, P883, DOI 10.1016/S0092-8674(04)00216-8
   Ye X, 2010, TRENDS MOL MED, V16, P417, DOI 10.1016/j.molmed.2010.07.003
   Ye X, 2009, CELL, V139, P285, DOI 10.1016/j.cell.2009.07.047
NR 39
TC 5
Z9 5
U1 0
U2 7
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD APR 21
PY 2014
VL 9
IS 4
AR e95546
DI 10.1371/journal.pone.0095546
PG 11
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA AG2DX
UT WOS:000335227400071
PM 24751879
OA DOAJ Gold, Green Published
DA 2019-07-19
ER

PT J
AU Bickel, ST
   Juliano, JD
   Nagy, JD
AF Bickel, Scott T.
   Juliano, Joseph D.
   Nagy, John D.
TI Evolution of Proliferation and the Angiogenic Switch in Tumors with High
   Clonal Diversity
SO PLOS ONE
LA English
DT Article
ID ENDOTHELIAL GROWTH-FACTOR; CANCER; SELECTION; NECROSIS; VEGF; PDGF
AB Natural selection among tumor cell clones is thought to produce hallmark properties of malignancy. Efforts to understand evolution of one such hallmark-the angiogenic switch-has suggested that selection for angiogenesis can "run away'' and generate a hypertumor, a form of evolutionary suicide by extreme vascular hypo-or hyperplasia. This phenomenon is predicted by models of tumor angiogenesis studied with the techniques of adaptive dynamics. These techniques also predict that selection drives tumor proliferative potential towards an evolutionarily stable strategy (ESS) that is also convergence-stable. However, adaptive dynamics are predicated on two key assumptions: (i) no more than two distinct clones or evolutionary strategies can exist in the tumor at any given time; and (ii) mutations cause small phenotypic changes. Here we show, using a stochastic simulation, that relaxation of these assumptions has no effect on the predictions of adaptive dynamics in this case. In particular, selection drives proliferative potential towards, and angiogenic potential away from, their respective ESSs. However, these simulations also show that tumor behavior is highly contingent on mutational history, particularly for angiogenesis. Individual tumors frequently grow to lethal size before the evolutionary endpoint is approached. In fact, most tumor dynamics are predicted to be in the evolutionarily transient regime throughout their natural history, so that clinically, the ESS is often largely irrelevant. In addition, we show that clonal diversity as measured by the Shannon Information Index correlates with the speed of approach to the evolutionary endpoint. This observation dovetails with results showing that clonal diversity in Barrett's esophagus predicts progression to malignancy.
C1 [Bickel, Scott T.; Nagy, John D.] Scottsdale Community Coll, Dept Life Sci, Scottsdale, AZ 85256 USA.
   [Juliano, Joseph D.] Arizona State Univ, Dept Chem & Biochem, Tempe, AZ USA.
   [Nagy, John D.] Arizona State Univ, Sch Math & Stat Sci, Tempe, AZ USA.
RP Nagy, JD (reprint author), Scottsdale Community Coll, Dept Life Sci, Scottsdale, AZ 85256 USA.
EM jdnagy@asu.edu
FU Scottsdale Community College; Arizona State University's Barrett Honors
   College
FX This research is supported in part by Scottsdale Community College and
   Arizona State University's Barrett Honors College. The funders had no
   role in study design, data collection and analysis, decision to publish,
   or preparation of the manuscript.
CR Ataullakhanov FI, 2002, BIOSCIENCE REP, V22, P501, DOI 10.1023/A:1022069718709
   Baeriswyl V, 2009, SEMIN CANCER BIOL, V19, P329, DOI 10.1016/j.semcancer.2009.05.003
   Benjamin LE, 1998, DEVELOPMENT, V125, P1591
   Bergers G, 2003, NAT REV CANCER, V3, P401, DOI 10.1038/nrc1093
   Cairns RA, 2011, NAT REV CANCER, V11, P85, DOI 10.1038/nrc2981
   Colombo MP, 1996, AM J PATHOL, V148, P473
   Dieckmann U, 1997, TRENDS ECOL EVOL, V12, P128, DOI 10.1016/S0169-5347(97)01004-5
   Dunn IF, 2000, J NEURO-ONCOL, V50, P121, DOI 10.1023/A:1006436624862
   ESHEL I, 1981, THEOR POPUL BIOL, V19, P420, DOI 10.1016/0040-5809(81)90029-0
   Geritz SAH, 1998, EVOL ECOL, V12, P35, DOI 10.1023/A:1006554906681
   Greaves M, 2012, NATURE, V481, P306, DOI 10.1038/nature10762
   Hanahan D, 1996, CELL, V86, P353, DOI 10.1016/S0092-8674(00)80108-7
   Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9
   Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013
   Hardie DG, 1998, ANNU REV BIOCHEM, V67, P821, DOI 10.1146/annurev.biochem.67.1.821
   Hartl D. L., 2006, PRINCIPLES POPULATIO
   Holash J, 1999, SCIENCE, V284, P1994, DOI 10.1126/science.284.5422.1994
   Kaelin WG, 2008, MOL CELL, V30, P393, DOI 10.1016/j.molcel.2008.04.009
   KILBURN DG, 1969, J CELL SCI, V4, P645
   Kops GJPL, 2005, NAT REV CANCER, V5, P773, DOI 10.1038/nrc1714
   Lande R, 1996, OIKOS, V76, P5, DOI 10.2307/3545743
   Maley CC, 2006, NAT GENET, V38, P468, DOI 10.1038/ng1768
   Martinov MV, 2000, BBA-GEN SUBJECTS, V1474, P75, DOI 10.1016/S0304-4165(99)00218-4
   Merlo LMF, 2006, NAT REV CANCER, V6, P924, DOI 10.1038/nrc2013
   METZ JAJ, 1992, TRENDS ECOL EVOL, V7, P198, DOI 10.1016/0169-5347(92)90073-K
   Nagy JD, 2005, MATH BIOSCI ENG, V2, P381, DOI 10.3934/mbe.2005.2.381
   Nagy JD, 2004, B MATH BIOL, V66, P663, DOI 10.1016/j.bulm.2003.10.001
   Nagy JD, 2007, INTEGR COMP BIOL, V47, P317, DOI 10.1093/icb/icm062
   Nagy JD, 2012, MATH BIOSCI ENG, V9, P843, DOI 10.3934/mbe.2012.9.843
   Neufeld G, 1999, FASEB J, V13, P9
   Parvinen K, 2005, ACTA BIOTHEOR, V53, P241, DOI 10.1007/s10441-005-2531-5
   PLATE KH, 1992, NATURE, V359, P845, DOI 10.1038/359845a0
   Rong Y, 2006, J NEUROPATH EXP NEUR, V65, P529, DOI 10.1097/00005072-200606000-00001
   Shannon C. E., 1962, MATH THEORY COMMUNIC
   SMITH JM, 1973, NATURE, V246, P15, DOI 10.1038/246015a0
   Smith John Maynard, 1982, EVOLUTION THEORY GAM
   Upadhyay M, 2013, PHARMACOL THERAPEUT, V137, P318, DOI 10.1016/j.pharmthera.2012.11.003
   Vajkoczy P, 2002, J CLIN INVEST, V109, P777, DOI 10.1172/JCI200214105
   Vermeij GJ, 2006, P NATL ACAD SCI USA, V103, P1804, DOI 10.1073/pnas.0508724103
   Weinberg RA, 2007, BIOL CANC
NR 40
TC 5
Z9 6
U1 0
U2 6
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD APR 14
PY 2014
VL 9
IS 4
AR e91992
DI 10.1371/journal.pone.0091992
PG 13
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA AI6GP
UT WOS:000336970400001
PM 24732428
OA DOAJ Gold, Green Published
DA 2019-07-19
ER

PT J
AU Choi, HY
   Moon, SJ
   Ratliff, BB
   Ahn, SH
   Jung, A
   Lee, M
   Lee, S
   Lim, BJ
   Kim, BS
   Plotkin, MD
   Ha, SK
   Park, HC
AF Choi, Hoon Young
   Moon, Sung Jin
   Ratliff, Brian B.
   Ahn, Sun Hee
   Jung, Ara
   Lee, Mirae
   Lee, Seol
   Lim, Beom Jin
   Kim, Beom Seok
   Plotkin, Matthew D.
   Ha, Sung Kyu
   Park, Hyeong Cheon
TI Microparticles from Kidney-Derived Mesenchymal Stem Cells Act as
   Carriers of Proangiogenic Signals and Contribute to Recovery from Acute
   Kidney Injury
SO PLOS ONE
LA English
DT Article
ID MICROVASCULAR ENDOTHELIAL-CELLS; ISCHEMIA-REPERFUSION INJURY; ACUTE
   TUBULAR INJURY; UMBILICAL VEIN; MESSENGER-RNA; HORIZONTAL TRANSFER;
   STROMAL CELLS; GROWTH-FACTOR; PROTECT; ANGIOGENESIS
AB We recently demonstrated the use of in vitro expanded kidney-derived mesenchymal stem cells (KMSC) protected peritubular capillary endothelial cells in acute renal ischemia-reperfusion injury. Herein, we isolated and characterized microparticles (MPs) from KMSC. We investigated their in vitro biologic effects on human endothelial cells and in vivo renoprotective effects in acute ischemia-reperfusion renal injury. MPs were isolated from the supernatants of KMSC cultured in anoxic conditions in serum-deprived media for 24 hours. KMSC-derived MPs demonstrated the presence of several adhesion molecules normally expressed on KMSC membranes, such as CD29, CD44, CD73, alpha 4, 5, and 6 integrins. Quantitative real time PCR confirmed the presence of 3 splicing variants of VEGF-A (120, 164, 188), bFGF and IGF-1 in isolated MPs. MPs labeled with PKH26 red fluorescence dye were incorporated by cultured human umbilical vein endothelial cells (HUVEC) via surface molecules such as CD44, CD29, and alpha 4, 5, and 6 integrins. MP dose dependently improved in vitro HUVEC proliferation and promoted endothelial tube formation on growth factor reduced Matrigel. Moreover, apoptosis of human microvascular endothelial cell was inhibited by MPs. Administration of KMSC-derived MPs into mice with acute renal ischemia was followed by selective engraftment in ischemic kidneys and significant improvement in renal function. This was achieved by improving proliferation, of peritubular capillary endothelial cell and amelioration of peritubular microvascular rarefaction. Our results support the hypothesis that KMSC-derived MPs may act as a source of proangiogenic signals and confer renoprotective effects in ischemic kidneys.
C1 [Choi, Hoon Young; Ahn, Sun Hee; Jung, Ara; Lee, Mirae; Lee, Seol; Ha, Sung Kyu; Park, Hyeong Cheon] Gangnam Severance Hosp, Div Nephrol, Dept Internal Med, Seoul, South Korea.
   [Choi, Hoon Young; Park, Hyeong Cheon] Yonsei Univ, Coll Med, Severance Inst Vasc & Metab Res, Seoul, South Korea.
   [Moon, Sung Jin] Kwandong Univ, Coll Med, Dept Internal Med, Gangneung, *.
   [Ratliff, Brian B.; Plotkin, Matthew D.] New York Med Coll, Dept Med, Valhalla, NY 10595 USA.
   [Ratliff, Brian B.; Plotkin, Matthew D.] New York Med Coll, Dept Pharmacol, Valhalla, NY 10595 USA.
   [Ratliff, Brian B.; Plotkin, Matthew D.] New York Med Coll, Dept Physiol, Valhalla, NY 10595 USA.
   [Lim, Beom Jin] Yonsei Univ, Coll Med, Dept Pathol, Seoul, South Korea.
   [Kim, Beom Seok] Yonsei Univ, Coll Med, Dept Internal Med, Div Nephrol,Severance Hosp, Seoul, South Korea.
RP Park, HC (reprint author), Gangnam Severance Hosp, Div Nephrol, Dept Internal Med, Seoul, South Korea.
EM amp97@yuhs.ac
OI Lim, Beom Jin/0000-0003-2856-0133; Kim, Beom Seok/0000-0002-5732-2583;
   CHOI, HOON YOUNG/0000-0002-4245-0339; Park,
   Hyeong-Cheon/0000-0002-1550-0812
FU Basic Science Research Program through the National Research Foundation
   of Korea - Ministry of Education, Science, and Technology of the
   Republic of Korea [NRF-2010-0013373]; Yonsei University College of
   Medicine [6-2010-0044]
FX This research was supported by the Basic Science Research Program
   (NRF-2010-0013373) through the National Research Foundation of Korea
   funded by the Ministry of Education, Science, and Technology of the
   Republic of Korea and by the faculty research grant of Yonsei University
   College of Medicine in 2010 (No. 6-2010-0044). The funders had no role
   in study design, data collection and analysis, decision to publish, or
   preparation of the manuscript.
CR Arnaoutova I, 2010, NAT PROTOC, V5, P628, DOI 10.1038/nprot.2010.6
   Baj-Krzyworzeka M, 2006, CANCER IMMUNOL IMMUN, V55, P808, DOI 10.1007/s00262-005-0075-9
   Beck GC, 1999, CLIN EXP IMMUNOL, V118, P298
   Bi B, 2007, J AM SOC NEPHROL, V18, P2486, DOI 10.1681/ASN.2007020140
   Bruno S, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0033115
   Bruno S, 2009, J AM SOC NEPHROL, V20, P1053, DOI 10.1681/ASN.2008070798
   Camussi G, 2010, KIDNEY INT, V78, P838, DOI 10.1038/ki.2010.278
   Cantaluppi V, 2012, KIDNEY INT, V82, P412, DOI 10.1038/ki.2012.105
   Chen J, 2008, KIDNEY INT, V74, P879, DOI 10.1038/ki.2008.304
   Deregibus MC, 2007, BLOOD, V110, P2440, DOI 10.1182/blood-2007-03-078709
   Dib H, 2012, PROTEOMICS, V12, P2547, DOI 10.1002/pmic.201200060
   Gatti S, 2011, NEPHROL DIAL TRANSPL, V26, P1474, DOI 10.1093/ndt/gfr015
   Giordano A, 2007, J CELL PHYSIOL, V211, P27, DOI 10.1002/jcp.20959
   Kang DH, 2001, AM J PHYSIOL-RENAL, V280, pF727
   Kassem M, 2006, ANN NY ACAD SCI, V1067, P436, DOI 10.1196/annals.1354.062
   Morel O, 2004, CURR OPIN HEMATOL, V11, P156, DOI 10.1097/01.moh.0000131441.10020.87
   Nanobashvili J., 2003, EUR SURG, V35, P214
   Neufeld G, 1999, FASEB J, V13, P9
   Phinney DG, 2007, STEM CELLS, V25, P2896, DOI 10.1634/stemcells.2007-0637
   Plotkin MD, 2006, AM J PHYSIOL-RENAL, V291, pF902, DOI 10.1152/ajpreanal.00396.2005
   Ratajczak J, 2006, LEUKEMIA, V20, P847, DOI 10.1038/sj.leu.2404132
   Robert B, 2000, AM J PHYSIOL-RENAL, V279, pF275
   Salcedo R, 2000, FASEB J, V14, P2055, DOI 10.1096/fj.99-0963com
   Schorey JS, 2008, TRAFFIC, V9, P871, DOI 10.1111/j.1600-0854.2008.00734.x
   Togel F, 2005, AM J PHYSIOL-RENAL, V289, pF31, DOI 10.1152/ajprenal.00007.2005
   Togel F, 2007, AM J PHYSIOL-RENAL, V292, pF1626, DOI 10.1152/ajprenal.00339.2006
   Yamada K, 2004, J IMMUNOL, V172, P3869, DOI 10.4049/jimmunol.172.6.3869
   ZETTER BR, 1981, DIABETES, V30, P24, DOI 10.2337/diab.30.2.S24
   Zoja C, 2012, AM J PHYSIOL-RENAL, V303, pF1370, DOI 10.1152/ajprenal.00057.2012
NR 29
TC 24
Z9 25
U1 0
U2 5
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD FEB 4
PY 2014
VL 9
IS 2
AR e87853
DI 10.1371/journal.pone.0087853
PG 13
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA AI6GY
UT WOS:000336971300004
PM 24504266
OA DOAJ Gold, Green Published
DA 2019-07-19
ER

PT J
AU Pais, RS
   Moreno-Barriuso, N
   Hernandez-Porras, I
   Lopez, IP
   De Las Rivas, J
   Pichel, JG
AF Sofia Pais, Rosete
   Moreno-Barriuso, Nuria
   Hernandez-Porras, Isabel
   Paula Lopez, Iciar
   De Las Rivas, Javier
   Garcia Pichel, Jose
TI Transcriptome Analysis in Prenatal IGF1-Deficient Mice Identifies
   Molecular Pathways and Target Genes Involved in Distal Lung
   Differentiation
SO PLOS ONE
LA English
DT Article
ID GROWTH-FACTOR-I; MESSENGER-RNA EXPRESSION; CELL-PROLIFERATION; BRANCHING
   MORPHOGENESIS; BINDING-PROTEINS; MOUSE LUNG; IGF-I; BRONCHOPULMONARY
   DYSPLASIA; ALVEOLAR DEVELOPMENT; ENTERIC INNERVATION
AB Background: Insulin-like Growth Factor 1 (IGF1) is a multifunctional regulator of somatic growth and development throughout evolution. IGF1 signaling through IGF type 1 receptor (IGF1R) controls cell proliferation, survival and differentiation in multiple cell types. IGF1 deficiency in mice disrupts lung morphogenesis, causing altered prenatal pulmonary alveologenesis. Nevertheless, little is known about the cellular and molecular basis of IGF1 activity during lung development.
   Methods/Principal Findings: Prenatal Igf1(-/-) mutant mice with a C57Bl/6J genetic background displayed severe disproportional lung hypoplasia, leading to lethal neonatal respiratory distress. Immuno-histological analysis of their lungs showed a thickened mesenchyme, alterations in extracellular matrix deposition, thinner smooth muscles and dilated blood vessels, which indicated immature and delayed distal pulmonary organogenesis. Transcriptomic analysis of Igf1(-/-) E18.5 lungs using RNA microarrays identified deregulated genes related to vascularization, morphogenesis and cellular growth, and to MAP-kinase, Wnt and cell-adhesion pathways. Up-regulation of immunity-related genes was verified by an increase in inflammatory markers. Increased expression of Nfib and reduced expression of Klf2, Egr1 and Ctgf regulatory proteins as well as activation of ERK2 MAP-kinase were corroborated by Western blot. Among IGF-system genes only IGFBP2 revealed a reduction in mRNA expression in mutant lungs. Immuno-staining patterns for IGF1R and IGF2, similar in both genotypes, correlated to alterations found in specific cell compartments of Igf1(-/-) lungs. IGF1 addition to Igf1(-/-) embryonic lungs cultured ex vivo increased airway septa remodeling and distal epithelium maturation, processes accompanied by upregulation of Nfib and Klf2 transcription factors and Cyr61 matricellular protein.
   Conclusions/Significance: We demonstrated the functional tissue specific implication of IGF1 on fetal lung development in mice. Results revealed novel target genes and gene networks mediators of IGF1 action on pulmonary cellular proliferation, differentiation, adhesion and immunity, and on vascular and distal epithelium maturation during prenatal lung development.
C1 [Sofia Pais, Rosete; Paula Lopez, Iciar; Garcia Pichel, Jose] Fdn Rioja Salud, Ctr Invest Biomed Rioja, Logrono, Spain.
   [Moreno-Barriuso, Nuria; Hernandez-Porras, Isabel; De Las Rivas, Javier] Univ Salamanca, CSIC, Ctr Invest Canc, Inst Biol Mol & Celular Canc, E-37008 Salamanca, Spain.
RP Pichel, JG (reprint author), Fdn Rioja Salud, Ctr Invest Biomed Rioja, Logrono, Spain.
EM jgpichel@riojasalud.es
RI De Las Rivas, Javier/G-5936-2014
OI De Las Rivas, Javier/0000-0002-0984-9946; Pichel,
   Jose/0000-0001-8580-0952
FU Fundacion Rioja Salud (Logrono); Ministerio de Ciencia e Innovacion
   (Spain) [BFU200501437]
FX This work was partially supported by the Fundacion Rioja Salud (Logrono)
   and Ministerio de Ciencia e Innovacion (BFU200501437) (Spain). R. S. P.
   was a pre-doctoral fellow from Fundacion Rioja Salud, N.M.-B. was a
   doctoral fellow from the Ministerio de Ciencia e Innovacion and I.H.-P.
   was a JAE fellow from the Consejo Superior de Investigaciones
   Cientificas (Spain). The funders had no role in study design, data
   collection and analysis, decision to publish, or preparation of the
   manuscript.
CR Akram A, 2010, AM J RESP CRIT CARE, V182, P489, DOI 10.1164/rccm.200906-0925OC
   Al-Shahrour F, 2005, NUCLEIC ACIDS RES, V33, pW460, DOI 10.1093/nar/gki456
   Asaoka Y, 2010, J BIOCHEM, V148, P393, DOI 10.1093/jb/mvq098
   Baguma-Nibasheka M, 2008, DEV DYNAM, V237, P485, DOI 10.1002/dvdy.21433
   BAKER J, 1993, CELL, V75, P73, DOI 10.1016/S0092-8674(05)80085-6
   Banski P, 2010, J BIOL CHEM, V285, P21858, DOI 10.1074/jbc.M110.117291
   Berg K, 1996, BRIT J CANCER, V74, P688, DOI 10.1038/bjc.1996.423
   Bourbon J, 2005, PEDIATR RES, V57, p38R, DOI 10.1203/01.PDR.0000159630.35883.BE
   Brigstock DR, 2003, J ENDOCRINOL, V178, P169, DOI 10.1677/joe.0.1780169
   Camarero G, 2001, J NEUROSCI, V21, P7630
   Capoluongo E, 2008, CLIN CHEM LAB MED, V46, P1061, DOI 10.1515/CCLM.2008.211
   Carmona-Saez P, 2007, GENOME BIOL, V8, DOI 10.1186/gb-2007-8-1-r3
   Castellano E, 2007, ONCOGENE, V26, P917, DOI 10.1038/sj.onc.1209845
   Chen CC, 2009, INT J BIOCHEM CELL B, V41, P771, DOI 10.1016/j.biocel.2008.07.025
   CHEN JM, 1987, DEV BIOL, V120, P311, DOI 10.1016/0012-1606(87)90234-X
   Chen PP, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0000534
   Chen XN, 2006, P NATL ACAD SCI USA, V103, P11724, DOI 10.1073/pnas.0604946103
   Chetty A, 2004, PEDIATR PULM, V37, P128, DOI 10.1002/ppul.10415
   Chetty A, 2006, PEDIATR RES, V60, P389, DOI 10.1203/01.pdr.0000238257.15502.f4
   Chien W, 2006, MOL CANCER RES, V4, P591, DOI 10.1158/1541-7786.MCR.06-0029
   Chinoy MR, 2003, FRONT BIOSCI-LANDMRK, V8, pD392, DOI 10.2741/974
   COCCIA EM, 1992, MOL CELL BIOL, V12, P3514, DOI 10.1128/MCB.12.8.3514
   Compernolle V, 2002, NAT MED, V8, P702, DOI 10.1038/nm721
   Da Cruz S, 2003, J BIOL CHEM, V278, P41566, DOI 10.1074/jbc.M304940200
   Demidyuk IV, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0055752
   Dolinay T, 2006, PHYSIOL GENOMICS, V26, P68, DOI 10.1152/physiolgenomics.00110.2005
   Dooley AL, 2011, GENE DEV, V25, P1470, DOI 10.1101/gad.2046711
   Dupont J, 2001, ENDOCRINOLOGY, V142, P4969, DOI 10.1210/en.142.11.4969
   Epaud R, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0048071
   FLEMING TJ, 1993, J IMMUNOL, V151, P2399
   Frago LM, 2000, HISTOL HISTOPATHOL, V15, P657, DOI 10.14670/HH-15.657
   Fredriksson L, 2004, EMBO J, V23, P3793, DOI 10.1038/sj.emboj.7600397
   Ghosh MC, 2013, AM J PHYSIOL-LUNG C, V305, P1222, DOI 10.1152/ajplung.00014.2013
   Grunder A, 2002, MECH DEVELOP, V112, P69, DOI 10.1016/S0925-4773(01)00640-2
   Han RNN, 2003, AM J RESP CELL MOL, V28, P159, DOI 10.1165/rcmb.4764
   Hetzel M, 2005, LUNG, V183, P225, DOI 10.1007/s00408-004-2534-z
   Hsieh T, 2003, J BIOL CHEM, V278, P42886, DOI 10.1074/jbc.M303835200
   Hsu YC, 2011, DEV BIOL, V354, P242, DOI 10.1016/j.ydbio.2011.04.002
   Inanlou MR, 2005, DEV DYNAM, V233, P772, DOI 10.1002/dvdy.20381
   Irizarry RA, 2003, BIOSTATISTICS, V4, P249, DOI 10.1093/biostatistics/4.2.249
   Jiang Y, 2006, J CELL BIOCHEM, V98, P208, DOI 10.1002/jcb.20771
   Kang JH, 2004, EUR J BIOCHEM, V271, P2452, DOI 10.1111/j.1432-1033.2004.04175.x
   Kim HS, 1997, P NATL ACAD SCI USA, V94, P12981, DOI 10.1073/pnas.94.24.12981
   Kohno K, 2003, BIOESSAYS, V25, P691, DOI 10.1002/bies.10300
   Krein PM, 2002, CHEST, V122, p289S, DOI 10.1378/chest.122.6_suppl.289S
   Krop I, 2005, CANCER RES, V65, P9659, DOI 10.1158/0008-5472.CAN-05-1663
   Kruis T, 2010, J CLIN ENDOCR METAB, V95, P1137, DOI 10.1210/jc.2009-1433
   Lawan A, 2013, CELL MOL LIFE SCI, V70, P223, DOI 10.1007/s00018-012-1041-2
   Lebeche D, 1999, MECH DEVELOP, V86, P125, DOI 10.1016/S0925-4773(99)00124-0
   Lee GH, 2003, ONCOGENE, V22, P2374, DOI 10.1038/sj.onc.1206387
   Lee JH, 2001, AM J PHYSIOL-LUNG C, V280, pL1019
   Lee JI, 2003, J MOL BIOL, V328, P147, DOI 10.1016/S0022-2836(03)00237-7
   LeRoith D, 2003, CANCER LETT, V195, P127, DOI 10.1016/S0304-3835(03)00159-9
   LIU JP, 1993, CELL, V75, P59, DOI 10.1016/0092-8674(93)90679-K
   Liu Y, 2008, DEV BIOL, V314, P224, DOI 10.1016/j.ydbio.2007.12.003
   Lu D, 2007, BIOCHEM J, V401, P559, DOI 10.1042/BJ20061081
   Maeda Y, 2007, PHYSIOL REV, V87, P219, DOI 10.1152/physrev.00028.2006
   Matsumoto N, 2006, BLOOD, V107, P1357, DOI 10.1182/blood-2005-05-1916
   Mesas-Burgos C, 2009, J PEDIATR SURG, V44, P720, DOI 10.1016/j.jpedsurg.2008.06.020
   Millien G, 2006, BMC DEV BIOL, V6, DOI 10.1186/1471-213X-6-35
   MINER JH, 1994, J CELL BIOL, V127, P879, DOI 10.1083/jcb.127.3.879
   Miyazaki E, 1998, J PEDIATR SURG, V33, P1476, DOI 10.1016/S0022-3468(98)90478-X
   Mo FE, 2002, MOL CELL BIOL, V22, P8709, DOI 10.1128/MCB.22.24.8709-8720.2002
   Moreno-Barriuso N, 2006, DEV DYNAM, V235, P2040, DOI 10.1002/dvdy.20842
   Morris DG, 2003, NATURE, V422, P169, DOI 10.1038/nature01413
   Morrisey EE, 2010, DEV CELL, V18, P8, DOI 10.1016/j.devcel.2009.12.010
   Muglia LJ, 1999, AM J RESP CELL MOL, V20, P181, DOI 10.1165/ajrcmb.20.2.3381
   Nagata K, 2007, PEDIATR SURG INT, V23, P953, DOI 10.1007/s00383-007-1977-8
   Neufeld G, 1999, FASEB J, V13, P9
   Nguyet NM, 2005, DEV BIOL, V282, P111, DOI 10.1016/j.ydbio.2005.02.031
   Nogueira-Silva C, 2008, EARLY HUM DEV, V84, pS79
   Pauling MH, 2004, CURR TOP DEV BIOL, V64, P73, DOI 10.1016/S0070-2153(04)64005-1
   Perez-Moreno M, 2006, CELL, V124, P631, DOI 10.1016/j.cell.2005.11.043
   Pichel JG, 1996, COLD SPRING HARB SYM, V61, P445
   Pichel JG, 2003, MECH DEVELOP, V120, P349, DOI 10.1016/S0925-4773(02)00449-5
   Pichel JG, 1996, NATURE, V382, P73, DOI 10.1038/382073a0
   Pollak M, 2008, NAT REV CANCER, V8, P915, DOI 10.1038/nrc2536
   Ponticos M, 2013, VASC PHARMACOL, V58, P189, DOI 10.1016/j.vph.2013.01.004
   POWELLBRAXTON L, 1993, GENE DEV, V7, P2609, DOI 10.1101/gad.7.12b.2609
   Prince LS, 2004, AM J PHYSIOL-LUNG C, V287, pL999, DOI 10.1152/ajplung.00111.2004
   Qiang Y, 2003, J IMMUNOL, V170, P1473, DOI 10.4049/jimmunol.170.3.1473
   Ramirez MI, 2003, DEV BIOL, V256, P61, DOI 10.1016/S0012-1606(02)00098-2
   RetschBogart GZ, 1996, AM J RESP CELL MOL, V14, P61, DOI 10.1165/ajrcmb.14.1.8534487
   ROBACK EW, 1991, AM J MED GENET, V38, P74, DOI 10.1002/ajmg.1320380117
   Saiga H, 2008, J IMMUNOL, V181, P8521, DOI 10.4049/jimmunol.181.12.8521
   Sakai T, 2003, NATURE, V423, P876, DOI 10.1038/nature01712
   Sanchez-Calderon H, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0008699
   Schniedermann J, 2010, BMC CELL BIOL, V11, DOI 10.1186/1471-2121-11-50
   SCHULLER AGP, 1995, J MOL ENDOCRINOL, V14, P349, DOI 10.1677/jme.0.0140349
   Shapiro P, 1997, AM J PHYSIOL-LUNG C, V273, pL459
   Shen HC, 2012, FEBS OPEN BIO, V2, P1, DOI 10.1016/j.fob.2011.12.001
   Silva D, 2006, ENDOCRINOLOGY, V147, P5584, DOI 10.1210/en.2006-0498
   Soriano C, 2012, LUNG CANCER, V77, P38, DOI 10.1016/j.lungcan.2012.01.017
   Srisuma S, 2010, AM J RESP CRIT CARE, V181, P838, DOI 10.1164/rccm.200904-0544OC
   Starcher BC, 2000, CHEST, V117, p229S, DOI 10.1378/chest.117.5_suppl_1.229S-a
   Steele-Perkins G, 2005, MOL CELL BIOL, V25, P685, DOI 10.1128/MCB.25.2.685-698.2005
   Stewart CEH, 1996, PHYSIOL REV, V76, P1005
   Svegliati-Baroni G, 1999, HEPATOLOGY, V29, P1743, DOI 10.1002/hep.510290632
   TENHAVEOPBROEK AAW, 1991, EXP LUNG RES, V17, P111, DOI 10.3109/01902149109064406
   Thrane EV, 2001, EXP LUNG RES, V27, P387, DOI 10.1080/019021401750193638
   Tong XJ, 2004, ONCOGENE, V23, P4847, DOI 10.1038/sj.onc.1207628
   Tusher VG, 2001, P NATL ACAD SCI USA, V98, P5116, DOI 10.1073/pnas.091062498
   Usui H, 2004, BIOCHEM BIOPH RES CO, V322, P887, DOI 10.1016/j.bbrc.2004.07.198
   Ventura JJ, 2007, NAT GENET, V39, P750, DOI 10.1038/ng2037
   Wagner KF, 2004, AM J RESP CELL MOL, V31, P276, DOI 10.1165/rcmb.2003-03190C
   Walenkamp MJE, 2005, J CLIN ENDOCR METAB, V90, P2855, DOI 10.1210/jc.2004-1254
   Wang J, 2005, TISSUE CELL, V37, P25, DOI 10.1016/j.tice.2004.09.002
   Wani MA, 1999, J BIOL CHEM, V274, P21180, DOI 10.1074/jbc.274.30.21180
   Warner JR, 2009, MOL CELL, V34, P3, DOI 10.1016/j.molcel.2009.03.006
   Wendel DP, 2000, AM J RESP CELL MOL, V23, P320, DOI 10.1165/ajrcmb.23.3.3906
   Werner Haim, 2008, Archives of Physiology and Biochemistry, V114, P17, DOI [10.1080/13813450801900694, 10.1080/13813450801900694 ]
   Williams MC, 2003, ANNU REV PHYSIOL, V65, P669, DOI 10.1146/annurev.physiol.65.092101.142446
   Winnay JN, 2000, J BIOL CHEM, V275, P10545, DOI 10.1074/jbc.275.14.10545
   Wu JH, 2008, J BIOL CHEM, V283, P3942, DOI 10.1074/jbc.M707882200
   Wu S, 2009, PEDIATR RES, V65, P381, DOI 10.1203/PDR.0b013e3181991c67
   Xie P, 2011, BIOCHEM BIOPH RES CO, V407, P254, DOI 10.1016/j.bbrc.2011.03.016
   Xu Y, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0037046
   Zhang YJ, 2013, TUMOR BIOL, V34, P1605, DOI 10.1007/s13277-013-0691-5
   Zhao L, 2008, BLOOD CELL MOL DIS, V41, P188, DOI 10.1016/j.bcmd.2008.03.006
NR 119
TC 17
Z9 18
U1 1
U2 12
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD DEC 31
PY 2013
VL 8
IS 12
AR e83028
DI 10.1371/journal.pone.0083028
PG 20
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 284NF
UT WOS:000329325200031
PM 24391734
OA DOAJ Gold, Green Published
DA 2019-07-19
ER

PT J
AU Binder, BYK
   Sondergaard, CS
   Nolta, JA
   Leach, JK
AF Binder, Bernard Y. K.
   Sondergaard, Claus S.
   Nolta, Jan A.
   Leach, J. Kent
TI Lysophosphatidic Acid Enhances Stromal Cell-Directed Angiogenesis
SO PLOS ONE
LA English
DT Article
ID MESENCHYMAL STEM-CELLS; SELF-ASSEMBLING PEPTIDES; GROWTH-FACTOR
   DELIVERY; SPHINGOSINE 1-PHOSPHATE; THERAPEUTIC TARGET; PROGENITOR CELLS;
   CARDIAC-FUNCTION; VEGF; DIFFERENTIATION; ACTIVATION
AB Ischemic diseases such as peripheral vascular disease (PVD) affect more than 15% of the general population and in severe cases result in ulcers, necrosis, and limb loss. While the therapeutic delivery of growth factors to promote angiogenesis has been widely investigated, large-scale implementation is limited by strategies to effectively deliver costly recombinant proteins. Multipotent adipose-derived stromal cells (ASC) and progenitor cells from other tissue compartments secrete bioactive concentrations of angiogenic molecules, making cell-based strategies for in situ delivery of angiogenic cytokines an exciting alternative to the use of recombinant proteins. Here, we show that the phospholipid lysophosphatidic acid (LPA) synergistically improves the proangiogenic effects of ASC in ischemia. We found that LPA upregulates angiogenic growth factor production by ASC under two-and three-dimensional in vitro models of serum deprivation and hypoxia (SD/H), and that these factors significantly enhance endothelial cell migration. The concurrent delivery of LPA and ASC in fibrin gels significantly improves vascularization in a murine critical hindlimb ischemia model compared to LPA or ASC alone, thus exhibiting the translational potential of this method. Furthermore, these results are achieved using an inexpensive lipid molecule, which is orders-of-magnitude less costly than recombinant growth factors that are under investigation for similar use. Our results demonstrate a novel strategy for enhancing cell-based strategies for therapeutic angiogenesis, with significant applications for treating ischemic diseases.
C1 [Binder, Bernard Y. K.; Leach, J. Kent] Univ Calif Davis, Dept Biomed Engn, Davis, CA 95616 USA.
   [Leach, J. Kent] Univ Calif Davis, Sch Med, Dept Orthopaed Surg, Davis, CA 95616 USA.
   [Sondergaard, Claus S.] Univ Calif Davis, Sch Med, Dept Surg, Div Cardiothorac Surg, Sacramento, CA 95817 USA.
   [Nolta, Jan A.] Univ Calif Davis, Sch Med, Dept Hematol Oncol, Sacramento, CA 95817 USA.
   [Nolta, Jan A.] Univ Calif Davis, Sch Med, Dept Cell Biol, Sacramento, CA 95817 USA.
   [Nolta, Jan A.] Univ Calif Davis, Sch Med, Dept Human Anat, Sacramento, CA 95817 USA.
   [Nolta, Jan A.] Univ Calif Davis, Sch Med, Stem Cell Program, Sacramento, CA 95817 USA.
RP Leach, JK (reprint author), Univ Calif Davis, Dept Biomed Engn, Davis, CA 95616 USA.
EM jkleach@ucdavis.edu
OI Nolta, Jan/0000-0003-4576-8542
FU National Institutes of Health [1R21AG036963]; AO Craniomaxillofacial
   Foundation [C10-39L]; California Institute for Regenerative Medicine UC
   Davis Stem Cell Training Program [CIRM T1-00006, CIRM TG2-01163]
FX This project was supported by grants from the National Institutes of
   Health 1R21AG036963 and AO Craniomaxillofacial Foundation (C10-39L) to
   JKL. This project was also supported by the California Institute for
   Regenerative Medicine UC Davis Stem Cell Training Program (BYB, CIRM
   T1-00006, CIRM TG2-01163). The funders had no role in study design, data
   collection and analysis, decision to publish, or preparation of the
   manuscript.
CR Armulik A, 2005, CIRC RES, V97, P512, DOI 10.1161/01.RES.0000182903.16652.d7
   Awojoodu AO, 2013, P NATL ACAD SCI USA, V110, P13785, DOI 10.1073/pnas.1221309110
   Binder BY, 2013, TISSUE EN A IN PRESS
   Bunnell BA, 2008, METHODS, V45, P115, DOI 10.1016/j.ymeth.2008.03.006
   Cao YH, 2010, NAT REV DRUG DISCOV, V9, P107, DOI 10.1038/nrd3055
   Chamberlain G, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002934
   Chen JH, 2008, STEM CELLS, V26, P135, DOI 10.1634/stemcells.2007-0098
   Cheung WK, 2010, CYTOTHERAPY, V12, P554, DOI 10.3109/14653241003709694
   Davis HE, 2011, ACTA BIOMATER, V7, P691, DOI 10.1016/j.actbio.2010.09.007
   Davis HE, 2011, ANN BIOMED ENG, V39, P1, DOI 10.1007/s10439-010-0135-y
   de Villiers JA, 2009, STEM CELL REV REP, V5, P256, DOI 10.1007/s12015-009-9084-y
   Deshmane SL, 2009, J INTERF CYTOK RES, V29, P313, DOI 10.1089/jir.2008.0027
   Ferrara N, 2005, NATURE, V438, P967, DOI 10.1038/nature04483
   Fierro FA, 2011, STEM CELLS, V29, P1727, DOI 10.1002/stem.720
   Guo HD, 2012, BIOCHEM BIOPH RES CO, V424, P105, DOI 10.1016/j.bbrc.2012.06.080
   He JW, 2010, TISSUE ENG PT A, V16, P127, DOI [10.1089/ten.tea.2009.0255, 10.1089/ten.TEA.2009.0255]
   He JW, 2010, J CELL BIOCHEM, V110, P87, DOI 10.1002/jcb.22514
   Hoch AI, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0035579
   Jeon ES, 2010, EXP MOL MED, V42, P280, DOI 10.3858/emm.2010.42.4.027
   Katare R, 2013, ARTERIOSCL THROM VAS, V33, P1872, DOI 10.1161/ATVBAHA.113.301217
   Kim JH, 2011, BIOMATERIALS, V32, P6080, DOI 10.1016/j.biomaterials.2011.05.003
   Lee J, 2006, CLIN CANCER RES, V12, P6351, DOI 10.1158/1078-0432.CCR-06-1252
   Lee MJ, 2008, J CELL BIOCHEM, V104, P499, DOI 10.1002/jcb.21641
   Lin K, 2008, CYTOTHERAPY, V10, P417, DOI 10.1080/14653240801982979
   Liu XB, 2009, STEM CELLS DEV, V18, P947, DOI 10.1089/scd.2008.0352
   Mansell JP, 2013, BBA-MOL CELL BIOL L, V1831, P105, DOI 10.1016/j.bbalip.2012.04.005
   Masiello LM, 2006, BONE, V39, P72, DOI 10.1016/j.bone.2005.12.013
   MOOLENAAR WH, 1995, J BIOL CHEM, V270, P12949, DOI 10.1074/jbc.270.22.12949
   Murphy Kaitlin C, 2012, BMC Res Notes, V5, P423, DOI 10.1186/1756-0500-5-423
   Nakagami H, 2006, J ATHEROSCLER THROMB, V13, P77, DOI 10.5551/jat.13.77
   Neufeld G, 1999, FASEB J, V13, P9
   Ozaki Harunobu, 2003, J Atheroscler Thromb, V10, P125
   Park SY, 2007, CANCER LETT, V258, P63, DOI 10.1016/j.canlet.2007.08.011
   Peach G, 2012, BMJ-BRIT MED J, V345, DOI 10.1136/bmj.e5208
   Pyne NJ, 2008, BBA-MOL CELL BIOL L, V1781, P467, DOI 10.1016/j.bbalip.2008.05.004
   Riordan NH, 2009, J TRANSL MED, V7, DOI 10.1186/1479-5876-7-29
   Rivera-Lopez CM, 2008, ANGIOGENESIS, V11, P301, DOI 10.1007/s10456-008-9113-5
   Saranadasa M, 2011, CYTOKINE, V53, P115, DOI 10.1016/j.cyto.2010.06.012
   Shammas NW, 2007, VASC HEALTH RISK MAN, V3, P229, DOI 10.2147/vhrm.2007.3.2.229
   Silva EA, 2007, J THROMB HAEMOST, V5, P590, DOI 10.1111/j.1538-7836.2007.02386.x
   Silva EA, 2008, P NATL ACAD SCI USA, V105, P14347, DOI 10.1073/pnas.0803873105
   Spiegel S, 2003, NAT REV MOL CELL BIO, V4, P397, DOI 10.1038/nrm1103
   Sun QH, 2010, PHARM RES-DORDR, V27, P264, DOI 10.1007/s11095-009-0014-0
   Systems RD, 2012, R D SYST ANN CAT
   Tigyi G, 2010, BRIT J PHARMACOL, V161, P241, DOI 10.1111/j.1476-5381.2010.00815.x
   van Hinsbergh VWM, 2001, ANN NY ACAD SCI, V936, P426
   Walter DH, 2007, ARTERIOSCL THROM VAS, V27, P275, DOI 10.1161/01.ATV.0000254669.12675.70
   Zisch AH, 2003, FASEB J, V17, P2260, DOI 10.1096/fj.02-1041fje
NR 48
TC 7
Z9 7
U1 0
U2 6
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD DEC 2
PY 2013
VL 8
IS 12
AR e82134
DI 10.1371/journal.pone.0082134
PG 8
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 265IN
UT WOS:000327944500119
PM 24312635
OA DOAJ Gold, Green Published
DA 2019-07-19
ER

PT J
AU Zhu, JW
   Wu, XJ
   Lu, ZF
   Luo, D
   Cai, SQ
   Zheng, M
AF Zhu, Jian-Wei
   Wu, Xian-Jie
   Lu, Zhong-Fa
   Luo, Dan
   Cai, Sui-Qing
   Zheng, Min
TI Role of VEGF Receptors in Normal and Psoriatic Human Keratinocytes:
   Evidence from Irradiation with Different UV Sources
SO PLOS ONE
LA English
DT Article
ID ENDOTHELIAL GROWTH-FACTOR; PROTEIN-KINASE-C; HUMAN
   EPIDERMAL-KERATINOCYTES; ULTRAVIOLET-B; TYROSINE KINASE; SKIN
   INFLAMMATION; FACTOR EXPRESSION; ACTIVATION; RADIATION; CELLS
AB Vascular endothelial growth factor (VEGF) promotes angiogenesis and plays important roles both in physiological and pathological conditions. VEGF receptors (VEGFRs) are high-affinity receptors for VEGF and are originally considered specific to endothelial cells. We previously reported that VEGFRs were also constitutively expressed in normal human keratinocytes and overexpressed in psoriatic epidermis. In addition, UVB can activate VEGFRs in normal keratinocytes, and the activated VEGFR-2 signaling is involved in the pro-survival mechanism. Here, we show that VEGFRs were also upregulated and activated by UVA in normal human keratinocytes via PKC, and interestingly, both the activated VEGFR-1 and VEGFR-2 protected against UVA-induced cell death. As VEGFRs were over-expressed in psoriatic epidermis, we further investigated whether narrowband UVB (NB-UVB) phototherapy or topical halomethasone monohydrate 0.05% cream could affect their expression. Surprisingly, the over-expressed VEGFRs in psoriatic epidermis were significantly attenuated by both treatments. During NB-UVB therapy, VEGFRs declined first in the basal, and then gradually in the upper psoriatic epidermis. VEGFRs were activated in psoriatic epidermis, their activation was enhanced by NB-UVB, but turned undetectable after whole therapy. This process was quite different from that by halomethasone, in which VEGFRs and phospho-VEGFRs decreased in a gradual, homogeneous manner. Our findings further suggest that UV-induced activation of VEGFRs serves as a pro-survival signal for keratinocytes. In addition, VEGFRs may be involved in the pathological process of psoriasis, and UV phototherapy is effective for psoriasis by directly modulating the expression of VEGFRs.
C1 [Zhu, Jian-Wei; Wu, Xian-Jie; Lu, Zhong-Fa; Cai, Sui-Qing; Zheng, Min] Zhejiang Univ, Sch Med, Affiliated Hosp 2, Dept Dermatol, Hangzhou 310003, Zhejiang, Peoples R China.
   [Luo, Dan] Nanjing Med Univ, Affiliated Hosp 1, Dept Dermatol, Nanjing, Jiangsu, Peoples R China.
RP Zheng, M (reprint author), Zhejiang Univ, Sch Med, Affiliated Hosp 2, Dept Dermatol, Hangzhou 310003, Zhejiang, Peoples R China.
EM minz@zju.edu.cn
FU National Natural Science Fundation of China (NSFC) [30972643, 81171497,
   81171521]
FX This work was supported by grant 30972643, 81171497 and 81171521 from
   the National Natural Science Fundation of China (NSFC). The funders had
   no role in study design, data collection and analysis, decision to
   publish, or preparation of the manuscript.
CR Akman A, 2009, CLIN EXP DERMATOL, V34, pE202, DOI 10.1111/j.1365-2230.2008.02991.x
   Arun SN, 2011, ONCOGENE, V30, P1586, DOI 10.1038/onc.2010.540
   Barbagallo J, 2001, CUTIS, V68, P345
   Battie C, 2012, INDIAN J DERMATOL VE, V78, P9, DOI 10.4103/0378-6323.97350
   Brauchle M, 1996, J BIOL CHEM, V271, P21793, DOI 10.1074/jbc.271.36.21793
   BROWN LF, 1992, J EXP MED, V176, P1375, DOI 10.1084/jem.176.5.1375
   Byeon SH, 2010, INVEST OPHTH VIS SCI, V51, P1190, DOI 10.1167/iovs.09-4144
   Canavese M, 2010, J DERMATOL SCI, V58, P171, DOI 10.1016/j.jdermsci.2010.03.023
   Carmeliet P, 2001, NAT MED, V7, P575, DOI 10.1038/87904
   Dayanir V, 2001, J BIOL CHEM, V276, P17686, DOI 10.1074/jbc.M009128200
   de Gruijl FR, 1999, EUR J CANCER, V35, P2003, DOI 10.1016/S0959-8049(99)00283-X
   Decraene D, 2004, J INVEST DERMATOL, V122, P484, DOI 10.1046/j.0022-202X.2004.22215.x
   DETMAR M, 1994, J EXP MED, V180, P1141, DOI 10.1084/jem.180.3.1141
   Detmar M, 1997, J INVEST DERMATOL, V108, P263, DOI 10.1111/1523-1747.ep12286453
   Detmar M, 1998, J INVEST DERMATOL, V111, P1, DOI 10.1046/j.1523-1747.1998.00262.x
   Ferrara N, 2004, ENDOCR REV, V25, P581, DOI 10.1210/er.2003-0027
   Flisiak I, 2010, CYTOKINE, V52, P225, DOI 10.1016/j.cyto.2010.09.012
   Fuh G, 2000, J BIOL CHEM, V275, P26690
   Gille J, 2000, J INVEST DERMATOL, V115, P30, DOI 10.1046/j.1523-1747.2000.00020.x
   GSCHWENDT M, 1994, FEBS LETT, V347, P85, DOI 10.1016/0014-5793(94)00514-1
   Halin C, 2008, AM J PATHOL, V173, P265, DOI 10.2353/ajpath.2008.071074
   He YY, 2004, J BIOL CHEM, V279, P53867, DOI 10.1074/jbc.M405781200
   Herve MAJ, 2006, J ENDOCRINOL, V188, P91, DOI 10.1677/joe.1.06184
   Hirakawa S, 2005, BLOOD, V105, P2392, DOI 10.1182/blood-2004-06-2435
   JEANMOUGIN M, 1987, ANN DERMATOL VENER, V114, P671
   Kim EJ, 2005, EXP DERMATOL, V14, P625, DOI 10.1111/j.0906-6705.2005.00345.x
   Kosmadaki MG, 2003, FASEB J, V17, P446, DOI 10.1096/fj.02-0379fje
   Lapolla W, 2011, J AM ACAD DERMATOL, V64, P936, DOI 10.1016/j.jaad.2009.12.054
   Lauer G, 2000, J INVEST DERMATOL, V115, P12, DOI 10.1046/j.1523-1747.2000.00036.x
   Lee EJ, 2010, FREE RADICAL BIO MED, V48, P1133, DOI 10.1016/j.freeradbiomed.2010.01.034
   Li CM, 2011, MOL CELL BIOCHEM, V346, P173, DOI 10.1007/s11010-010-0602-7
   Man XY, 2009, CLIN EXP DERMATOL, V34, P396, DOI 10.1111/j.1365-2230.2008.03104.x
   Man XY, 2008, J CELL MOL MED, V12, P649, DOI 10.1111/j.1582-4934.2007.00112.x
   Man XY, 2006, MOL MED, V12, P127, DOI 10.2119/2006-00024.Man
   MATSUI MS, 1994, PHOTOCHEM PHOTOBIOL, V59, P53
   Matsui MS, 1996, PHOTODERMATOL PHOTO, V12, P103, DOI 10.1111/j.1600-0781.1996.tb00185.x
   Mildner M, 1999, PHOTOCHEM PHOTOBIOL, V70, P674, DOI 10.1111/j.1751-1097.1999.tb08269.x
   MILLAUER B, 1993, CELL, V72, P835, DOI 10.1016/0092-8674(93)90573-9
   Neufeld G, 1999, FASEB J, V13, P9
   Nofal A, 2009, J EUR ACAD DERMATOL, V23, P803, DOI 10.1111/j.1468-3083.2009.03181.x
   Petrova TV, 1999, EXP CELL RES, V253, P117, DOI 10.1006/excr.1999.4707
   Ravnbak MH, 2007, ARCH DERMATOL RES, V299, P25, DOI 10.1007/s00403-006-0728-3
   Rosenberger C, 2007, J INVEST DERMATOL, V127, P2445, DOI 10.1038/sj.jid.5700874
   SEETHARAM L, 1995, ONCOGENE, V10, P135
   Slominski A, 2000, ENDOCR REV, V21, P457, DOI 10.1210/er.21.5.457
   Slominski AT, 2012, ADV ANAT EMBRYOL CEL, V212, P1
   Soker S, 1998, CELL, V92, P735, DOI 10.1016/S0092-8674(00)81402-6
   Supp DM, 2000, J INVEST DERMATOL, V114, P5, DOI 10.1046/j.1523-1747.2000.00824.x
   Syed DN, 2012, PHOTOCHEM PHOTOBIOL, V88, P1184, DOI 10.1111/j.1751-1097.2012.01115.x
   Tapia JA, 2003, J BIOL CHEM, V278, P35220, DOI 10.1074/jbc.M303119200
   TERMAN BI, 1992, BIOCHEM BIOPH RES CO, V187, P1579, DOI 10.1016/0006-291X(92)90483-2
   Umeda J, 2003, FASEB J, V17, P610, DOI 10.1096/fj.02-0597com
   Wang HQ, 2003, J BIOL CHEM, V278, P45737, DOI 10.1074/jbc.M300574200
   Weninger W, 1996, LAB INVEST, V75, P647
   Whitaker GB, 2001, J BIOL CHEM, V276, P25520, DOI 10.1074/jbc.M102315200
   Wilgus TA, 2005, AM J PATHOL, V167, P1257, DOI 10.1016/S0002-9440(10)61213-8
   Xia YP, 2003, BLOOD, V102, P161, DOI 10.1182/blood-2002-12-3793
   Yang XH, 2006, BIOCHEM BIOPH RES CO, V349, P31, DOI 10.1016/j.bbrc.2006.07.213
   Zhou Q, 2009, FREE RADICAL BIO MED, V47, P891, DOI 10.1016/j.freeradbiomed.2009.06.033
   Zhu JW, 2012, INT J BIOCHEM CELL B, V44, P246, DOI 10.1016/j.biocel.2011.10.022
NR 60
TC 10
Z9 10
U1 0
U2 8
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD JAN 31
PY 2013
VL 8
IS 1
AR e55463
DI 10.1371/journal.pone.0055463
PG 11
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 085JH
UT WOS:000314610600107
PM 23383198
OA DOAJ Gold, Green Published
DA 2019-07-19
ER

PT J
AU Kaur, H
   Li, JJ
   Bay, BH
   Yung, LYL
AF Kaur, Harleen
   Li, Jasmine J.
   Bay, Boon-Huat
   Yung, Lin-Yue Lanry
TI Investigating the Antiproliferative Activity of High Affinity DNA
   Aptamer on Cancer Cells
SO PLOS ONE
LA English
DT Article
ID ENDOTHELIAL GROWTH-FACTOR; COLORECTAL-CANCER; FACTOR VEGF;
   BREAST-CANCER; ANTISENSE OLIGONUCLEOTIDES; COMBINATORIAL SELECTION;
   VASCULAR-PERMEABILITY; SIGNALING PATHWAYS; FACTOR RECEPTOR-1; IN-VITRO
AB Vascular endothelial growth factor (VEGF) is an angiogenic mitogen involved in promoting tumor angiogenesis inside the body. VEGF is a key protein required for progression of tumor from benign to malignant phenotype. In this study, we investigated the binding affinity of a previously selected 26-mer DNA aptamer sequence (SL2-B) against heparin binding domain (HBD) of VEGF(165) protein. The SL2-B was first chemically modified by introduction of phosphorothioate linkages (PS-linkages). Subsequently, surface plasmon resonance (SPR) spectroscopy and circular dichroism (CD) were used to determine the binding affinity, specificity and to deduce the conformation of PS-modified SL2-B sequence. Finally, antiproliferative activity of the modified SL2-B sequence on Hep G2 cancer cells was investigated. Our results demonstrate a marked enhancement in the biostability of the SL2-B sequence after PS modification. The modified SL2-B sequence also exhibits enhanced antiproliferative activity against Hep G2 cancer cells in hypoxia conditions. In addition, modified SL2-B sequence inhibits the expression of Jagged-1 protein, which is one of the ligands to VEGF linked delta/jagged-notch signaling pathway.
C1 [Kaur, Harleen; Li, Jasmine J.; Yung, Lin-Yue Lanry] Natl Univ Singapore, Fac Engn, Dept Chem & Biomol Engn, Singapore 117548, Singapore.
   [Li, Jasmine J.; Bay, Boon-Huat] Natl Univ Singapore, Yong Loo Lin Sch Med, Dept Anat, Singapore 117595, Singapore.
RP Yung, LYL (reprint author), Natl Univ Singapore, Fac Engn, Dept Chem & Biomol Engn, Singapore 117548, Singapore.
EM cheyly@nus.edu.sg
RI Yung, Lanry/B-6515-2009
OI Yung, Lanry/0000-0001-7579-6347
FU Singapore Ministry of Education [MOE2008-T2-1-046, R279000282112]; NUS
FX This work was supported by research funding from the Singapore Ministry
   of Education Academic Research Fund Tier 2 grant MOE2008-T2-1-046 and
   Tier 1 grant R279000282112. The authors also appreciated the doctoral
   scholarship (for H.K.) from NUS. The funders had no role in study
   design, data collection and analysis, decision to publish, or
   preparation of the manuscript.
CR AGRAWAL S, 1995, CLIN PHARMACOKINET, V28, P7, DOI 10.2165/00003088-199528010-00002
   Barleon B, 1996, BLOOD, V87, P3336
   Baselga J, 2010, J CLIN ONCOL, V28, P1138, DOI 10.1200/JCO.2009.24.2024
   Bates PJ, 2009, EXP MOL PATHOL, V86, P151, DOI 10.1016/j.yexmp.2009.01.004
   Boomer RM, 2005, OLIGONUCLEOTIDES, V15, P183, DOI 10.1089/oli.2005.15.183
   BROWN LF, 1992, J EXP MED, V176, P1375, DOI 10.1084/jem.176.5.1375
   Burmeister PE, 2005, CHEM BIOL, V12, P25, DOI 10.1016/j.chembiol.2004.10.017
   Calvani M, 2008, CANCER RES, V68, P285, DOI 10.1158/0008-5472.CAN-07-5564
   Costa RB, 2010, ANN ONCOL, V21, P2153, DOI 10.1093/annonc/mdq096
   DESMIDT PC, 1991, NUCLEIC ACIDS RES, V19, P4695, DOI 10.1093/nar/19.17.4695
   EATON BE, 1995, CHEM BIOL, V2, P633, DOI 10.1016/1074-5521(95)90023-3
   ELLINGTON AD, 1990, NATURE, V346, P818, DOI 10.1038/346818a0
   Fan F, 2005, ONCOGENE, V24, P2647, DOI 10.1038/sj.onc.1208246
   Ferlay J, 2010, INT J CANCER, V127, P2893, DOI 10.1002/ijc.25516
   Ferrara N, 2004, NAT REV DRUG DISCOV, V3, P391, DOI 10.1038/nrd1381
   Frampton JE, 2010, DRUGS, V70, P1987, DOI 10.2165/11205010-000000000-00000
   Gao J, 2007, BIOCHEM BIOPH RES CO, V356, P341, DOI 10.1016/j.bbrc.2007.02.130
   HOUCK KA, 1992, J BIOL CHEM, V267, P26031
   Hurwitz H, 2004, NEW ENGL J MED, V350, P2335, DOI 10.1056/NEJMoa032691
   Itakura J, 2000, INT J CANCER, V85, P27
   Jayasena SD, 1999, CLIN CHEM, V45, P1628
   Jemal A, 2011, CA-CANCER J CLIN, V61, P69, DOI 10.3322/caac.20107
   Jemal A, 2010, CA-CANCER J CLIN, V60, P277, DOI [10.1002/caac.20073, 10.3322/caac.20073]
   [ JIANG Xin], 2007, [. , Journal of Central South University. Medical Sciences], V32, P1031
   Kang J, 2008, BIOORG MED CHEM LETT, V18, P1835, DOI 10.1016/j.bmcl.2008.02.023
   Kaur H, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0031196
   KAWASAKI AM, 1993, J MED CHEM, V36, P831, DOI 10.1021/jm00059a007
   Keyt BA, 1996, J BIOL CHEM, V271, P7788, DOI 10.1074/jbc.271.13.7788
   Kypr J, 2009, NUCLEIC ACIDS RES, V37, P1713, DOI 10.1093/nar/gkp026
   Leighl NB, 2010, J THORAC ONCOL, V5, P1970, DOI 10.1097/JTO.0b013e3181f49c22
   Lin Y, 1996, NUCLEIC ACIDS RES, V24, P3407, DOI 10.1093/nar/24.17.3407
   Los M, 2007, ONCOLOGIST, V12, P443, DOI 10.1634/theoncologist.12-4-443
   Masood R, 2001, BLOOD, V98, P1904, DOI 10.1182/blood.V98.6.1904
   MILLAUER B, 1993, CELL, V72, P835, DOI 10.1016/0092-8674(93)90573-9
   Neufeld G, 1999, FASEB J, V13, P9
   Oswald J, 2007, CANCER LETT, V254, P102, DOI 10.1016/j.canlet.2007.02.016
   Price DJ, 2001, CELL GROWTH DIFFER, V12, P129
   Radtke F, 2003, NAT REV CANCER, V3, P756, DOI 10.1038/nrc1186
   Robinson CJ, 2001, J CELL SCI, V114, P853
   Ruckman J, 1998, J BIOL CHEM, V273, P20556, DOI 10.1074/jbc.273.32.20556
   Saint-Geniez M, 2009, P NATL ACAD SCI USA, V106, P18751, DOI 10.1073/pnas.0905010106
   Santagata S, 2004, CANCER RES, V64, P6854, DOI 10.1158/0008-5472.CAN-04-2500
   Sayyed SG, 2009, DIABETOLOGIA, V52, P2445, DOI 10.1007/s00125-009-1493-6
   Strizzi L, 2001, J PATHOL, V193, P468, DOI 10.1002/path.824
   Suzuki H, 1999, AM J PHYSIOL-GASTR L, V276, pG92
   Thiviyanathan V, 2007, BIOCHEM SOC T, V35, P50, DOI 10.1042/BST0350050
   Thurston G, 2008, BRIT J CANCER, V99, P1204, DOI 10.1038/sj.bjc.6604484
   TUERK C, 1990, SCIENCE, V249, P505, DOI 10.1126/science.2200121
   Vester B, 2004, BIOCHEMISTRY-US, V43, P13233, DOI 10.1021/bi0485732
   WALTENBERGER J, 1994, J BIOL CHEM, V269, P26988
   Wang ZW, 2010, J CELL BIOCHEM, V109, P726, DOI 10.1002/jcb.22451
   Wang ZW, 2008, ANTICANCER RES, V28, P3621
   Wey JS, 2005, CANCER-AM CANCER SOC, V104, P427, DOI 10.1002/cncr.21145
   Wong SF, 2005, CLIN THER, V27, P684, DOI 10.1016/j.clinthera.2005.06.003
   Yang JC, 2003, NEW ENGL J MED, V349, P427, DOI 10.1056/NEJMoa021491
NR 55
TC 17
Z9 17
U1 0
U2 53
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD JAN 16
PY 2013
VL 8
IS 1
AR e50964
DI 10.1371/journal.pone.0050964
PG 11
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 072OV
UT WOS:000313682700007
PM 23341879
OA DOAJ Gold, Green Published
DA 2019-07-19
ER

PT J
AU Barash, U
   Arvatz, G
   Farfara, R
   Naroditsky, I
   Doweck, I
   Feld, S
   Ben-Izhak, O
   Ilan, N
   Nativ, O
   Vlodavsky, I
AF Barash, Uri
   Arvatz, Gil
   Farfara, Roy
   Naroditsky, Inna
   Doweck, Ilana
   Feld, Sari
   Ben-Izhak, Ofer
   Ilan, Neta
   Nativ, Ofer
   Vlodavsky, Israel
TI Clinical Significance of Heparanase Splice Variant (T5) in Renal Cell
   Carcinoma: Evaluation by a Novel T5-Specific Monoclonal Antibody
SO PLOS ONE
LA English
DT Article
ID TUMOR PROGRESSION; MAMMALIAN HEPARANASE; CANCER METASTASIS; EXPRESSION;
   LOCALIZATION; DISEASE; CLONING; ANGIOGENESIS; ACTIVATION; RECEPTOR
AB T5 is a novel splice variant of heparanase, an endo-beta-D-glucuronidase capable of cleaving heparan sulfate side chains at a limited number of sites. T5 splice variant is endowed with pro-tumorigenic properties, enhancing cell proliferation, anchorage independent growth and tumor xenograft development despite lack of heparan sulfate-degrading activity typical of heparanase. T5 is over expressed in the majority of human renal cell carcinoma biopsies examined, suggesting that this splice variant is clinically relevant. T5 is thought to assume a distinct three-dimensional conformation compared with the wild type heparanase protein. We sought to exploit this presumed feature by generating monoclonal antibodies that will recognize the unique structure of T5 without, or with minimal recognition of heparanase, thus enabling more accurate assessment of the clinical relevance of T5. We provide evidence that such a monoclonal antibody, 9c9, preferentially recognizes T5 compared with heparanase by ELISA, immunoblotting and immunohistochemistry. In order to uncover the clinical significance of T5, a cohort of renal cell carcinoma specimens was subjected to immunostaining applying the 9c9 antibody. Notably, T5 staining intensity was significantly associated with tumor size (p = 0.004) and tumor grade (p = 0.02). Our results suggest that T5 is a functional, pro-tumorigenic entity.
C1 [Barash, Uri; Arvatz, Gil; Feld, Sari; Ilan, Neta; Vlodavsky, Israel] Technion Israel Inst Technol, Rappaport Fac Med, Canc & Vasc Biol Res Ctr, Haifa, Israel.
   [Farfara, Roy; Nativ, Ofer] Bnai Zion Med Ctr, Dept Urol, Haifa, Israel.
   [Naroditsky, Inna; Ben-Izhak, Ofer] Rambam Hlth Care Campus, Dept Pathol, Haifa, Israel.
   [Doweck, Ilana] Carmel Hosp, Dept Otolaryngol Head & Neck Surg, Haifa, Israel.
RP Vlodavsky, I (reprint author), Technion Israel Inst Technol, Rappaport Fac Med, Canc & Vasc Biol Res Ctr, Haifa, Israel.
EM Vlodavsk@cc.huji.ac.il
FU Israel Science Foundation [593/10]; National Cancer Institute, National
   Institutes of Health [CA106456]; Israel Cancer Research Fund (ICRF);
   US-Israel Binational Science Foundation (BSF); Rappaport Family
   Institute Fund
FX This work was supported by grants from the Israel Science Foundation
   (grant 593/10); National Cancer Institute, National Institutes of Health
   (grant CA106456); the Israel Cancer Research Fund (ICRF); the US-Israel
   Binational Science Foundation (BSF), and the Rappaport Family Institute
   Fund to I. Vlodavsky. I. Vlodavsky is a Research Professor of the ICRF.
   The funders had no role in study design, data collection and analysis,
   decision to publish, or preparation of the manuscript.
CR Arvatz G, 2011, CANCER METAST REV, V30, P253, DOI 10.1007/s10555-011-9288-x
   Barash U, 2010, FEBS J, V277, P3890, DOI 10.1111/j.1742-4658.2010.07799.x
   Barash U, 2010, FASEB J, V24, P1239, DOI 10.1096/fj.09-147074
   Bertolesi GE, 2011, DEV DYNAM, V240, P2657, DOI 10.1002/dvdy.22770
   CASU B, 2008, PATHOPHYSIOL HAEMO T, V36, P195
   Cheville JC, 2003, AM J SURG PATHOL, V27, P612, DOI 10.1097/00000478-200305000-00005
   Cohen-Kaplan V, 2008, INT J CANCER, V123, P2566, DOI 10.1002/ijc.23898
   Cohen-Kaplan V, 2008, CANCER RES, V68, P10077, DOI 10.1158/0008-5472.CAN-08-2910
   Cooper TA, 2009, CELL, V136, P777, DOI 10.1016/j.cell.2009.02.011
   Dempsey LA, 2000, GLYCOBIOLOGY, V10, P467, DOI 10.1093/glycob/10.5.467
   Dempsey LA, 2000, TRENDS BIOCHEM SCI, V25, P349, DOI 10.1016/S0968-0004(00)01619-4
   Doweck I, 2006, NEOPLASIA, V8, P1055, DOI 10.1593/neo.06577
   Edge SB, 2010, AJCC CANC STAGING MA
   Fux L, 2009, TRENDS BIOCHEM SCI, V34, P511, DOI 10.1016/j.tibs.2009.06.005
   Fux L, 2009, CANCER RES, V69, P1758, DOI 10.1158/0008-5472.CAN-08-1837
   Gingis-Velitski S, 2007, FASEB J, V21, P3986, DOI 10.1096/fj.07-8866com
   Haimov-Kochman R, 2002, MOL HUM REPROD, V8, P566, DOI 10.1093/molehr/8.6.566
   Ilan N, 2006, INT J BIOCHEM CELL B, V38, P2018, DOI 10.1016/j.biocel.2006.06.004
   Levy-Adam F, 2010, SEMIN CANCER BIOL, V20, P153, DOI 10.1016/j.semcancer.2010.06.005
   Levy-Adam F, 2010, J BIOL CHEM, V285, P28010, DOI 10.1074/jbc.M110.116384
   McKenzie E, 2000, BIOCHEM BIOPH RES CO, V276, P1170, DOI 10.1006/bbrc.2000.3586
   Mikami S, 2008, CLIN CANCER RES, V14, P6055, DOI 10.1158/1078-0432.CCR-08-0750
   Nardella C, 2004, BIOCHEMISTRY-US, V43, P1862, DOI 10.1021/bi030203a
   Nasser NJ, 2007, BIOCHEM BIOPH RES CO, V354, P33, DOI 10.1016/j.bbrc.2006.12.189
   Nasser NJ, 2005, P NATL ACAD SCI USA, V102, P15161, DOI 10.1073/pnas.0507279102
   Neufeld G, 1999, FASEB J, V13, P9
   Parish CR, 2001, BBA-REV CANCER, V1471, pM99, DOI 10.1016/S0304-419X(01)00017-8
   Ramani VC, 2011, J BIOL CHEM, V286, P6490, DOI 10.1074/jbc.M110.183277
   Ren JC, 2011, WORLD J SURG ONCOL, V9, DOI 10.1186/1477-7819-9-158
   Sato M, 2008, CELL BIOCHEM FUNCT, V26, P676, DOI 10.1002/cbf.1492
   Shafat I, 2006, BIOCHEM BIOPH RES CO, V341, P958, DOI 10.1016/j.bbrc.2006.01.048
   Skotheim RI, 2007, INT J BIOCHEM CELL B, V39, P1432, DOI 10.1016/j.biocel.2007.02.016
   Srebrow A, 2006, J CELL SCI, V119, P2635, DOI 10.1242/jcs.03053
   Tazi J, 2009, BBA-MOL BASIS DIS, V1792, P14, DOI 10.1016/j.bbadis.2008.09.017
   van Alphen RJ, 2009, BRIT J CANCER, V100, P228, DOI 10.1038/sj.bjc.6604801
   Vlodavsky I, 2001, J CLIN INVEST, V108, P341, DOI 10.1172/JCI13662
   Vreys V, 2007, J CELL MOL MED, V11, P427, DOI 10.1111/j.1582-4934.2007.00039.x
   Weidle UH, 2011, CANCER GENOM PROTEOM, V8, P211
   White ES, 2008, J PATHOL, V216, P1, DOI 10.1002/path.2388
   Zetser A, 2004, J CELL SCI, V117, P2249, DOI 10.1242/jcs.01068
   Zisman A, 2002, J CLIN ONCOL, V20, P4559, DOI 10.1200/JCO.2002.05.111
NR 41
TC 5
Z9 5
U1 0
U2 2
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD DEC 12
PY 2012
VL 7
IS 12
AR e51494
DI 10.1371/journal.pone.0051494
PG 7
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 066QV
UT WOS:000313236200123
PM 23251556
OA DOAJ Gold, Green Published
DA 2019-07-19
ER

PT J
AU Liu, ZK
   Wang, RC
   Han, BC
   Yang, Y
   Peng, JP
AF Liu, Zhen-Kun
   Wang, Rong-Chun
   Han, Bing-Chen
   Yang, Ying
   Peng, Jing-Pian
TI A Novel Role of IGFBP7 in Mouse Uterus: Regulating Uterine Receptivity
   through Th1/Th2 Lymphocyte Balance and Decidualization
SO PLOS ONE
LA English
DT Article
ID PROTEIN-RELATED PROTEIN-1; GROWTH-FACTOR VEGF; T-CELLS; EARLY-PREGNANCY;
   DNA METHYLATION; IMPLANTATION; EXPRESSION; FETAL; ANGIOGENESIS;
   CYTOKINES
AB Previously we have screened out Insulin-like Growth Factor Binding Protein 7 (IGFBP7) as a differentially expressed gene in post-implantation uterus versus pre-implantation uterus by suppressive subtractive hybridation. However its function in uterus was not clearly identified. In this research, the expression and function of IGFBP7 during post-implantation were studied. We found that IGFBP7 was mainly located in the glandular epithelium and the stroma, and was upregulated after embryo implantation. The vector pCR3.1-IGFBP7-t expressing partial IGFBP7 was constructed. Inhibition of IGFBP7 by specific DNA immunization induced significant reduction of implanted embryos and pregnancy rate. The number of implanted embryos (5.68 +/- 0.46) was significantly reduced after immunization with pCR3.1-IGFBP7-t, as compared with that of the mice immunized with the control vector (12.29 +/- 0.36) or saline (14.58 +/- 0.40) (p<0.01). After specific inhibition of IGFBP7, the T helper type 1 (Th1) cytokine IFN gamma, was significantly elevated (p<0.05) and the Th2 cytokines IL-4 and IL-10, were reduced in uteri (p<0.05). The increase of Tbet and the decrease of Gata3 were found in mice peripheral lymphocytes by flow cytometry. The expression of decidualization marker IGFBP1 and angiogenesis regulator VEGF were declined in uteri (p<0.05). The expression of apoptosis-associated proteins, caspase3 and Bcl-2, were also declined (p<0.05). These results showed that inhibition of IGFBP7 induced pregnancy failure by shifting uterine cytokines to Th1 type dominance and repressing uterine decidualization.
C1 [Liu, Zhen-Kun; Wang, Rong-Chun; Han, Bing-Chen; Yang, Ying; Peng, Jing-Pian] Chinese Acad Sci, Inst Zool, State Key Lab Reprod Biol, Beijing, Peoples R China.
   [Liu, Zhen-Kun] Chinese Acad Sci, Grad Univ, Beijing, Peoples R China.
RP Peng, JP (reprint author), Chinese Acad Sci, Inst Zool, State Key Lab Reprod Biol, Beijing, Peoples R China.
EM pengjp@ioz.ac.cn
FU National Basic Research Program of China [2011CB944402]; National
   Natural Science Foundation of China [31171435]; National Key Technology
   RD Program [2012BAI31B07]
FX This work was supported by grants from the National Basic Research
   Program of China (No. 2011CB944402;
   http://www.973.gov.cn/English/Index.aspx), the National Natural Science
   Foundation of China (No. 31171435;
   http://www.nsfc.gov.cn/e_nsfc/desktop/zn/0101.htm), and the National Key
   Technology R&D Program (2012BAI31B07;
   http://www.most.gov.cn/eng/programmes1/200610/t20061009_36224.htm). The
   funders had no role in study design, data collection and analysis,
   decision to publish, or preparation of the manuscript.
CR Chang JJ, 2006, REPRODUCTION, V131, P183, DOI 10.1530/rep.1.00262
   Chaouat G, 2003, AM J REPROD IMMUNOL, V50, P177, DOI 10.1034/j.1600-0897.2003.00080.x
   Chen Y, 2002, MOL CELL BIOCHEM, V231, P89, DOI 10.1023/A:1014408713826
   Collet C, 1998, MOL CELL ENDOCRINOL, V139, P1, DOI 10.1016/S0303-7207(98)00078-1
   Dey SK, 2004, ENDOCR REV, V25, P341, DOI 10.1210/er.2003-0020
   Dominguez F, 2003, J CLIN ENDOCR METAB, V88, P1849, DOI 10.1210/jc.2002-020724
   Heesch S, 2011, CANCER SCI, V102, P253, DOI 10.1111/j.1349-7006.2010.01760.x
   Hefler L, 2000, ACTA OBSTET GYN SCAN, V79, P77, DOI 10.1034/j.1600-0412.2000.079001077.x
   Hwa V, 1999, ENDOCR REV, V20, P761, DOI 10.1210/er.20.6.761
   Krussell JS, 2001, MOL HUM REPROD, V7, P57, DOI 10.1093/molehr/7.1.57
   Kutsukake M, 2007, MOL HUM REPROD, V13, P737, DOI 10.1093/molehr/gam058
   Lai ZB, 2011, HYPERTENSION, V57, P505, DOI 10.1161/HYPERTENSIONAHA.110.163329
   Leber A, 2010, AM J REPROD IMMUNOL, V63, P445, DOI 10.1111/j.1600-0897.2010.00821.x
   Liu ZK, 2012, CELL BIOCHEM BIOPHYS, V63, P73, DOI 10.1007/s12013-012-9342-5
   Lockwood CJ, 2007, SEMIN THROMB HEMOST, V33, P111, DOI 10.1055/s-2006-958469
   Mikhailov V, 2001, J BIOL CHEM, V276, P18361, DOI 10.1074/jbc.M100655200
   Neufeld G, 1999, FASEB J, V13, P9
   Nevers T, 2011, AM J REPROD IMMUNOL, V66, P88, DOI 10.1111/j.1600-0897.2011.01040.x
   Norwitz ER, 2001, NEW ENGL J MED, V345, P1400, DOI 10.1056/NEJMra000763
   Oh YM, 1996, J BIOL CHEM, V271, P30322, DOI 10.1074/jbc.271.48.30322
   Peck A, 2010, IMMUNOLOGY, V129, P147, DOI 10.1111/j.1365-2567.2009.03189.x
   Robertson SA, 2000, REV REPROD, V5, P164, DOI 10.1530/revreprod/5.3.164
   Saito S, 2010, AM J REPROD IMMUNOL, V63, P601, DOI 10.1111/j.1600-0897.2010.00852.x
   SCHLAFKE S, 1985, ANAT REC, V212, P47, DOI 10.1002/ar.1092120107
   Sherer DM, 2001, PLACENTA, V22, P1, DOI 10.1053/plac.2000.0588
   Svensson L, 2001, J REPROD IMMUNOL, V51, P3, DOI 10.1016/S0165-0378(01)00065-1
   Tamura K, 2004, ENDOCRINOLOGY, V145, P5243, DOI 10.1210/en.2004-0415
   Tamura K, 2009, EUR J PHARMACOL, V610, P61, DOI 10.1016/j.ejphar.2009.01.045
   Tseng L, 2002, FRONT BIOSCI, V7, pD1566, DOI 10.2741/tseng
   Vairo G, 1996, ONCOGENE, V13, P1511
   Wajapeyee N, 2008, CELL, V132, P363, DOI 10.1016/j.cell.2007.12.032
   WEGMANN TG, 1993, IMMUNOL TODAY, V14, P353, DOI 10.1016/0167-5699(93)90235-D
   Wheeler T, 1999, HUM REPROD, V14, P1619, DOI 10.1093/humrep/14.6.1619
   Xiong GF, 2011, MOL CELL ENDOCRINOL, V331, P23, DOI 10.1016/j.mce.2010.06.003
   Yamashita S, 2006, CANCER SCI, V97, P64, DOI 10.1111/j.1349-7006.2006.00136.x
   Ye F, 2007, J CANCER RES CLIN, V133, P305, DOI 10.1007/s00432-006-0171-z
   Zenclussen AC, 2006, EUR J IMMUNOL, V36, P82, DOI 10.1002/eji.200535428
   Zenclussen AC, 2006, SPRINGER SEMIN IMMUN, V28, P31, DOI 10.1007/s00281-006-0023-6
   Zhang JH, 2011, CELL MOL IMMUNOL, V8, P1, DOI 10.1038/cmi.2010.38
NR 39
TC 9
Z9 10
U1 0
U2 11
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD SEP 17
PY 2012
VL 7
IS 9
AR e45224
DI 10.1371/journal.pone.0045224
PG 8
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 019MC
UT WOS:000309742800041
PM 23028860
OA DOAJ Gold, Green Published
DA 2019-07-19
ER

PT J
AU Jellbauer, S
   Panthel, K
   Hetrodt, JH
   Russmann, H
AF Jellbauer, Stefan
   Panthel, Klaus
   Hetrodt, Justin H.
   Ruessmann, Holger
TI CD8 T-Cell Induction against Vascular Endothelial Growth Factor Receptor
   2 by Salmonella for Vaccination Purposes against a Murine Melanoma
SO PLOS ONE
LA English
DT Article
ID III SECRETION SYSTEM; STEM-LIKE CELLS; ANTIGEN DELIVERY; TUMOR-GROWTH;
   SELECTIVE EXPRESSION; BACTERIAL-INFECTION; MEMORY CELLS; HOST-CELLS;
   ANGIOGENESIS; IMMUNOTHERAPY
AB The Salmonella type III secretion system (T3SS) efficiently translocates heterologous proteins into the cytosol of eukaryotic cells. This leads to an antigen-specific CD8 T-cell induction in mice orally immunized with recombinant Salmonella. Recently, we have used Salmonella's T3SS as a prophylactic and therapeutic intervention against a murine fibrosarcoma. In this study, we constructed a recombinant Salmonella strain translocating the immunogenic H-2D(b)-specific CD8 T-cell epitope VILTNPISM (KDR2) from the murine vascular endothelial growth factor receptor 2 (VEGFR2). VEGFR2 is a member of the tyrosine protein kinase family and is upregulated on proliferating endothelial cells of the tumor vasculature. After single orogastric vaccination, we detected significant numbers of KDR2-tetramer-positive CD8 T cells in the spleens of immunized mice. The efficacy of these cytotoxic T cells was evaluated in a prophylactic setting to protect mice from challenges with B16F10 melanoma cells in a flank tumor model, and to reduce dissemination of spontaneous pulmonary melanoma metastases. Vaccinated mice revealed a reduction of angiogenesis by 62% in the solid tumor and consequently a significant decrease of tumor growth as compared to non-immunized mice. Moreover, in the lung metastasis model, immunization with recombinant Salmonella resulted in a reduction of the metastatic melanoma burden by approximately 60%.
C1 [Jellbauer, Stefan; Panthel, Klaus; Hetrodt, Justin H.] Univ Munich, Max von Pettenkofer Inst Hyg & Med Microbiol, Munich, Germany.
   [Jellbauer, Stefan] Univ Calif Irvine, Dept Microbiol & Mol Genet, Irvine, CA 92717 USA.
   [Ruessmann, Holger] HELIOS Clin Emil von Behring, Inst Microbiol Immunol & Lab Med, Berlin, Germany.
RP Jellbauer, S (reprint author), Univ Munich, Max von Pettenkofer Inst Hyg & Med Microbiol, Munich, Germany.
EM holger.ruessmann@helios-kliniken.de
FU Deutsche Forschungsgemeinschaft [RU 838/2-1, RU 838/3-1]
FX SJ and HR were supported by the Deutsche Forschungsgemeinschaft (grants
   RU 838/2-1 and RU 838/3-1). The funders had no role in study design,
   data collection and analysis, decision to publish, or preparation of the
   manuscript.
CR Berchtold C, 2009, INFECT IMMUN, V77, P5501, DOI 10.1128/IAI.00700-09
   Busch DH, 1998, IMMUNITY, V8, P353, DOI 10.1016/S1074-7613(00)80540-3
   Busch DH, 1998, J EXP MED, V188, P61, DOI 10.1084/jem.188.1.61
   DeLisser HM, 1997, AM J PATHOL, V151, P671
   Domenech VES, 2005, MICROBES INFECT, V7, P860, DOI 10.1016/j.mincinf.2005.02.007
   Dong YJ, 2006, J IMMUNOTHER, V29, P32, DOI 10.1097/01.cji.0000175494.13476.56
   Ferrara N, 2003, NAT MED, V9, P669, DOI 10.1038/nm0603-669
   Folkman J, 1992, Semin Cancer Biol, V3, P65
   Folkman J, 2007, NAT REV DRUG DISCOV, V6, P273, DOI 10.1038/nrd2115
   Galan JE, 2001, ANNU REV CELL DEV BI, V17, P53, DOI 10.1146/annurev.cellbio.17.1.53
   Galan JE, 1998, P NATL ACAD SCI USA, V95, P14006, DOI 10.1073/pnas.95.24.14006
   Garrido F, 1997, IMMUNOL TODAY, V18, P89, DOI 10.1016/S0167-5699(96)10075-X
   Guttinger M, 2000, CANCER RES, V60, P4211
   Hapfelmeier S, 2005, TRENDS MICROBIOL, V13, P497, DOI 10.1016/j.tim.2005.08.008
   HOISETH SK, 1981, NATURE, V291, P238, DOI 10.1038/291238a0
   Huster KM, 2006, CURR OPIN IMMUNOL, V18, P458, DOI 10.1016/j.coi.2006.05.008
   Huster KM, 2006, EUR J IMMUNOL, V36, P1453, DOI 10.1002/eji.200635874
   Huster KM, 2004, P NATL ACAD SCI USA, V101, P5610, DOI 10.1073/pnas.0308054101
   Kaech SM, 2003, NAT IMMUNOL, V4, P1191, DOI 10.1038/ni1009
   Kaniga K, 1996, MOL MICROBIOL, V21, P633, DOI 10.1111/j.1365-2958.1996.tb02571.x
   Kotton CN, 2004, INFECT IMMUN, V72, P5535, DOI 10.1128/IAI.72.10.5535-5547.2004
   Lauvau G, 2001, SCIENCE, V294, P1735, DOI 10.1126/science.1064571
   Li YW, 2002, J EXP MED, V195, P1575, DOI 10.1084/jem.20020072
   Liu JY, 2003, BLOOD, V102, P1815, DOI 10.1182/blood-2002-12-3772
   Lyons JA, 2007, GENE THER, V14, P503, DOI 10.1038/sj.gt.3302889
   Masopust D, 2001, SCIENCE, V291, P2413, DOI 10.1126/science.1058867
   Medina E, 2001, VACCINE, V19, P1573, DOI 10.1016/S0264-410X(00)00354-6
   Nair S, 2003, BLOOD, V102, P964, DOI 10.1182/blood-2002-12-3738
   Neufeld G, 1999, FASEB J, V13, P9
   Niethammer AG, 2002, NAT MED, V8, P1369, DOI 10.1038/nm794
   Nishikawa H, 2006, J CLIN INVEST, V116, P1946, DOI 10.1172/JCI28045
   Okaji Y, 2006, EJSO, V32, P363, DOI 10.1016/j.ejso.2006.01.016
   Panthel K, 2006, MICROBES INFECT, V8, P2539, DOI 10.1016/j.micinf.2006.07.004
   Plum SM, 2000, VACCINE, V19, P1294, DOI 10.1016/S0264-410X(00)00210-3
   POSTE G, 1980, CANCER RES, V40, P1636
   Ricci-Vitiani L, 2010, NATURE, V468, P824, DOI 10.1038/nature09557
   Roider E, 2011, CANCER IMMUNOL IMMUN, V60, P371, DOI 10.1007/s00262-010-0950-x
   Russmann H, 1998, SCIENCE, V281, P565, DOI 10.1126/science.281.5376.565
   Russmann H, 2001, J IMMUNOL, V167, P357, DOI 10.4049/jimmunol.167.1.357
   Salgaller ML, 2003, CURR OPIN MOL THER, V5, P657
   Sallusto F, 1999, NATURE, V401, P708, DOI 10.1038/44385
   Schesser K, 1996, J BACTERIOL, V178, P7227, DOI 10.1128/jb.178.24.7227-7233.1996
   Seliger B, 1997, IMMUNOL TODAY, V18, P292, DOI 10.1016/S0167-5699(97)01052-9
   SHALABY F, 1995, NATURE, V376, P62, DOI 10.1038/376062a0
   Sory MP, 1995, P NATL ACAD SCI USA, V92, P11998, DOI 10.1073/pnas.92.26.11998
   Suzuki H, 2010, EUR J IMMUNOL, V40, P197, DOI 10.1002/eji.200939887
   Wang R, 2010, NATURE, V468, P829, DOI 10.1038/nature09624
   Wei YQ, 2000, NAT MED, V6, P1160, DOI 10.1038/80506
NR 48
TC 14
Z9 14
U1 0
U2 4
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD APR 12
PY 2012
VL 7
IS 4
AR e34214
DI 10.1371/journal.pone.0034214
PG 11
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 959TZ
UT WOS:000305338600020
PM 22511934
OA DOAJ Gold, Green Published
DA 2019-07-19
ER

PT J
AU Kapur, NK
   Shenoy, C
   Yunis, AA
   Mohammad, NN
   Wilson, S
   Paruchuri, V
   Mackey, EE
   Qiao, XY
   Shah, A
   Esposito, ML
   Karas, RH
   Jaffe, IZ
AF Kapur, Navin K.
   Shenoy, Chetan
   Yunis, Adil A.
   Mohammad, Najwa N.
   Wilson, Szuhuei
   Paruchuri, Vikram
   Mackey, Emily E.
   Qiao, Xiaoying
   Shah, Ameer
   Esposito, Michele L.
   Karas, Richard H.
   Jaffe, Iris Z.
TI Distinct Effects of Unfractionated Heparin versus Bivalirudin on
   Circulating Angiogenic Peptides
SO PLOS ONE
LA English
DT Article
ID PERCUTANEOUS CORONARY INTERVENTION; ENDOTHELIAL GROWTH-FACTOR; SOLUBLE
   ENDOGLIN; PREECLAMPSIA; VEGF; CHALLENGES; THERAPY; BINDING; SYSTEM;
   CANCER
AB Background: Human studies of therapeutic angiogenesis, stem-cell, and progenitor-cell therapy have failed to demonstrate consistent clinical benefit. Recent studies have shown that heparin increases circulating levels of anti-angiogenic peptides. Given the widely prevalent use of heparin in percutaneous and surgical procedures including those performed as part of studies examining the benefit of therapeutic angiogenesis and cell-based therapy, we compared the effects of unfractionated heparin (UFH) on angiogenic peptides with those of bivalirudin, a relatively newer anticoagulant whose effects on angiogenic peptides have not been studied.
   Methodology/Principal Findings: We measured soluble fms-like tyrosine kinase-1 (sFLT1), placental growth factor (PlGF), vascular endothelial growth factor (VEGF), and soluble Endoglin (sEng) serum levels by enzyme linked immunosorbent assays (ELISA) in 16 patients undergoing elective percutaneous coronary intervention. Compared to baseline values, sFLT1 and PlGF levels increased by 2629 +/- 313% and 253 +/- 54%, respectively, within 30 minutes of UFH therapy (p<0.01 for both; n = 8). VEGF levels decreased by 93.2 +/- 5% in patients treated with UFH (p, 0.01 versus baseline). No change in sEng levels were observed after UFH therapy. No changes in sFLT1, PlGF, VEGF, or sEng levels were observed in any patients receiving bivalirudin (n = 8). To further explore the direct effect of anticoagulation on circulating angiogenic peptides, adult, male wild-type mice received venous injections of clinically dosed UFH or bivalirudin. Compared to saline controls, sFLT1 and PlGF levels increased by >500% (p<0.01, for both) and VEGF levels increased by 221 +/- 101% (p<0.05) 30 minutes after UFH treatment. Bivalirudin had no effect on peptide levels. To study the cellular origin of peptides after anticoagulant therapy, human coronary endothelial cells were treated with UFH and demonstrated increased sFLT1 and PlGF levels (ANOVA p<0.01 for both) with reduced VEGF levels (ANOVA p<0.05). Bivalirudin had no effect on peptide levels in vitro.
   Conclusions/Significance: Circulating levels of sFLT1, PlGF, and VEGF are significantly altered by UFH, while bivalirudin therapy has no effect. These findings may have significant implications for clinical studies of therapeutic angiogenesis, stem-cell and progenitor-cell therapy.
C1 [Kapur, Navin K.; Yunis, Adil A.; Mohammad, Najwa N.; Wilson, Szuhuei; Paruchuri, Vikram; Mackey, Emily E.; Qiao, Xiaoying; Shah, Ameer; Esposito, Michele L.; Karas, Richard H.; Jaffe, Iris Z.] Tufts Med Ctr, Mol Cardiol Res Inst, Boston, MA 02111 USA.
   [Kapur, Navin K.; Shenoy, Chetan; Karas, Richard H.; Jaffe, Iris Z.] Tufts Med Ctr, Dept Med, Div Cardiol, Boston, MA USA.
RP Kapur, NK (reprint author), Tufts Med Ctr, Mol Cardiol Res Inst, Boston, MA 02111 USA.
EM nkapur@tuftsmedicalcenter.org
FU NHLBI NIH HHS [K08 HL094909, R01 HL095590]
CR Carroll TY, 2011, AM J REPROD IMMUNOL, V66, P286, DOI 10.1111/j.1600-0897.2011.01007.x
   Castonguay R, 2011, J BIOL CHEM, V286, P30034, DOI 10.1074/jbc.M111.260133
   CHEIFETZ S, 1992, J BIOL CHEM, V267, P19027
   FOLKMAN J, 1983, SCIENCE, V221, P719, DOI 10.1126/science.6192498
   Gibbons RJ, 1999, J AM COLL CARDIOL, V33, P2092, DOI 10.1016/S0735-1097(99)00150-3
   Kapur NK, 2011, ARTERIOSCL THROM VAS, V31, P443, DOI 10.1161/ATVBAHA.110.215897
   Kastrati A, 2008, NEW ENGL J MED, V359, P688, DOI 10.1056/NEJMoa0802944
   KENDALL RL, 1994, BIOCHEM BIOPH RES CO, V201, P326, DOI 10.1006/bbrc.1994.1705
   Kimmelstiel C, 2011, CIRC-CARDIOVASC INTE, V4, P171, DOI 10.1161/CIRCINTERVENTIONS.110.959098
   Kut C, 2007, BRIT J CANCER, V97, P978, DOI 10.1038/sj.bjc.6603923
   Levine RJ, 2006, NEW ENGL J MED, V355, P992, DOI 10.1056/NEJMoa055352
   Lopez-Novoa JM, 2010, AM J PHYSIOL-HEART C, V299, pH959, DOI 10.1152/ajpheart.01251.2009
   MAGLIONE D, 1991, P NATL ACAD SCI USA, V88, P9267, DOI 10.1073/pnas.88.20.9267
   MATTHEWS W, 1991, CELL, V65, P1143, DOI 10.1016/0092-8674(91)90010-V
   Maynard SE, 2003, J CLIN INVEST, V111, P649, DOI 10.1172/JCI200317189
   Neufeld G, 1999, FASEB J, V13, P9
   Rak J, 2003, ARTERIOSCL THROM VAS, V23, P1954, DOI 10.1161/01.ATV.0000100563.16983.19
   Rassen JA, 2010, EUR HEART J, V31, P561, DOI 10.1093/eurheartj/ehp437
   Searle J, 2011, ARTERIOSCLER THROMB
   Sela S, 2011, CIRC RES, V108, P1063, DOI 10.1161/CIRCRESAHA.110.239665
   Tongers J, 2011, EUR HEART J, V32, P1197, DOI 10.1093/eurheartj/ehr018
   Venkatesha S, 2006, NAT MED, V12, P642, DOI 10.1038/nm1429
   Wong NS, 2010, J CLIN ONCOL, V28, P723, DOI 10.1200/JCO.2009.24.0143
   Zachary I, 2011, HEART, V97, P181, DOI 10.1136/hrt.2009.180414
NR 24
TC 7
Z9 8
U1 0
U2 3
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD APR 11
PY 2012
VL 7
IS 4
AR e34344
DI 10.1371/journal.pone.0034344
PG 8
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 959TP
UT WOS:000305336600025
PM 22509290
OA DOAJ Gold, Green Published
DA 2019-07-19
ER

PT J
AU Kaur, H
   Yung, LYL
AF Kaur, Harleen
   Yung, Lin-Yue Lanry
TI Probing High Affinity Sequences of DNA Aptamer against VEGF(165)
SO PLOS ONE
LA English
DT Article
ID ENDOTHELIAL GROWTH-FACTOR; MESSENGER-RNA STABILITY; FACTOR VEGF;
   EXPONENTIAL ENRICHMENT; SYSTEMATIC EVOLUTION; IN-VITRO; CELLS;
   SELECTION; LIGANDS; HYPOXIA
AB Vascular endothelial growth factor (VEGF(165)) is a potent angiogenic mitogen commonly overexpressed in cancerous cells. It contains two main binding domains, the receptor-binding domain (RBD) and the heparin-binding domain (HBD). This study attempted to identify the specific sequences of the VEa5 DNA aptamer that exhibit high binding affinity towards the VEGF(165) protein by truncating the original VEa5 aptamer into different segments. Using surface plasmon resonance (SPR) spectroscopy for binding affinity analysis, one of the truncated aptamers showed a >200-fold increase in the binding affinity for HBD. This truncated aptamer also exhibited high specificity to HBD with negligible binding affinity for VEGF(121), an isoform of VEGF lacking HBD. Exposing colorectal cancer cells to the truncated aptamer sequence further confirmed the binding affinity and specificity of the aptamer to the target VEGF(165) protein. Hence, our approach of aptamer truncation can potentially be useful in identifying high affinity aptamer sequences for the biological molecules and targeting them as antagonist for cancer cell detection.
C1 [Kaur, Harleen; Yung, Lin-Yue Lanry] Natl Univ Singapore, Dept Chem & Biomol Engn, Singapore 117548, Singapore.
RP Kaur, H (reprint author), Natl Univ Singapore, Dept Chem & Biomol Engn, Singapore 117548, Singapore.
EM cheyly@nus.edu.sg
RI Yung, Lanry/B-6515-2009
OI Yung, Lanry/0000-0001-7579-6347
FU Singapore Ministry of Education [MOE2008-T2-1-046, R279000282112]
FX This work was supported by research funding from the Singapore Ministry
   of Education Academic Research Fund Tier 2 grant MOE2008-T2-1-046 and
   Tier 1 grant R279000282112. The funders had no role in study design,
   data collection and analysis, decision to publish, or preparation of the
   manuscript.
CR Bates PJ, 2009, EXP MOL PATHOL, V86, P151, DOI 10.1016/j.yexmp.2009.01.004
   Berezovski M, 2005, J AM CHEM SOC, V127, P3165, DOI 10.1021/ja042394q
   Biesecker G, 1999, IMMUNOPHARMACOLOGY, V42, P219, DOI 10.1016/S0162-3109(99)00020-X
   BOCK LC, 1992, NATURE, V355, P564, DOI 10.1038/355564a0
   Boomer RM, 2005, OLIGONUCLEOTIDES, V15, P183, DOI 10.1089/oli.2005.15.183
   Calvani M, 2008, CANCER RES, V68, P285, DOI 10.1158/0008-5472.CAN-07-5564
   Chan MY, 2008, CIRCULATION, V117, P2865, DOI 10.1161/CIRCULATIONAHA.107.745687
   Chelliserrykattil J, 2004, NAT BIOTECHNOL, V22, P1155, DOI 10.1038/nbt1001
   COHEN T, 1995, J BIOL CHEM, V270, P11322, DOI 10.1074/jbc.270.19.11322
   Daniels DA, 2003, P NATL ACAD SCI USA, V100, P15416, DOI 10.1073/pnas.2136683100
   Davis JH, 2002, P NATL ACAD SCI USA, V99, P11616, DOI 10.1073/pnas.182095699
   Davis KA, 1998, NUCLEIC ACIDS RES, V26, P3915, DOI 10.1093/nar/26.17.3915
   Diener JL, 2009, J THROMB HAEMOST, V7, P1155, DOI 10.1111/j.1538-7836.2009.03459.x
   ELLINGTON AD, 1990, NATURE, V346, P818, DOI 10.1038/346818a0
   Green LS, 1996, BIOCHEMISTRY-US, V35, P14413, DOI 10.1021/bi961544+
   Hasegawa H, 2008, BIOTECHNOL LETT, V30, P829, DOI 10.1007/s10529-007-9629-6
   Hasegawa H, 2008, SENSORS-BASEL, V8, P1090, DOI 10.3390/s8021090
   Hernandez FJ, 2009, BIOORG MED CHEM LETT, V19, P6585, DOI 10.1016/j.bmcl.2009.10.039
   HOUCK KA, 1991, MOL ENDOCRINOL, V5, P1806, DOI 10.1210/mend-5-12-1806
   IKEDA E, 1995, J BIOL CHEM, V270, P19761, DOI 10.1074/jbc.270.34.19761
   Jayasena SD, 1999, CLIN CHEM, V45, P1628
   JELLINEK D, 1995, BIOCHEMISTRY-US, V34, P11363, DOI 10.1021/bi00036a009
   Katilius E, 2007, NUCLEIC ACIDS RES, V35, P7626, DOI 10.1093/nar/gkm922
   Kato T, 2000, NUCLEIC ACIDS RES, V28, P1963, DOI 10.1093/nar/28.9.1963
   KAWASAKI AM, 1993, J MED CHEM, V36, P831, DOI 10.1021/jm00059a007
   Keyt BA, 1996, J BIOL CHEM, V271, P7788, DOI 10.1074/jbc.271.13.7788
   MINCHENKO A, 1994, LAB INVEST, V71, P374
   Misono TS, 2005, ANAL BIOCHEM, V342, P312, DOI 10.1016/j.ab.2005.04.013
   Neufeld G, 1999, FASEB J, V13, P9
   Ninichuk V, 2008, AM J PATHOL, V172, P628, DOI 10.2353/ajpath.2008.070601
   Oswald J, 2007, CANCER LETT, V254, P102, DOI 10.1016/j.canlet.2007.02.016
   Pagratis NC, 1997, NAT BIOTECHNOL, V15, P68, DOI 10.1038/nbt0197-68
   PARK JE, 1993, MOL BIOL CELL, V4, P1317
   Potty ASR, 2009, BIOPOLYMERS, V91, P145, DOI 10.1002/bip.21097
   Ruckman J, 1998, J BIOL CHEM, V273, P20556, DOI 10.1074/jbc.273.32.20556
   Sayer NM, 2004, J BIOL CHEM, V279, P13102, DOI 10.1074/jbc.M310928200
   Sayyed SG, 2009, DIABETOLOGIA, V52, P2445, DOI 10.1007/s00125-009-1493-6
   Schmidt KS, 2004, NUCLEIC ACIDS RES, V32, P5757, DOI 10.1093/nar/gkh862
   Shangguan D, 2007, CHEMBIOCHEM, V8, P603, DOI 10.1002/cbic.200600532
   SHIMA DT, 1995, FEBS LETT, V370, P203, DOI 10.1016/0014-5793(95)00831-S
   Somasunderam A, 2005, BIOCHEMISTRY-US, V44, P10388, DOI 10.1021/bi0507074
   Tok JBH, 2008, CHEM COMMUN, P1883, DOI 10.1039/b717936g
   TUERK C, 1990, SCIENCE, V249, P505, DOI 10.1126/science.2200121
   Vaupel P, 2007, CANCER METAST REV, V26, P225, DOI 10.1007/s10555-007-9055-1
   WALEH NS, 1995, CANCER RES, V55, P6222
   WATERS EK, 2009, J THROMB HAEMOST, V7, P683
   Wrzesinski J, 2005, BIOCHEMISTRY-US, V44, P6257, DOI 10.1021/bi047397u
   Zuker M, 2003, NUCLEIC ACIDS RES, V31, P3406, DOI 10.1093/nar/gkg595
NR 48
TC 56
Z9 56
U1 1
U2 85
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD FEB 16
PY 2012
VL 7
IS 2
AR e31196
DI 10.1371/journal.pone.0031196
PG 9
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 925XS
UT WOS:000302796200042
PM 22359573
OA DOAJ Gold, Green Published
DA 2019-07-19
ER

PT J
AU Kohn-Luque, A
   de Back, W
   Starruss, J
   Mattiotti, A
   Deutsch, A
   Perez-Pomares, JM
   Herrero, MA
AF Koehn-Luque, Alvaro
   de Back, Walter
   Starruss, Joern
   Mattiotti, Andrea
   Deutsch, Andreas
   Maria Perez-Pomares, Jose
   Herrero, Miguel A.
TI Early Embryonic Vascular Patterning by Matrix-Mediated Paracrine
   Signalling: A Mathematical Model Study
SO PLOS ONE
LA English
DT Article
ID ENDOTHELIAL GROWTH-FACTOR; IN-VITRO VASCULOGENESIS;
   EXTRACELLULAR-MATRIX; FACTOR VEGF; DIFFERENTIAL ADHESION; FRACTAL
   PARAMETERS; EXPRESSION; ANGIOGENESIS; MORPHOGENESIS; RECEPTOR
AB During embryonic vasculogenesis, endothelial precursor cells of mesodermal origin known as angioblasts assemble into a characteristic network pattern. Although a considerable amount of markers and signals involved in this process have been identified, the mechanisms underlying the coalescence of angioblasts into this reticular pattern remain unclear. Various recent studies hypothesize that autocrine regulation of the chemoattractant vascular endothelial growth factor (VEGF) is responsible for the formation of vascular networks in vitro. However, the autocrine regulation hypothesis does not fit well with reported data on in vivo early vascular development. In this study, we propose a mathematical model based on the alternative assumption that endodermal VEGF signalling activity, having a paracrine effect on adjacent angioblasts, is mediated by its binding to the extracellular matrix (ECM). Detailed morphometric analysis of simulated networks and images obtained from in vivo quail embryos reveals the model mimics the vascular patterns with high accuracy. These results show that paracrine signalling can result in the formation of fine-grained cellular networks when mediated by angioblast-produced ECM. This lends additional support to the theory that patterning during early vascular development in the vertebrate embryo is regulated by paracrine signalling.
C1 [Koehn-Luque, Alvaro; Herrero, Miguel A.] Univ Complutense Madrid, Fac Math, Dept Appl Math, Madrid, Spain.
   [Koehn-Luque, Alvaro; Herrero, Miguel A.] Univ Complutense Madrid, Fac Math, Inst Interdisciplinary Math, Madrid, Spain.
   [de Back, Walter; Starruss, Joern; Deutsch, Andreas] Tech Univ Dresden, Ctr Informat Serv & High Performance Comp, Dresden, Germany.
   [Mattiotti, Andrea; Maria Perez-Pomares, Jose] Univ Malaga, Cardiovasc Dev & Angiogenesis Lab, Dept Anim Biol, Fac Sci, E-29071 Malaga, Spain.
RP Kohn-Luque, A (reprint author), Univ Complutense Madrid, Fac Math, Dept Appl Math, Madrid, Spain.
EM Miguel_Herrero@mat.ucm.es
RI Perez-Pomares, Jose/G-7885-2015
OI Perez-Pomares, Jose/0000-0001-5487-7252; de Back,
   Walter/0000-0003-4641-8472
FU Spanish Ministry of Education; Spanish Ministry of Science and
   Innovation [BFU2009-07929]; Junta de Andalucia [P08-CTS-03618]; Human
   Frontier Science Program (HFSP); BMBF;  [MTM2008-01867]
FX AKL and MAH have been partially supported by Spanish grant MTM2008-01867
   (www.micinn.es). AKL is grateful to the FPU fellowship program funded by
   the Spanish Ministry of Education (www.educacion.es). MAH received no
   additional external funding for this study. JMPP's research is funded by
   grants BFU2009-07929 (Spanish Ministry of Science and Innovation,
   www.micinn.es), P08-CTS-03618 (Junta de Andalucia,
   www.juntadeandalucia.es) and the cooperative research networks TERCEL
   and RECAVA (ISCIII, www.isciii.es). AD is a member of the DFG Research
   Center for Regenerative Therapies Dresden -Cluster of
   Excellence-(www.crt-dresden.de) and gratefully acknowledges support by
   the Center. AD also acknowledges a research grant of the Human Frontier
   Science Program (HFSP, www.hfsp.org) and support by the BMBF through its
   Virtual Liver program (www.bmbf.de/en/1140.php). The funders had no role
   in study design, data collection and analysis, decision to publish, or
   preparation of the manuscript.
CR Ambrosi D., 2005, J THEOR MED, V6, P1
   Argraves WS, 2005, ANAT REC PART A, V286A, P875, DOI 10.1002/ar.a.20232
   ASHIKARIHADA S, 2005, J BIOL CHEM, V35, P1508
   Beysens DA, 2000, P NATL ACAD SCI USA, V97, P9467, DOI 10.1073/pnas.97.17.9467
   BREIER G, 1992, DEVELOPMENT, V114, P521
   Chen TT, 2010, J CELL BIOL, V188, P595, DOI 10.1083/jcb.200906044
   Cleaver O., 2010, HEART DEV REGENERATI, P487, DOI 10.1016/B978-0-12-381332-9.00023-2
   Davis GE, 2005, CIRC RES, V97, P1093, DOI 10.1161/01.RES.0000191547.64391.e3
   Davis S, 1996, CELL, V87, P1161, DOI 10.1016/S0092-8674(00)81812-7
   Drake CJ, 2000, DEV BIOL, V224, P178, DOI 10.1006/dbio.2000.9744
   DRAKE CJ, 1995, P NATL ACAD SCI USA, V92, P7657, DOI 10.1073/pnas.92.17.7657
   DRAKE DJ, 1997, DEV BIOL, V192, P17
   DUMONT DJ, 1995, DEV DYNAM, V203, P80, DOI 10.1002/aja.1002030109
   Ferrara N, 1999, J MOL MED, V77, P527, DOI 10.1007/s001099900019
   FLAMME I, 1995, DEV BIOL, V169, P699, DOI 10.1006/dbio.1995.1180
   Francis SE, 2002, ARTERIOSCL THROM VAS, V22, P927, DOI 10.1161/01.ATV.0000016045.93313.F2
   Gamba A, 2003, PHYS REV LETT, V90, DOI 10.1103/PhysRevLett.90.118101
   GEORGES AL, 2004, J BIOL CHEM, V279, P2307
   GLAZIER JA, 1993, PHYS REV E, V47, P2128, DOI 10.1103/PhysRevE.47.2128
   Guidolin D, 2004, LEUKEMIA, V18, P1745, DOI 10.1038/sj.leu.2403526
   Guidolin D, 2004, MICROVASC RES, V67, P117, DOI 10.1016/j.mvr.2003.11.002
   Herrero MA, 2009, MATH MOD METH APPL S, V19, P1483, DOI 10.1142/S021820250900384X
   HOUCK KA, 1992, J BIOL CHEM, V267, P26031
   Karperien A, FRACLAC IMAGEJ VERSI
   Kirchner LM, 1996, MICROVASC RES, V51, P2, DOI 10.1006/mvre.1996.0002
   LAI L, 2003, DEVELOPMENT, V120, P6465
   Larsson J, 2001, EMBO J, V20, P1663, DOI 10.1093/emboj/20.7.1663
   Mancardi D, 2008, THEOR BIOL MED MODEL, V5, DOI 10.1186/1742-4682-5-12
   Manoussaki D, 1996, ACTA BIOTHEOR, V44, P271, DOI 10.1007/BF00046533
   Meinhardt H, 1997, INT J BIFURCAT CHAOS, V7, P1, DOI 10.1142/S0218127497000029
   Merks RMH, 2006, NONLINEARITY, V19, pC1, DOI 10.1088/0951-7715/19/1/000
   Merks RMH, 2006, DEV BIOL, V289, P44, DOI 10.1016/j.ydbio.2005.10.003
   Merks RMH, 2004, LECT NOTES COMPUT SC, V3305, P425
   Merks RMH, 2008, PLOS COMPUT BIOL, V4, DOI 10.1371/journal.pcbi.1000163
   MILLAUER B, 1993, CELL, V72, P835, DOI 10.1016/0092-8674(93)90573-9
   Miura T, 2009, MATH MODEL NAT PHENO, V4, P118, DOI 10.1051/mmnp/20094404
   Neufeld G, 1999, FASEB J, V13, P9
   Nico B, 2001, HISTOCHEM J, V33, P283, DOI 10.1023/A:1017977007479
   PARK JE, 1993, MOL BIOL CELL, V4, P1317
   Poole TJ, 2001, DEV DYNAM, V220, P1, DOI 10.1002/1097-0177(2000)9999:9999<::AID-DVDY1087>3.0.CO;2-2
   Rasband Wayne, IMAGEJ
   RISAU W, 1988, DEV BIOL, V125, P441, DOI 10.1016/0012-1606(88)90225-4
   Rissau W, 1995, ANNU REV CELL DEV BI, V11, P73
   Robins V, 2002, LECT NOTES PHYS, V600, P261
   Ruhrberg C, 2002, GENE DEV, V16, P2684, DOI 10.1101/gad.242002
   Serini G, 2003, EMBO J, V22, P1771, DOI 10.1093/emboj/cdg176
   Smith TG, 1996, J NEUROSCI METH, V69, P123, DOI 10.1016/S0165-0270(96)00080-5
   SOKER S, 1993, J BIOL CHEM, V268, P7685
   Stringer SE, 2006, BIOCHEM SOC T, V34, P451, DOI 10.1042/BST0340451
   SZABO A, 2007, PHYS REV LETT, V98
   Szabo A, 2008, BIOPHYS J, V95, P2702, DOI 10.1529/biophysj.108.129668
   Tolle CR, 2008, PHYSICA D, V237, P306, DOI 10.1016/j.physd.2007.09.017
   Tosin A, 2006, B MATH BIOL, V68, P1819, DOI 10.1007/s11538-006-9071-2
   Vokes SA, 2002, DEVELOPMENT, V129, P775
   Volin MV, 1998, BIOCHEM BIOPH RES CO, V242, P46, DOI 10.1006/bbrc.1997.7890
   WATT SM, 1995, LEUKEMIA LYMPHOMA, V17, P229, DOI 10.3109/10428199509056827
   Wijelath ES, 2006, CIRC RES, V99, P853, DOI 10.1161/01.RES.0000246849.17887.66
   WOLPERT L, 2006, PRINCIPLES DEV
   Wu LW, 2000, J BIOL CHEM, V275, P5096, DOI 10.1074/jbc.275.7.5096
   YAMAGUCHI TP, 1993, DEVELOPMENT, V118, P489
   Zajac M, 2003, J THEOR BIOL, V222, P247, DOI 10.1016/S0022-5193(03)00033-X
   Zamir EA, 2006, P NATL ACAD SCI USA, V103, P19806, DOI 10.1073/pnas.0606100103
   Zhou XM, 2008, GENE DEV, V22, P1231, DOI 10.1101/gad.1643308
NR 63
TC 25
Z9 25
U1 0
U2 17
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD SEP 19
PY 2011
VL 6
IS 9
AR e24175
DI 10.1371/journal.pone.0024175
PG 12
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 825FZ
UT WOS:000295257900006
PM 21949696
OA DOAJ Gold, Green Published
DA 2019-07-19
ER

PT J
AU Lee, TY
   Folkman, J
   Javaherian, K
AF Lee, Tong-Young
   Folkman, Judah
   Javaherian, Kashi
TI HSPG-Binding Peptide Corresponding to the Exon 6a-Encoded Domain of VEGF
   Inhibits Tumor Growth by Blocking Angiogenesis in Murine Model
SO PLOS ONE
LA English
DT Article
ID HEPARAN-SULFATE; SIGNAL-TRANSDUCTION; EXTRACELLULAR-MATRIX;
   ENDOTHELIAL-CELLS; SPLICE VARIANTS; DROSOPHILA; RECEPTORS;
   IDENTIFICATION; PROLIFERATION; MIGRATION
AB Vascular endothelial growth factor VEGF165 is a critical element for development of the vascular system in physiological and pathological angiogenesis. VEGF isoforms have different affinities for heparan sulphate proteoglycan (HSPG) as well as for VEGF receptors; HSPGs are important regulators in vascular development. Therefore, inhibition of interactions between VEGF and HSPGs may prevent angiogenesis. Here, we demonstrate that an HSPG-binding synthetic peptide, corresponding to exon 6a-encoded domain of VEGF gene, has anti-angiogenic property. This 20 amino acids synthetic peptide prevents VEGF165 binding to several different cell types, mouse embryonic sections and inhibits endothelial cell migration, despite its absence in VEGF165 sequence. Our in vivo anti-tumor studies show that the peptide inhibits tumor growth in both mouse Lewis-Lung Carcinoma and human Liposarcoma tumor-bearing animal models. This is the first evidence that a synthetic VEGF fragment corresponding to exon 6a has functional antagonism both in vitro and in vivo. We conclude that the above HPSG binding peptide (6a-P) is a potent inhibitor of angiogenesis-dependent diseases.
C1 [Lee, Tong-Young; Folkman, Judah; Javaherian, Kashi] Childrens Hosp, Dept Surg, Vasc Biol Program, Boston, MA 02115 USA.
   [Lee, Tong-Young; Folkman, Judah; Javaherian, Kashi] Harvard Univ, Sch Med, Boston, MA USA.
   [Javaherian, Kashi] Tufts Univ, Sch Med, St Elizabeths Med Ctr, Dept Med,Ctr Canc Syst Biol, Boston, MA 02111 USA.
RP Lee, TY (reprint author), Childrens Hosp, Dept Surg, Vasc Biol Program, Boston, MA 02115 USA.
EM tongyounglee@gmail.com; kashi.javaherian@caritaschristi.org
FU National Institutes of Health (NIH) [R01-CA064481, P01-CA45548]; The
   Breast Cancer Research Foundation [DOE (DE-SC0002606)]
FX This work was supported by National Institutes of Health (NIH) grants
   R01-CA064481 (J.F.), NIH P01-CA45548 (J.F.), Department of Defense Grant
   W81XWH-05-1-0115 (J.F.), a grant from The Breast Cancer Research
   Foundation (J.F.), and a grant from DOE (DE-SC0002606) (K.J.). The
   funders had no role in study design, data collection and analysis,
   decision to publish, or preparation of the manuscript.
CR Brekken RA, 1998, CANCER RES, V58, P1952
   Carmeliet P, 2003, NAT MED, V9, P653, DOI 10.1038/nm0603-653
   COHEN T, 1995, J BIOL CHEM, V270, P11322, DOI 10.1074/jbc.270.19.11322
   Desbordes SC, 2003, DEVELOPMENT, V130, P6245, DOI 10.1242/dev.00874
   DEVRIES C, 1992, SCIENCE, V255, P989, DOI 10.1126/science.1312256
   Folkman J, 2006, ANNU REV MED, V57, P1, DOI 10.1146/annutev.med.57.121304.131306
   GAVRIELI Y, 1992, J CELL BIOL, V119, P493, DOI 10.1083/jcb.119.3.493
   GUO DQ, 1995, J BIOL CHEM, V270, P6729, DOI 10.1074/jbc.270.12.6729
   Hacker U, 2005, NAT REV MOL CELL BIO, V6, P530, DOI 10.1038/nrm1681
   Han C, 2004, DEVELOPMENT, V131, P601, DOI 10.1242/dev.00958
   Herve MA, 2005, EXP CELL RES, V309, P24, DOI 10.1016/j.yexer.2005.05.022
   Holash J, 2002, P NATL ACAD SCI USA, V99, P11393, DOI 10.1073/pnas.172398299
   HOUCK KA, 1991, MOL ENDOCRINOL, V5, P1806, DOI 10.1210/mend-5-12-1806
   HOUCK KA, 1992, J BIOL CHEM, V267, P26031
   Keyt BA, 1996, J BIOL CHEM, V271, P5638, DOI 10.1074/jbc.271.10.5638
   LIN X, 2003, GLYCOCONJ J, V19, P363
   Lin XH, 1999, NATURE, V400, P281
   Lindahl U, 1998, J BIOL CHEM, V273, P24979, DOI 10.1074/jbc.273.39.24979
   MUSTONEN T, 1995, J CELL BIOL, V129, P895, DOI 10.1083/jcb.129.4.895
   Neufeld G, 1999, FASEB J, V13, P9
   Neufeld G, 1996, CANCER METAST REV, V15, P153, DOI 10.1007/BF00437467
   Nybakken K, 2002, BBA-GEN SUBJECTS, V1573, P280, DOI 10.1016/S0304-4165(02)00395-1
   OLANDER JV, 1991, BIOCHEM BIOPH RES CO, V175, P68, DOI 10.1016/S0006-291X(05)81201-X
   PARK JE, 1993, MOL BIOL CELL, V4, P1317
   Poltorak Z, 1997, J BIOL CHEM, V272, P7151, DOI 10.1074/jbc.272.11.7151
   Robinson CJ, 2006, J BIOL CHEM, V281, P1731, DOI 10.1074/jbc.M510760200
   Robinson CJ, 2001, J CELL SCI, V114, P853
   Selleck SB, 2001, SEMIN CELL DEV BIOL, V12, P127, DOI 10.1006/scdb.2000.0242
   Stringer SE, 1997, INT J BIOCHEM CELL B, V29, P709, DOI 10.1016/S1357-2725(96)00170-7
   TERMAN B, 1992, BIOCHEM BIOPH RES CO, V787, P1579
   TISCHER E, 1991, J BIOL CHEM, V266, P11947
   Tournaire R, 2004, EMBO REP, V5, P262, DOI 10.1038/sj.embor.7400100
   WALTENBERGER J, 1994, J BIOL CHEM, V269, P26988
NR 33
TC 28
Z9 29
U1 0
U2 11
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD APR 1
PY 2010
VL 5
IS 3
AR e9945
DI 10.1371/journal.pone.0009945
PG 8
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 580AG
UT WOS:000276418200021
PM 20376344
OA DOAJ Gold, Green Published
DA 2019-07-19
ER

PT J
AU Grimaldi, A
   Banfi, S
   Gerosa, L
   Tettamanti, G
   Noonan, DM
   Valvassori, R
   de Eguileor, M
AF Grimaldi, Annalisa
   Banfi, Serena
   Gerosa, Laura
   Tettamanti, Gianluca
   Noonan, Douglas M.
   Valvassori, Roberto
   de Eguileor, Magda
TI Identification, Isolation and Expansion of Myoendothelial Cells Involved
   in Leech Muscle Regeneration
SO PLOS ONE
LA English
DT Article
ID ENDOTHELIAL GROWTH-FACTOR; ADULT SKELETAL-MUSCLE; STEM-CELLS; PROGENITOR
   CELLS; SATELLITE CELLS; IN-VIVO; VEGF; DIFFERENTIATION; RECEPTORS;
   HIRUDINEA
AB Adult skeletal muscle in vertebrates contains myoendothelial cells that express both myogenic and endothelial markers, and which are able to differentiate into myogenic cells to contribute to muscle regeneration. In spite of intensive research efforts, numerous questions remain regarding the role of cytokine signalling on myoendothelial cell differentiation and muscle regeneration. Here we used Hirudo medicinalis (Annelid, leech) as an emerging new model to study myoendothelial cells and muscle regeneration. Although the leech has relative anatomical simplicity, it shows a striking similarity with vertebrate responses and is a reliable model for studying a variety of basic events, such as tissue repair. Double immunohistochemical analysis were used to characterize myoendothelial cells in leeches and, by injecting in vivo the matrigel biopolymer supplemented with the cytokine Vascular Endothelial Growth Factor (VEGF), we were able to isolate this specific cell population expressing myogenic and endothelial markers. We then evaluated the effect of VEGF on these cells in vitro. Our data indicate that, similar to that proposed for vertebrates, myoendothelial cells of the leech directly participate in myogenesis both in vivo and in vitro, and that VEGF secretion is involved in the recruitment and expansion of these muscle progenitor cells.
RP Grimaldi, A (reprint author), Univ Insubria, Dept Biotechnol & Mol Sci, Varese, Italy.
EM annalisa.grimaldi@uninsubria.it
RI Tettamanti, Gianluca/L-8748-2019; Tettamanti, Gianluca/E-5465-2012;
   Noonan, Douglas/A-8620-2010
OI Tettamanti, Gianluca/0000-0002-0665-828X; Tettamanti,
   Gianluca/0000-0002-0665-828X; Noonan, Douglas/0000-0001-8058-0719;
   Grimaldi, Annalisa/0000-0002-9258-7595
FU Associazione Italiana per la Ricerca sul Cancro
CR Arsic N, 2004, MOL THER, V10, P844, DOI 10.1016/j.ymthe.2004.08.007
   Asakura A, 2003, TRENDS CARDIOVAS MED, V13, P123, DOI 10.1016/S1050-1738(03)00024-0
   Beauchamp JR, 2000, J CELL BIOL, V151, P1221, DOI 10.1083/jcb.151.6.1221
   CHOI J, 1990, P NATL ACAD SCI USA, V87, P7988, DOI 10.1073/pnas.87.20.7988
   de Eguileor M, 2000, TISSUE CELL, V32, P437
   De Eguileor M., 2001, Angiogenesis, V4, P299, DOI 10.1023/A:1016025803370
   De Eguileor M, 1999, J MICROSC-OXFORD, V196, P6, DOI 10.1046/j.1365-2818.1999.00600.x
   De Eguileor M, 1998, J EXP ZOOL, V281, P171, DOI 10.1002/(SICI)1097-010X(19980615)281:3<171::AID-JEZ3>3.0.CO;2-K
   FALINI B, 1993, AM J PATHOL, V142, P1359
   Gerber HP, 2003, J MOL MED-JMM, V81, P20, DOI 10.1007/s00109-002-0397-4
   Germani A, 2003, AM J PATHOL, V163, P1417, DOI 10.1016/S0002-9440(10)63499-2
   Grimaldi A, 2006, CURR PHARM DESIGN, V12, P3033, DOI 10.2174/138161206777947443
   Grimaldi A., 2004, ISJ, P38
   Grimaldi A, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0001910
   Hatzopoulos AK, 1998, DEVELOPMENT, V125, P1457
   HUGUET G, 1994, J EXP ZOOL, V269, P23, DOI 10.1002/jez.1402690104
   Huguet G, 1996, J EXP ZOOL, V275, P308, DOI 10.1002/(SICI)1097-010X(19960701)275:4<308::AID-JEZ9>3.0.CO;2-T
   HYNES RO, 1987, CELL, V48, P549, DOI 10.1016/0092-8674(87)90233-9
   Jackson KA, 1999, P NATL ACAD SCI USA, V96, P14482, DOI 10.1073/pnas.96.25.14482
   Kalka C, 2000, CIRC RES, V86, P1198, DOI 10.1161/01.RES.86.12.1198
   KLEINMAN HK, 1986, BIOCHEMISTRY-US, V25, P312, DOI 10.1021/bi00350a005
   KOCH AE, 1994, J IMMUNOL, V152, P4149
   Krause DS, 2001, CELL, V105, P369, DOI 10.1016/S0092-8674(01)00328-2
   LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0
   Lagasse E, 2001, IMMUNITY, V14, P425, DOI 10.1016/S1074-7613(01)00123-6
   Le Grand F, 2004, EXP CELL RES, V301, P232, DOI 10.1016/j.yexcr.2004.07.028
   Lee TH, 2006, INT J CANCER, V119, P839, DOI 10.1002/ijc.21916
   LEGORE RS, 1971, J INVERTEBR PATHOL, V18, P40, DOI 10.1016/0022-2011(91)90006-C
   MAURO A, 1961, J BIOPHYS BIOCHEM CY, V9, P493, DOI 10.1083/jcb.9.2.493
   Neufeld G, 1999, FASEB J, V13, P9
   Pesce M, 2003, CIRC RES, V93, pE51, DOI 10.1161/01.RES.0000090624.04507.45
   SCHULTZ E, 1994, REV PHYSIOL BIOCH P, V123, P213, DOI 10.1007/BFb0030904
   Seale P, 2001, DEV CELL, V1, P333, DOI 10.1016/S1534-5807(01)00049-1
   Tamaki T, 2002, J CELL BIOL, V157, P571, DOI 10.1083/jcb.200112106
   Tettamanti G, 2003, CYTOKINE, V22, P168, DOI 10.1016/S1043-4666(03)00176-5
   Tettamanti G, 2003, TISSUE CELL, V35, P199, DOI 10.1016/S0040-8166(03)00027-2
   Towbin H, 1992, Biotechnology, V24, P145
   VOYTA JC, 1984, J CELL BIOL, V99, P2034, DOI 10.1083/jcb.99.6.2034
   Wang SS, 2008, P NATL ACAD SCI USA, V105, P7738, DOI 10.1073/pnas.0802857105
   Zhang SJ, 2006, CELL RES, V16, P577, DOI 10.1038/sj.cr.7310075
   Zheng B, 2007, NAT BIOTECHNOL, V25, P1025, DOI 10.1038/nbt1334
NR 41
TC 9
Z9 9
U1 0
U2 3
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD OCT 30
PY 2009
VL 4
IS 10
AR e7652
DI 10.1371/journal.pone.0007652
PG 13
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 514RW
UT WOS:000271414300010
PM 19876402
OA DOAJ Gold, Green Published
DA 2019-07-19
ER

PT J
AU Yang, CC
   Shih, YH
   Ko, MH
   Hsu, SY
   Cheng, H
   Fu, YS
AF Yang, Chang-Ching
   Shih, Yang-Hsin
   Ko, Miau-Hwa
   Hsu, Shao-Yun
   Cheng, Henrich
   Fu, Yu-Show
TI Transplantation of Human Umbilical Mesenchymal Stem Cells from Wharton's
   Jelly after Complete Transection of the Rat Spinal Cord
SO PLOS ONE
LA English
DT Article
AB Background: Human umbilical mesenchymal stem cells (HUMSCs) isolated from Wharton's jelly of the umbilical cord can be easily obtained and processed compared with embryonic or bone marrow stem cells. These cells may be a valuable source in the repair of spinal cord injury.
   Methodology/Principal Findings: We examine the effects of HUMSC transplantation after complete spinal cord transection in rats. Approximately 5610 5 HUMSCs were transplanted into the lesion site. Three groups of rats were implanted with either untreated HUMSCs (referred to as the stem cell group), or HUMSCs treated with neuronal conditioned medium (NCM) for either three days or six days (referred to as NCM-3 and NCM-6 days, respectively). The control group received no HUMSCs in the transected spinal cord. Three weeks after transplantation, significant improvements in locomotion were observed in all the three groups receiving HUMSCs (stem cell, NCM-3 and NCM-6 days groups). This recovery was accompanied by increased numbers of regenerated axons in the corticospinal tract and neurofilament-positive fibers around the lesion site. There were fewer microglia and reactive astrocytes in both the rostral and caudal stumps of the spinal cord in the stem cell group than in the control group. Transplanted HUMSCs survived for 16 weeks and produced large amounts of human neutrophil-activating protein-2, neurotrophin-3, basic fibroblast growth factor, glucocorticoid induced tumor necrosis factor receptor, and vascular endothelial growth factor receptor 3 in the host spinal cord, which may help spinal cord repair.
   Conclusions/Significance: Transplantation of HUMSCs is beneficial to wound healing after spinal cord injury in rats.
C1 [Yang, Chang-Ching; Hsu, Shao-Yun] Natl Yang Ming Univ, Inst Anat & Cell Biol, Sch Med, Taipei 112, Taiwan.
   [Shih, Yang-Hsin] Taipei Vet Gen Hosp, Neurol Inst, Dept Neurosurg, Taipei, Taiwan.
   [Shih, Yang-Hsin] Taipei Med Univ, Sch Med, Taipei, Taiwan.
   [Ko, Miau-Hwa] China Med Univ, Sch Med, Dept Anat, Taichung, Taiwan.
   [Cheng, Henrich] Taipei Vet Gen Hosp, Neurol Inst, Dept Neurosurg, Neural Regenerat Lab, Taipei, Taiwan.
   [Cheng, Henrich] Natl Yang Ming Univ, Sch Med, Dept Pharmacol, Taipei, Taiwan.
   [Fu, Yu-Show] Natl Yang Ming Univ, Sch Med, Dept Anat & Cell Biol, Taipei, Taiwan.
   [Fu, Yu-Show] Taipei City Hosp, Dept Ed & Res, Taipei, Taiwan.
RP Yang, CC (reprint author), Natl Yang Ming Univ, Inst Anat & Cell Biol, Sch Med, Taipei 112, Taiwan.
EM hc_cheng@vghtpe.gov.tw; ysfu@ym.edu.tw
FU National Science Council [NSC97-2314-B-075-011-MY3]; Taipei Veterans
   General Hospital [V96C1-102]; Ministry of Education, Aim for the Top
   University Plan [97A-C-T159]
FX This work was supported by the Grant NSC97-2314-B-075-011-MY3 from the
   National Science Council, Grant V96C1-102 from the Taipei Veterans
   General Hospital, Grant 97A-C-T159 from Ministry of Education, Aim for
   the Top University Plan.
CR Allan SM, 2001, NAT REV NEUROSCI, V2, P734, DOI 10.1038/35094583
   Bao F, 2004, J NEUROCHEM, V88, P1335, DOI 10.1046/j.1471-4159.2003.02240.x
   BASSO DM, 1995, J NEUROTRAUM, V12, P1, DOI 10.1089/neu.1995.12.1
   Beattie MS, 2000, J NEUROTRAUM, V17, P915, DOI 10.1089/neu.2000.17.915
   BJORKLUND A, 1993, NATURE, V362, P414, DOI 10.1038/362414a0
   Bradbury EJ, 2002, NATURE, V416, P636, DOI 10.1038/416636a
   Cai D, 2001, J NEUROSCI, V21, P4731, DOI 10.1523/JNEUROSCI.21-13-04731.2001
   Cao QL, 2001, EXP NEUROL, V167, P48, DOI 10.1006/exnr.2000.7536
   Chao KC, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0001451
   Chau CH, 2004, FASEB J, V18, P194, DOI 10.1096/fj.03-0196fje
   Chen MS, 2000, NATURE, V403, P434, DOI 10.1038/35000219
   Cizkova D, 2006, CELL MOL NEUROBIOL, V26, P1167, DOI 10.1007/s10571-006-9093-1
   Dasari VR, 2007, NEUROCHEM RES, V32, P2080, DOI 10.1007/s11064-007-9368-z
   Fu YS, 2006, STEM CELLS, V24, P115, DOI 10.1634/stemcells.2005-0053
   Fu YS, 2004, J BIOMED SCI, V11, P652, DOI 10.1159/000079678
   Gibson CL, 2005, GLIA, V50, P417, DOI 10.1002/glia.20143
   Hanisch UK, 2002, GLIA, V40, P140, DOI 10.1002/glia.10161
   Horner PJ, 2000, J NEUROSCI, V20, P2218
   Imai F, 2007, J CEREBR BLOOD F MET, V27, P488, DOI 10.1038/sj.jcbfm.9600362
   Jin KL, 2000, P NATL ACAD SCI USA, V97, P10242, DOI 10.1073/pnas.97.18.10242
   Jones LL, 2003, EXP NEUROL, V182, P399, DOI 10.1016/S0014-4886(03)00087-6
   Kassam A, 2004, ENT-EAR NOSE THROAT, V83, P252
   Kassam A, 2004, ENT-EAR NOSE THROAT, V83, P250
   Kassam Amin, 2004, Ear Nose Throat J, V83, P246
   Kempermann G, 2003, SCIENCE, V302, P1689, DOI 10.1126/science.1092864
   Kitamura Y, 2005, J PHARMACOL SCI, V97, P289, DOI 10.1254/jphs.SC0040129
   Kitamura Y, 2004, J PHARMACOL SCI, V94, P203, DOI 10.1254/jphs.94.203
   Kojima A, 2000, J NEUROPATH EXP NEUR, V59, P687, DOI 10.1093/jnen/59.8.687
   Kojima A, 2002, J NEUROTRAUM, V19, P223, DOI 10.1089/08977150252806974
   Lalancette-Hebert M, 2007, J NEUROSCI, V27, P2596, DOI 10.1523/JNEUROSCI.5360-06.2007
   Lee TT, 1999, J NEUROTRAUM, V16, P347, DOI 10.1089/neu.1999.16.347
   Liu S, 2000, P NATL ACAD SCI USA, V97, P6126, DOI 10.1073/pnas.97.11.6126
   Lu P, 2003, EXP NEUROL, V181, P115, DOI 10.1016/S0014-4886(03)00037-2
   Manoonkitiwongsa PS, 2004, J CEREBR BLOOD F MET, V24, P693, DOI 10.1097/01.WCB.0000126236.54306.21
   Martens DJ, 2002, EUR J NEUROSCI, V16, P1045, DOI 10.1046/j.1460-9568.2002.02181.x
   Marti HH, 1998, P NATL ACAD SCI USA, V95, P15809, DOI 10.1073/pnas.95.26.15809
   Maurer MH, 2003, NEUROSCI LETT, V344, P165, DOI 10.1016/S0304-3940(03)00407-5
   Mitchell KE, 2003, STEM CELLS, V21, P50, DOI 10.1634/stemcells.21-1-50
   Moon LDF, 2001, NAT NEUROSCI, V4, P465
   Morgenstern DA, 2002, PROG BRAIN RES, V137, P313
   Nedergaard M, 2005, GLIA, V50, P281, DOI 10.1002/glia.20205
   Neufeld G, 1999, FASEB J, V13, P9
   Neuhuber B, 2005, BRAIN RES, V1035, P73, DOI 10.1016/j.brainres.2004.11.055
   Neumann J, 2006, FASEB J, V20, P714, DOI 10.1096/fj.05-4882fje
   Perrin LA, 2004, GENE THER, V11, P512, DOI 10.1038/sj.gt.3302173
   Petter-Puchner AH, 2007, EXP TOXICOL PATHOL, V58, P237, DOI 10.1016/j.etp.2006.07.004
   Rabchevsky AG, 2000, EXP NEUROL, V164, P280, DOI 10.1006/exnr.2000.7399
   Robinson CJ, 2001, J CELL SCI, V114, P853
   Rogove AD, 2002, CELL DEATH DIFFER, V9, P801, DOI 10.1038/sj.cdd.4401041
   Silver J, 2004, NAT REV NEUROSCI, V5, P146, DOI 10.1038/nrn1326
   Song S, 2004, EXP NEUROL, V185, P191, DOI 10.1016/j.expneurol.2003.09.003
   Streit WJ, 2002, GLIA, V40, P133, DOI 10.1002/glia.10154
   Svensson B, 2002, J CEREBR BLOOD F MET, V22, P1170
   Tang XF, 2003, J NEUROSCI RES, V71, P427, DOI 10.1002/jnr.10523
   Taoka Y, 1997, NEUROSCIENCE, V79, P1177, DOI 10.1016/S0306-4522(97)00011-0
   Taoka Y, 1998, PROG NEUROBIOL, V56, P341, DOI 10.1016/S0301-0082(98)00049-5
   Teng YD, 1999, J NEUROSCI, V19, P7037, DOI 10.1523/JNEUROSCI.19-16-07037.1999
   Tikka T, 2001, J NEUROSCI, V21, P2580, DOI 10.1523/JNEUROSCI.21-08-02580.2001
   Trivedi A, 2006, CLIN NEUROSCI RES, V6, P283, DOI 10.1016/j.cnr.2006.09.007
   Tsai EC, 2005, J NEUROPATH EXP NEUR, V64, P230, DOI 10.1093/jnen/64.3.230
   Tuszynski MH, 2003, EXP NEUROL, V181, P47, DOI 10.1016/S0014-4886(02)00055-9
   Wang HS, 2004, STEM CELLS, V22, P1330, DOI 10.1634/stemcells.2004-0013
   Wyss-Coray T, 2002, NEURON, V35, P419, DOI 10.1016/S0896-6273(02)00794-8
   Yick LW, 2003, EXP NEUROL, V182, P160, DOI 10.1016/S0014-4886(02)00052-3
   Yoshihara T, 2007, J NEUROTRAUM, V24, P1026, DOI 10.1089/neu.2007.132R
   Young Wise, 1993, Journal of Emergency Medicine, V11, P13
   Yrjanheikki J, 1999, P NATL ACAD SCI USA, V96, P13496, DOI 10.1073/pnas.96.23.13496
   Zhang SC, 2001, NAT BIOTECHNOL, V19, P1129, DOI 10.1038/nbt1201-1129
NR 68
TC 151
Z9 175
U1 2
U2 20
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD OCT 6
PY 2008
VL 3
IS 10
AR e3336
DI 10.1371/journal.pone.0003336
PG 11
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 432DK
UT WOS:000265113500004
PM 18852872
OA DOAJ Gold, Green Published
DA 2019-07-19
ER

PT J
AU Rueda, P
   Balabanian, K
   Lagane, B
   Staropoli, I
   Chow, K
   Levoye, A
   Laguri, C
   Sadir, R
   Delaunay, T
   Izquierdo, E
   Pablos, JL
   Lendinez, E
   Caruz, A
   Franco, D
   Baleux, F
   Lortat-Jacob, H
   Arenzana-Seisdedos, F
AF Rueda, Patricia
   Balabanian, Karl
   Lagane, Bernard
   Staropoli, Isabelle
   Chow, Ken
   Levoye, Angelique
   Laguri, Cedric
   Sadir, Rabia
   Delaunay, Thierry
   Izquierdo, Elena
   Luis Pablos, Jose
   Lendinez, Elena
   Caruz, Antonio
   Franco, Diego
   Baleux, Francoise
   Lortat-Jacob, Hugues
   Arenzana-Seisdedos, Fernando
TI The CXCL12 gamma Chemokine Displays Unprecedented Structural and
   Functional Properties that Make It a Paradigm of Chemoattractant
   Proteins
SO PLOS ONE
LA English
DT Article
AB The CXCL12 gamma chemokine arises by alternative splicing from Cxcl12, an essential gene during development. This protein binds CXCR4 and displays an exceptional degree of conservation (99%) in mammals. CXCL12 gamma is formed by a protein core shared by all CXCL12 isoforms, extended by a highly cationic carboxy-terminal (C-ter) domain that encompass four overlapped BBXB heparan sulfate (HS)-binding motifs. We hypothesize that this unusual domain could critically determine the biological properties of CXCL12 gamma through its interaction to, and regulation by extracellular glycosaminoglycans (GAG) and HS in particular. By both RT-PCR and immunohistochemistry, we mapped the localization of CXCL12 gamma both in mouse and human tissues, where it showed discrete differential expression. As an unprecedented feature among chemokines, the secreted CXCL12 gamma strongly interacted with cell membrane GAG, thus remaining mostly adsorbed on the plasmatic membrane upon secretion. Affinity chromatography and surface plasmon resonance allowed us to determine for CXCL12 gamma one of the higher affinity for HS (K-d = 0.9 nM) ever reported for a protein. This property relies in the presence of four canonical HS-binding sites located at the C-ter domain but requires the collaboration of a HS-binding site located in the core of the protein. Interestingly, and despite reduced agonist potency on CXCR4, the sustained binding of CXCL12 gamma to HS enabled it to promote in vivo intraperitoneal leukocyte accumulation and angiogenesis in matrigel plugs with much higher efficiency than CXCL12 alpha. In good agreement, mutant CXCL12 gamma chemokines selectively devoid of HS-binding capacity failed to promote in vivo significant cell recruitment. We conclude that CXCL12 gamma features unique structural and functional properties among chemokines which rely on the presence of a distinctive C-ter domain. The unsurpassed capacity to bind to HS on the extracellular matrix would make CXCL12 gamma the paradigm of haptotactic proteins, which regulate essential homeostatic functions by promoting directional migration and selective tissue homing of cells.
C1 [Rueda, Patricia; Lendinez, Elena; Caruz, Antonio; Franco, Diego] Univ Jaen, Dept Biol Expt, Jaen, Spain.
   [Rueda, Patricia; Balabanian, Karl; Lagane, Bernard; Staropoli, Isabelle; Chow, Ken; Levoye, Angelique; Arenzana-Seisdedos, Fernando] Inst Pasteur, Viral Pathogenesis lab, Paris, France.
   [Rueda, Patricia; Balabanian, Karl; Lagane, Bernard; Staropoli, Isabelle; Chow, Ken; Levoye, Angelique; Arenzana-Seisdedos, Fernando] INSERM U819, Paris, France.
   [Laguri, Cedric; Sadir, Rabia; Lortat-Jacob, Hugues] Inst Structural Biol, Gagophile lab, UMR 5075 CNRS CEA UJF, Grenoble, France.
   [Delaunay, Thierry] INRA, Villenave Dornon, France.
   [Izquierdo, Elena; Luis Pablos, Jose] Hosp Octubre 12, Unidad Investigac, Serv Reumatol, Madrid, Spain.
   [Baleux, Francoise] Inst Pasteur, Unite Chim Organ, Paris, France.
RP Rueda, P (reprint author), Univ Jaen, Dept Biol Expt, Jaen, Spain.
EM farenzan@pasteur.fr
RI Arenzana-Seisdedos, Fernando/E-5835-2016; Balabanian, Karl/S-6250-2019;
   Lagane, Bernard/K-8446-2016; Balabanian, Karl/I-2990-2016; Caruz,
   Antonio/N-5557-2014
OI Balabanian, Karl/0000-0002-0534-3198; Balabanian,
   Karl/0000-0002-0534-3198; Caruz, Antonio/0000-0002-5788-7840; Franco,
   Diego/0000-0002-5669-7164; lagane, bernard/0000-0002-3459-7867; Levoye,
   Angelique/0000-0002-7125-7327; laguri, cedric/0000-0002-5429-6914
FU French Agence National pour la Recherche (ANR); Agence National pour la
   Recherche sur le SIDA (ANRS); Institut National de la Sante et la
   Recherche Medicale (INSERM); Institut Pasteur; Fondo de Investigaciones
   Sanitarias [FIS 05/060]; FPDI program sponsored by the Andalucia
   autonomous government (Spain) [fellowship]; Croucher Foundation (Hong
   Kong); ANR-Maladies Rares
FX This work is supported by grants from the French Agence National pour la
   Recherche (ANR), the Agence National pour la Recherche sur le SIDA
   (ANRS) Institut National de la Sante et la Recherche Medicale (INSERM),
   Institut Pasteur and Fondo de Investigaciones Sanitarias (Spain, FIS
   05/060). PR is a fellowship recipient from the FPDI program sponsored by
   the Andalucia autonomous government (Spain). KC and AL are supported by
   Croucher Foundation (Hong Kong) and ANR-Maladies Rares, respectively. CL
   is supported by an ANR postdoctoral grant.
CR Aiuti A, 1997, J EXP MED, V185, P111, DOI 10.1084/jem.185.1.111
   Allen CDC, 2004, NAT IMMUNOL, V5, P943, DOI 10.1038/ni1100
   Altenburg JD, 2007, J VIROL, V81, P8140, DOI 10.1128/JVI.00268-07
   Amara A, 1999, J BIOL CHEM, V274, P23916, DOI 10.1074/jbc.274.34.23916
   Ara T, 2003, P NATL ACAD SCI USA, V100, P5319, DOI 10.1073/pnas.0730719100
   Balabanian K, 2005, BLOOD, V105, P2449, DOI 10.1182/blood-2004-06-2289
   Balabanian K, 2005, J BIOL CHEM, V280, P35760, DOI 10.1074/jbc.M508234200
   Balabanian K, 2004, J IMMUNOL, V173, P7150, DOI 10.4049/jimmunol.173.12.7150
   Bleul CC, 1996, NATURE, V382, P829, DOI 10.1038/382829a0
   Brelot A, 1999, J VIROL, V73, P2576
   Burger JA, 2006, BLOOD, V107, P1761, DOI 10.1182/blood-2005-08-3182
   Burns JM, 2006, J EXP MED, V203, P2201, DOI 10.1084/jem.20052144
   Campbell JJ, 1998, SCIENCE, V279, P381, DOI 10.1126/science.279.5349.381
   Ceradini DJ, 2004, NAT MED, V10, P858, DOI 10.1038/nm1075
   Coulomb-L'Hermine A, 1999, P NATL ACAD SCI USA, V96, P8585, DOI 10.1073/pnas.96.15.8585
   Esko JD, 2002, ANNU REV BIOCHEM, V71, P435, DOI 10.1146/annurev.biochem.71.110601.135458
   Ferrara N, 1999, CURR TOP MICROBIOL, V237, P1
   Ferrara N, 1999, NAT MED, V5, P1359, DOI 10.1038/70928
   Gallagher KA, 2007, J CLIN INVEST, V117, P1249, DOI 10.1172/JCI29710
   Gleichmann M, 2000, EUR J NEUROSCI, V12, P1857, DOI 10.1046/j.1460-9568.2000.00048.x
   Grabovsky V, 2000, J EXP MED, V192, P495, DOI 10.1084/jem.192.4.495
   HOUCK KA, 1992, J BIOL CHEM, V267, P26031
   Jones KS, 2005, J VIROL, V79, P12692, DOI 10.1128/JVI.79.20.12692-12702.2005
   Kantele JM, 2000, J IMMUNOL, V164, P5035, DOI 10.4049/jimmunol.164.10.5035
   Klein RS, 2001, DEVELOPMENT, V128, P1971
   Lagane B, 2005, MOL PHARMACOL, V67, P1966, DOI 10.1124/mol.104.009779
   Laguri C, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0001110
   Ma Q, 1998, P NATL ACAD SCI USA, V95, P9448, DOI 10.1073/pnas.95.16.9448
   Miao Z, 2007, P NATL ACAD SCI USA, V104, P15735, DOI 10.1073/pnas.0610444104
   Nagasawa T, 1998, SEMIN IMMUNOL, V10, P179, DOI 10.1006/smim.1998.0128
   Nanki T, 2000, J IMMUNOL, V165, P6590, DOI 10.4049/jimmunol.165.11.6590
   Neufeld G, 1999, FASEB J, V13, P9
   Nickel W, 2007, J CELL SCI, V120, P2295, DOI 10.1242/jcs.011080
   Orimo A, 2005, CELL, V121, P335, DOI 10.1016/j.cell.2005.02.034
   Pablos JL, 2003, J IMMUNOL, V170, P2147, DOI 10.4049/jimmunol.170.4.2147
   PASSANITI A, 1992, LAB INVEST, V67, P519
   Proudfoot AEI, 2003, P NATL ACAD SCI USA, V100, P1885, DOI 10.1073/pnas.0334864100
   Ruhrberg C, 2002, GENE DEV, V16, P2684, DOI 10.1101/gad.242002
   Sadir R, 2004, J BIOL CHEM, V279, P43854, DOI 10.1074/jbc.M405392200
   Sadir R, 2001, J BIOL CHEM, V276, P8288, DOI 10.1074/jbc.M008110200
   Sandhoff R, 2005, BBA-MOL CELL BIOL L, V1687, P52, DOI 10.1016/j.bbalip.2004.11.011
   Segret A, 2007, J HISTOCHEM CYTOCHEM, V55, P141, DOI 10.1369/jhc.6A7050.2006
   Shamri R, 2005, NAT IMMUNOL, V6, P497, DOI 10.1038/ni1194
   SHIROZU M, 1995, GENOMICS, V28, P495, DOI 10.1006/geno.1995.1180
   Soriano SF, 2002, J EXP MED, V196, P311, DOI 10.1084/jem.20012041
   Staropoli I, 2000, J BIOL CHEM, V275, P35137, DOI 10.1074/jbc.M003868200
   Stumm RK, 2002, J NEUROSCI, V22, P5865
   Sweeney EA, 2002, BLOOD, V99, P44, DOI 10.1182/blood.V99.1.44
   TASHIRO K, 1993, SCIENCE, V261, P600, DOI 10.1126/science.8342023
   TISCHER E, 1991, J BIOL CHEM, V266, P11947
   Valenzuela-Fernandez A, 2001, J BIOL CHEM, V276, P26550, DOI 10.1074/jbc.M100411200
   Yu L, 2006, GENE, V374, P174, DOI 10.1016/j.gene.2006.02.001
   ZIMRIN AB, 1995, BIOCHEM BIOPH RES CO, V213, P630, DOI 10.1006/bbrc.1995.2178
   Zou YR, 1998, NATURE, V393, P595, DOI 10.1038/31269
NR 54
TC 48
Z9 48
U1 0
U2 5
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD JUL 2
PY 2008
VL 3
IS 7
AR e2543
DI 10.1371/journal.pone.0002543
PG 12
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 406IM
UT WOS:000263288200015
PM 18648536
OA DOAJ Gold, Green Published
DA 2019-07-19
ER

PT J
AU Shen, RL
   Ye, Y
   Chen, L
   Yan, QT
   Barsky, SH
   Gao, JX
AF Shen, Rulong
   Ye, Yin
   Chen, Li
   Yan, Qingtao
   Barsky, Sanford H.
   Gao, Jian-Xin
TI Precancerous Stem Cells Can Serve As Tumor Vasculogenic Progenitors
SO PLOS ONE
LA English
DT Article
ID ENDOTHELIAL GROWTH-FACTOR; IN-VIVO; BONE-MARROW; THERAPEUTIC
   IMPLICATIONS; DENDRITIC CELLS; BLOOD-VESSELS; FACTOR VEGF; ANGIOGENESIS;
   CANCER; RECEPTOR
AB Tumor neo-vascularization is critical for tumor growth, invasion and metastasis, which has been considered to be mediated by a mechanism of angiogenesis. However, histopathological studies have suggested that tumor cells might be the progenitor for tumor vasculature. Recently, we have reported that the precancerous stem cells (pCSCs) representing the early stage of developing cancer stem cells (CSCs), have the potential for both benign and malignant differentiation. Therefore, we investigated whether pCSCs serve as progenitors for tumor vasculogenesis. Herein, we report that in the pCSC-derived tumors, most blood vessels were derived from pCSCs. Some pCSCs constitutively expressed vasculogenic receptor VEGFR-2, which can be up-regulated by hypoxia and angiogenesis-promoting cytokines, such as GM-CSF, Flt3 ligand, and IL-13. The pCSCs are much more potent in tumor vasculogenesis than the differentiated tumor monocytic cells (TMCs) from the same tumor, which had comparable or even higher capacity to produce some vascular growth factors, suggesting that the potent tumor vasculogenesis of pCSCs is associated with their intrinsic stem-like property. Consistently tumor vasculogenesis was also observed in human cancers such as cervical cancer and breast cancer and xenograft lymphoma. Our studies indicate that pCSCs can serve as tumor vasculogenic stem/progenitor cells (TVPCs), and may explain why anti-angiogenic cancer therapy trials are facing challenge.
C1 [Shen, Rulong; Ye, Yin; Chen, Li; Yan, Qingtao; Barsky, Sanford H.; Gao, Jian-Xin] Ohio State Univ, Dept Pathol, Columbus, OH 43210 USA.
RP Shen, RL (reprint author), Ohio State Univ, Dept Pathol, Columbus, OH 43210 USA.
EM Sanford.Barsky@osumc.edu; Jian-Xin.Gao@osumc.edu
RI Shen, Rulong/E-4079-2011
FU SIG OSU; Immunology Program Award; American Cancer society [IRG-112367];
   Davis/Bremer Medical Research
FX The work is supported from Strategy Initiative Grant(SIG, OSU),
   2006/2007 (JXG); Immunology Program Award 2007 (OSUCCC)(JXG); American
   Cancer society Grant #IRG-112367 (JXG); Davis/Bremer Medical Research
   Grant, OSU (RS); and SIG 2006(SHB).
CR Al-Rawi MAA, 2005, INT J ONCOL, V27, P721
   Medina MA, 2007, J CELL MOL MED, V11, P374, DOI 10.1111/j.1582-4934.2007.00056.x
   Bailey AS, 2006, P NATL ACAD SCI USA, V103, P13156, DOI 10.1073/pnas.0604203103
   Bailey AS, 2003, EXP HEMATOL, V31, P987, DOI 10.1016/j.exphem.2003.07.001
   Bao SD, 2006, CANCER RES, V66, P7843, DOI 10.1158/0008-5472.CAN-06-1010
   Bergers G, 2003, NAT REV CANCER, V3, P401, DOI 10.1038/nrc1093
   Bertolini F, 2006, NAT REV CANCER, V6, P833, DOI 10.1039/nrc1971
   Blouw B, 2003, CANCER CELL, V4, P133, DOI 10.1016/S1535-6108(03)00194-6
   Carmeliet P, 2000, NATURE, V407, P249, DOI 10.1038/35025220
   Chang YS, 2000, P NATL ACAD SCI USA, V97, P14608, DOI 10.1073/pnas.97.26.14608
   Chen L, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0000293
   Clarke Michael F, 2006, Cancer Res, V66, P9339, DOI 10.1158/0008-5472.CAN-06-3126
   Clauss M, 2000, SEMIN THROMB HEMOST, V26, P561, DOI 10.1055/s-2000-13213
   Dalerba P, 2007, ANNU REV MED, V58, P267, DOI 10.1146/annurev.med.58.062105.204854
   Deininger MWN, 2001, CANCER RES, V61, P8005
   Dentelli P, 1999, J IMMUNOL, V163, P2151
   Dome B, 2007, AM J PATHOL, V170, P1, DOI 10.2353/ajpath.2007.060302
   Eubank TD, 2004, IMMUNITY, V21, P831, DOI 10.1016/j.immuni.2004.10.011
   Ferrara N, 2003, NAT MED, V9, P669, DOI 10.1038/nm0603-669
   FOLKMAN J, 1971, NEW ENGL J MED, V285, P1182
   FUKUMURA D, 2007, MICROVASC RES
   Fukushi J, 2000, J IMMUNOL, V165, P2818, DOI 10.4049/jimmunol.165.5.2818
   Gao JX, 2003, J IMMUNOL, V170, P5927, DOI 10.4049/jimmunol.170.12.5927
   GAO JX, 2007, J CELL MOL MED ONLIN
   GAO JX, 2007, J CELL MOL IN PRESS
   Gottfried E, 2007, SCAND J IMMUNOL, V65, P329, DOI 10.1111/j.1365-3083.2007.01903.x
   HAMMERSEN F, 1985, INT J MICROCIRC, V4, P31
   Hashizume H, 2000, AM J PATHOL, V156, P1363, DOI 10.1016/S0002-9440(10)65006-7
   Hendrix MJC, 2003, NAT REV CANCER, V3, P411, DOI 10.1038/nrc1092
   Hicklin DJ, 2005, J CLIN ONCOL, V23, P1011, DOI 10.1200/JCO.2005.06.081
   Hilbe W, 2004, J CLIN PATHOL, V57, P965, DOI 10.1136/jcp.2004.016444
   Hong DL, 2008, SCIENCE, V319, P336, DOI 10.1126/science.1150648
   Kerbel RS, 2000, CARCINOGENESIS, V21, P505, DOI 10.1093/carcin/21.3.505
   Klug CA, 2000, BLOOD, V96, P894
   Koblizek TI, 1998, CURR BIOL, V8, P529, DOI 10.1016/S0960-9822(98)70205-2
   Kondo T, 2004, P NATL ACAD SCI USA, V101, P781, DOI 10.1073/pnas.0307618100
   Larrivee B, 2005, J IMMUNOL, V175, P2890, DOI 10.4049/jimmunol.175.5.2890
   Lyden D, 2001, NAT MED, V7, P1194, DOI 10.1038/nm1101-1194
   Maisonpierre PC, 1997, SCIENCE, V277, P55, DOI 10.1126/science.277.5322.55
   Maniotis AJ, 1999, AM J PATHOL, V155, P739, DOI 10.1016/S0002-9440(10)65173-5
   McClintock JY, 2005, J APPL PHYSIOL, V99, P861, DOI 10.1152/japplphysiol.00006.2005
   MILLAUER B, 1993, CELL, V72, P835, DOI 10.1016/0092-8674(93)90573-9
   Neufeld G, 1999, FASEB J, V13, P9
   Nolan DJ, 2007, GENE DEV, V21, P1546, DOI 10.1101/gad.436307
   O'Farrell AM, 2003, BLOOD, V101, P3597, DOI 10.1182/blood-2002-07-2307
   Papetti M, 2002, AM J PHYSIOL-CELL PH, V282, pC947, DOI 10.1152/ajpcell.00389.2001
   Peters KG, 2004, RECENT PROG HORM RES, V59, P51, DOI 10.1210/rp.59.1.51
   Pezzolo A, 2007, J CLIN ONCOL, V25, P376, DOI 10.1200/JCO.2006.09.0696
   Pujol BF, 2000, DIFFERENTIATION, V65, P287, DOI 10.1046/j.1432-0436.2000.6550287.x
   Reya T, 2001, NATURE, V414, P105, DOI 10.1038/35102167
   Reyes M, 2002, J CLIN INVEST, V109, P337, DOI 10.1172/JCI200214327
   Ribatti D, 2007, LEUKEMIA, V21, P2085, DOI 10.1038/sj.leu.2404900
   Rini BI, 2005, J CLIN ONCOL, V23, P1028, DOI 10.1200/JCO.2005.01.186
   Sakurai Y, 2005, P NATL ACAD SCI USA, V102, P1076, DOI 10.1073/pnas.0404984102
   Shaw JP, 2004, BLOOD CELL MOL DIS, V32, P168, DOI 10.1016/j.bcmd.2003.10.003
   Shibuya M, 2001, CELL STRUCT FUNCT, V26, P25, DOI 10.1247/csf.26.25
   Stratmann A, 2001, INT J CANCER, V91, P273, DOI 10.1002/1097-0215(200002)9999:9999<::AID-IJC1054>3.0.CO;2-Q
   TEPPER RI, 1989, CELL, V57, P503, DOI 10.1016/0092-8674(89)90925-2
   Valdembri D, 2001, FASEB J, V15, P225, DOI 10.1096/fj.01-0633fje
   Volpert OV, 1998, J EXP MED, V188, P1039, DOI 10.1084/jem.188.6.1039
   Warner JK, 2004, ONCOGENE, V23, P7164, DOI 10.1038/sj.onc.1207933
   Yamashita J, 2000, NATURE, V408, P92, DOI 10.1038/35040568
   Yang XJ, 1996, J NEUROSCI, V16, P6089
NR 63
TC 66
Z9 70
U1 0
U2 2
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD FEB 20
PY 2008
VL 3
IS 2
AR e1652
DI 10.1371/journal.pone.0001652
PG 13
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 367XR
UT WOS:000260586400045
PM 18286204
OA DOAJ Gold, Green Published
DA 2019-07-19
ER

EF